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ABSTRACT 
Novel approaches using human induced pluripotent stem cells and microRNAs in the 
development of relevant human hepatocyte models for drug-induced liver injury. 
 
 
Richard Yin Kit Kia 
 
Drug-induced liver injury (DILI) remains a prominent cause of patient morbidity and mortality, 
partly due to the lack of relevant in vitro hepatic models for accurate screening for drug-
induced hepatotoxicity at the early stages of drug development, and also the lack of 
sophisticated in vitro model systems to mechanistically understand the pathways that are 
perturbed following drug exposure. This thesis describes our endeavour to develop more 
relevant in vitro human hepatocyte models via novel investigative approaches using insights 
gained from the rapidly advancing research areas of human induced pluripotent stem cells 
and microRNAs (miRs).    
An emerging hepatic model is hepatocyte-like cells (HLCs) generated from human induced 
pluripotent stem cells (hiPSCs), though the functional phenotype of HLCs in general remains 
limited in comparison with the gold standard in vitro model of human primary hepatocytes 
(hPHs). As studies have shown that hiPSCs retain transient epigenetic memories of the 
donor cells despite cellular reprogramming with a resultant skewed propensity to differentiate 
towards the cell-type of origin, we evaluated the contribution of epigenetic memory towards 
hepatic differentiation by comparing HLCs generated from hPH- and non-hPH-derived 
hiPSC lines derived from a single donor. Our findings suggested that they were functionally 
similar, although comparison using hiPSC lines derived from other donors is still required to 
be conclusive. 
Although hPHs remain the gold standard in vitro model for DILI, they are commonly 
harvested from liver tissue of poor quality and rapidly lose their in vivo phenotype during 
extended in vitro culture, limiting its utility to acute toxicity studies only. Using an unbiased 
miR expression profiling approach, we identified a set of differentially-expressed miRs in 
dedifferentiating hPHs which are associated with many of the previously delineated 
perturbed pathways and biological functions. However, validation experiments are now 
required to confirm our findings from the bioinformatics analyses. 
Another approach taken to develop relevant and functional hepatic models includes efforts to 
better emulate the in vivo liver tissue environment by using complex hepatic models co-
cultured with non-parenchymal cells. However, for the application of these models in the 
study of drug-induced toxicity, a hepatocyte-specific marker of hepatocyte perturbation is 
needed to discriminate non-specific cellular toxicity contributed by non-hepatocyte cell types 
present within the model. We demonstrated that the detection of miR-122 in cell culture 
media can be applied as a hepatocyte-enriched marker of toxicity in heterogeneous cultures 
of hepatic cells. 
In summary, this thesis describes our contribution towards the continuing efforts to develop 
new and improve on existing hepatic models for DILI by evaluating the contribution of 
epigenetic memory towards the functional phenotype of HLCs, delineating the changing miR 
profile of dedifferentiating hPHs, and introduced the concept of using miR-122 as a cell-type 
specific marker of hepatocyte perturbation with a potential to bridge in vitro and in vivo 
findings.  
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1.1  INTRODUCTION 
Amongst the different types of adverse drug reactions, drug-induced liver injury (DILI) 
remains a prominent cause of patient morbidity and mortality, and confers major concerns to 
the pharmaceutical industry and regulatory agencies (Olsen and Whalen, 2009;  Russo et 
al., 2004;  Sgro et al., 2002). One of the major reasons for this is due to the lack of relevant 
in vitro hepatic models for accurate screening for drug-induced hepatotoxicity at the early 
stages of drug development, and also the lack of sophisticated in vitro model systems to 
mechanistically understand the pathways that are perturbed following drug exposure, 
especially after chronic low-dose regimes (Godoy et al., 2013;  LeCluyse et al., 2012). 
Consequently, there continues to be major gaps in the extrapolation of findings from in vitro 
hepatic systems to the in vivo environment (LeCluyse, et al., 2012).  
This thesis describes our endeavour to develop more relevant in vitro human hepatocyte 
models via novel investigative approaches using insights gained from the rapidly advancing 
research areas of human induced pluripotent stem cells and microRNAs.    
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1.2 DRUG-INDUCED LIVER INJURY 
1.2.1 Clinical aspects of drug-induced liver injury 
The clinical presentation of DILI can mimic any type of acute or chronic liver disease. Hence, 
DILI is largely a clinical diagnosis of exclusion based on the overall findings from the clinical 
features, the clinical course of suspected DILI cases, presence or absence of patient risk 
factors, exclusion of other diagnoses and the reported hepatotoxicity profile of the suspected 
culprit drug (Fontana et al., 2010). Therefore, it is not surprising that its diagnosis remains 
challenging with expert opinion in causality assessment still widely regarded as the gold 
standard, despite non-standardisation of what constitutes an expert, and how assimilation of 
information should be done to come to a diagnosis of DILI (Fontana, et al., 2010). 
Nevertheless, much progress has been achieved in addressing these issues via the 
refinement of causality instruments such as the Roussel Uclaf Causality Assessment Method 
(Danan and Benichou, 1993;  Maria and Victorino, 1997), and efforts to standardize the 
nomenclature used for defining clinical phenotypes of DILI (Fontana, et al., 2010).  
 
1.2.2 Burden of drug-induced liver injury 
The incidence of DILI in the general population remains largely unknown. In a French 
population-based study, the annual incidence of DILI was estimated to be as high as 13.9 
per 1,000,000 inhabitants (Sgro, et al., 2002). The true incidence was also suggested to be 
underestimated, as the incidence found in the prospective study was 16 times higher than 
the number derived from spontaneous reporting of DILI cases to the French regulatory 
authorities. Meanwhile, the incidence of DILI developing among patients who were 
hospitalised was estimated to be 1.4% (Meier et al., 2005), and 15% of liver transplants for 
acute liver failure deemed to be caused by DILI (Russo, et al., 2004). DILI is also a major 
concern to the pharmaceutical industry and the regulatory authorities as it is the leading 
cause of costly drug withdrawal from the market post-licensing, restriction of prescribing 
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indications and the main reason for drug attrition during pre-clinical drug development 
(Watkins, 2005;  Wilke et al., 2007).   
 
1.2.3 The role of drug metabolism in drug-induced liver injury 
Amongst its many unique functions, the liver is the main organ where drugs or xenobiotics 
undergo biotransformation via a series of enzymatic reactions classified as phase I and II 
processes (Figure 1.1), primarily to reduce their biological activity and increase hydrophilicity 
to facilitate drug clearance (Fraczek et al., 2013). Important phase I reactions include 
oxidation, reduction and hydrolysis and are facilitated by the various catalytic enzymes 
including cytochrome-P450 monooxygenases (CYPs) and alcohol dehydrogenases (ADH) 
(Guengerich, 2008). However, a few select CYP isoforms – namely CYP3A4, CYP2D6, 
CYP2C9 and CYP2C19 – are responsible for the biotransformation of the majority of 
marketed drugs (Hewitt et al., 2007). The phase I metabolites are then conjugated with 
water-soluble endogenous substances in phase II reactions mediated by various 
transferases, though predominantly by UDP-glucuronosyltransferases (UGTs) (Fraczek, et 
al., 2013). Excretion of the xenobiotics into the bile and urine is then facilitated through 
various transmembrane transporter proteins – the process being termed as phase III of 
xenobiotic biotransformation (Malarkey et al., 2005).    
 
Figure 1.1 Schematic diagram showing the important reactions in each phase of drug 
metabolism. 
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However, some xenobiotics can undergo metabolic bioactivation during the 
biotransformation process, resulting in chemically reactive metabolites that is thought to 
have the potential to form adducts with cellular proteins (Park et al., 2011). This covalent 
binding to biological macromolecules is then thought to cause cellular and organelle 
dysfunction via various poorly defined mechanisms including oxidative stress, DNA damage 
and protein dysfunction, which cumulatively manifests clinically as DILI (Park, et al., 2011).  
 
1.3 CONVENTIONAL HEPATIC MODELS FOR THE STUDY OF DRUG-
INDUCED HEPATOTOXICITY 
In view of the massive costs of unpredicted DILI to society, early detection of hepatotoxicity 
potential of a candidate drug during the early pre-clinical stages of drug discovery, and 
further mechanistic understanding of DILI is paramount. For these reasons, in vitro and in 
vivo hepatic models are important investigative tools, and are currently used throughout  the 
pre-clinical phases of drug discovery to aid in the lead optimisation process and satisfy 
regulatory requirements before clinical development of a candidate drug can be pursued 
(Bass et al., 2009). Although 40% of cells in the liver consist of many other cell-types 
including non-parenchymal cells such as endothelial cells, stellate cells, Kupffer cells, biliary 
epithelial cells and lymphoid cells (Godoy, et al., 2013), most liver-specific functions are 
performed by the hepatocyte, including xenobiotic biotransformation (Fraczek, et al., 2013). 
Therefore, most of the hepatic models currently used in safety pharmacology and toxicology 
research to understand the mechanisms of DILI, are based on hepatocytes.  
The main hepatic models available for studies into the pathophysiology of DILI include 
primary hepatocytes, immortalised cell lines and animal models, though their utility and 
relevance for such purposes are somewhat limited as discussed below (Godoy, et al., 2013;  
Kia et al., 2013).  
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1.3.1 Human primary hepatocytes 
The gold standard in vitro model for the study of DILI in humans is freshly-isolated human 
primary hepatocytes (hPHs) (Gomez-Lechon et al., 2004). However, the use of hPHs is 
impeded by their limited availability, phenotypic differences between donors, variable viability 
and attachment of hPHs to tissue culture vessels following isolation and rapid 
dedifferentiation of the hepatocyte phenotype in culture, particularly in the loss of expression 
of CYP enzymes (Gomez-Lechon, et al., 2004;  Guguen-Guillouzo and Guillouzo, 2010;  
LeCluyse, 2001). Furthermore, hPHs are commonly harvested from diseased liver tissue 
which is not suitable for transplantation and likely to have experienced complex drug 
regimes, resulting in a skewed population of hPHs being used. The problem of hepatocyte 
dedifferentiation resulting in a short duration of optimal hepatocyte function also limits the 
utility of the hPH model to acute toxicity studies only, and compromises their use in 
mechanistic studies of DILI which often occurs following prolonged exposure to drugs 
(Guguen-Guillouzo and Guillouzo, 2010;  Kalgutkar and Soglia, 2005;  LeCluyse, 2001). The 
phenotypic characterisation of dedifferentiating primary hepatocytes has been extensively 
performed previously, though various efforts to reverse and prevent this process have 
proved limited in success (Elaut et al., 2006;  Fraczek, et al., 2013). This will be discussed 
further in Chapter 3, which also describes our contribution towards better mechanistic 
understanding of dedifferentiation in hPHs by delineating the change in its global microRNA 
(miR) profile.  
 
1.3.2 Immortalised human cell lines 
Immortalised cell lines such as HepG2 (derived from liver tissue containing well-
differentiated hepatocellular carcinoma), Fa2N-4 (immortalised hPHs) and HepaRG (derived 
from hepatocellular carcinoma) have been used to overcome some of these problems mainly 
as their proliferation is unlimited and are readily available (LeCluyse, et al., 2012). However, 
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they generally are not representative systems for recapitulating hepatocyte function, do not 
contain all the families of metabolic enzymes required for drug metabolism, while expressed 
enzymes display reduced activity (Guguen-Guillouzo and Guillouzo, 2010;  LeCluyse, et al., 
2012). Transfection methods to enable overexpression of CYP enzymes in these cells have 
been adopted, but this approach is still limited to the expression of one CYP isoform per cell 
line and therefore does not fully recapitulate the metabolic capacity and physiology of a fully 
functional hepatocyte (Chen and Cederbaum, 1998;  Dai et al., 1993;  Goldring et al., 2006;  
Pfeifer et al., 1993).  
 
1.3.3 Animal models 
Although the use of animal models is a more amenable approach for in vivo studies, 
experimentation on animals raises ethical concerns, and public pressure to use animal-free 
assays has been reinforced with legislative changes that limit the use of animals for research 
and regulatory testing – most evidently exemplified in the cosmetic industry in Europe, which 
has an absolute ban on animal testing since 2013 (Fraczek, et al., 2013). Furthermore, 
cross-species extrapolation of in vivo findings using animal models to humans is also 
variable due to interspecies differences in life histories, tissue-specific gene expression and 
variations in toxic responses to xenobiotics, including possession of higher levels of CYP 
enzymes in comparison to humans (Celander et al., 2011;  Lee et al., 2006;  Saldana-Ruiz et 
al., 2012). 
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1.4 HUMAN PLURIPOTENT STEM CELL-DERIVED HEPATOCYTES 
In view of the difficulties in procuring the gold standard in vitro model of hPHs and the 
functional limitations of the currently used hepatic models, new hepatic models with potential 
for better prediction and understanding of the mechanisms causing DILI will need to be 
explored. With the rapidly advancing stem cell technology, it is hoped that progress will be 
made in bridging this gap in toxicology research through the use of human pluripotent stem 
cells (hPSCs). hPSCs consist of human embryonic stem cells (hESCs) – derived from 
human embryos, and human induced pluripotent stem cells (hiPSCs) – reprogrammed from 
differentiated cells; both characterised by their pluripotency – ability to differentiate into cells 
from all three germ layers – and their potential to proliferate indefinitely (Kia, et al., 2013). 
These unique features of hPSCs make them an attractive solution in safety pharmacology 
and toxicology research, as well as in the fields of regenerative medicine, tissue engineering 
and cell therapy (Bielby et al., 2004;  Hamazaki et al., 2001;  Lumelsky et al., 2001;  Vittet et 
al., 1996;  Wobus et al., 2002). Directed differentiation of hPSCs to somatic cells with mature 
phenotypes in the laboratory could potentially provide a readily available source of 
metabolically competent cells such as mature hepatocytes as a relevant and functional 
hepatic model (Figure 1.2).  
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Figure 1.2 The potential utility of human induced pluripotent stem cells reprogrammed 
(solid line) from easily accessible human somatic cells (red) to provide a readily 
available source of difficult to access cells such as hepatocytes (green) via directed 
differentiation in the laboratory (dashed lines). 
 
1.4.1 Human induced pluripotent stem cells 
The successful generation of hiPSCs from mature somatic cells by cellular reprogramming 
(Takahashi and Yamanaka, 2006), have provided an increasingly attractive source of 
hPSCs; avoiding the use of human embryonic tissue-derived stem cell lines for research, 
while providing a unique opportunity for in vitro modelling of normal and variant phenotypes 
from pre-selected adult donors for safety pharmacology and toxicology evaluations (Kia, et 
al., 2013). iPSCs were first generated by cellular reprogramming of murine fibroblasts using 
a retroviral vector that expressed transcription factors noted to be abundant in embryonic 
stem cells – namely Oct4, Sox2, Klf4, and c-Myc; collectively termed as the Yamanaka 
factors in recognition of the lead researcher who pioneered iPSC generation (Takahashi and 
Yamanaka, 2006). Since then, many reports using a variety of reprogramming techniques on 
various human somatic cells to induce pluripotency have been published, albeit with variable 
reprogramming efficiencies (Gonzalez et al., 2011). These methods include viral-free 
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approaches to deliver the pluripotency gene set expressing the essential transcription factors 
into target somatic cells using episomal vectors, piggyBac transposons or minicircle vectors 
(Jia et al., 2010;  Kaji et al., 2009;  Woltjen et al., 2009;  Yu et al., 2009;  Yusa et al., 2009). 
Reprogramming somatic cells via delivery of the reprogramming factors in their protein or 
messenger ribonucleic acid (RNA) form have also been reported (Kim et al., 2009;  Warren 
et al., 2010;  Zhou et al., 2009). Small molecules have also been used solely or with all or 
some of the Yamanaka factors in a bid to improve the efficiency of induction (Hou et al., 
2013;  Huangfu et al., 2008;  Mikkelsen et al., 2008;  Zhu et al., 2010). Reprogramming 
using miRs that were shown to be abundant in ESCs and known to play important roles 
during the process were also reported to be successful (Anokye-Danso et al., 2011;  Miyoshi 
et al., 2011). However, many of these latter approaches have not been widely adopted and 
cellular reprogramming using the Yamanaka factors remain the most robust thus far.  
 
1.4.2 Generation of hepatocyte-like cells from hPSCs 
Problems associated with freshly-isolated hPHs namely their limited availability, inter-donor 
differences and technical challenges of the isolation process, can theoretically be overcome 
by the use of a standard protocol-driven derivation of hepatocytes with batch-to-batch 
consistency and purity. In general, studies reporting on “hepatocytes” derived from hPSCs 
have been focussed on generating a closer representation of a freshly-isolated hPH 
phenotype. However, as no reports to date have confirmed complete recapitulation of a 
freshly isolated hPH, the term hepatocyte-like cells (HLCs) has been used to describe them.  
The in vitro direct differentiation of hPSCs towards HLCs largely mimics the developmental 
pathway of the liver in vivo during embryogenesis (Baxter et al., 2010). The aim is to derive 
mature hepatocytes from hPSCs using differentiation protocols encompassing the three 
main stages of hepatic development: induction of definitive endoderm, specification of 
hepatic endoderm and maturation of the HLCs (Baxter, et al., 2010;  Hay et al., 2008;  
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Sullivan et al., 2010). However, the differentiation efficiency in generating a pure culture of 
HLCs as defined by the presence of cells positive for hepatocyte-associated markers such 
as albumin and alpha-1-antitrypsin, has been reported to be variable (Kia, et al., 2013). To 
date however, the perfect differentiation protocol has remained elusive. This is also 
compounded by the lack of standardisation of methods used to characterise these HLCs and 
in assessing their differentiation efficiency, though helpful recommendations for minimal 
criteria to allow comparison of protocols have been proposed (Sancho-Bru et al., 2009).  
 
1.4.2.1  Functional assessment of hPSC-derived hepatocyte-like cells 
Although gene expression profiling of HLCs is useful for characterisation, ultimately it is the 
dynamic functional capabilities of these differentiated HLCs when compared to hPHs that will 
determine their suitability for use in safety pharmacology and toxicology. These functional 
assessments include drug metabolising enzyme activity, albumin secretion, glycogen 
storage, uptake of indocyanine green and uptake of low density lipoprotein (Kia, et al., 
2013). 
As drug-induced hepatotoxicity and clinically apparent DILI is widely accepted to be 
associated with the formation of reactive metabolites following metabolism by phase I and II 
catalytic enzymes, especially CYPs, one of the key tests for the functional relevance of 
HLCs as a model for pharmaco-toxicology would be the demonstration of CYP activity at 
levels similar to freshly-isolated hPHs. However, when the CYP activity profile of HLCs has 
been compared to hPHs, the results have been variable – ranging from 0-100% of the hPH 
comparator (Duan et al., 2010;  Ek et al., 2007;  Yildirimman et al., 2011). Comparison 
between studies is difficult due to major differences in the experimental factors such as 
different hPSC lines used as starting cell source, the differences in the multi-stage 
differentiation protocols employed, the difference in methods used to measure CYP activity 
and most pertinently, the variable quality of the reference hPHs being used in different 
  Chapter 1 
12 
 
studies (Kia, et al., 2013;  Wobus and Loser, 2011). It is also important to note that full 
description of the hPH comparators used in all of these studies were not reported, making it 
difficult to judge the quality of the hPHs and their metabolic capacity. In contrast to efforts to 
assess the activity of phase I enzymes in HLCs, only one study have reported the presence 
and activity of phase II enzymes (Soderdahl et al., 2007). In this study, glutathione-S-
transferases (GSTs) were found to have overall comparable activity to that of the reference 
hPHs, though again the quality of the reference hPHs used was not characterised. The 
albumin secretion capability of HLCs has also been compared infrequently with hPHs, and 
has ranged from 23-75% of the hPH comparators (Basma et al., 2009;  Bone et al., 2011). 
Nevertheless, in a recent study evaluating HLCs as an in vitro hepatic model for drug-
induced hepatotoxicity (Szkolnicka et al., 2014), hESC-derived HLCs and cryopreserved 
hPHs were shown to have comparable accuracy in predicting toxicity induced by a series of 
known hepatotoxicants, although the authors also reported variable metabolic and inducible 
CYP activities between HLCs generated from the two hESC and hiPSC lines examined, of 
which the reason(s) was unclear.  
Overall, none of the reports of HLCs generated have claimed full functional recapitulation of 
the hPH phenotype. Instead, HLCs are currently widely recognised as more similar to a 
foetal hepatocyte, especially with its persistent expression of the proto-typical marker alpha-
fetoprotein (Yi et al., 2012). More recently, the CYP1A and CYP3A activities of HLCs have 
also been shown to be akin to that of hPHs with a dedifferentiated phenotype following 48 
hours of in vitro culture (Ulvestad et al., 2013).    
 
1.4.2.2  Variations in hepatic differentiation from hPSCs 
The reason(s) for the variation in the hepatic differentiation efficiency reported in the 
literature (Kia, et al., 2013), is currently unclear and is likely to be at least due to the 
variations in the differentiation propensity of individual hPSC lines towards certain lineages 
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(Bock et al., 2011;  Osafune et al., 2008;  Ramos-Mejia et al., 2010), which in turn potentially 
contributed by a myriad of factors. These include the heterogeneous genetic background of 
the donors, the differences in culture conditions, and variations in the methods for hiPSC 
generation (Kajiwara et al., 2012). However, another potential factor could be the retention of 
epigenetic memory of the donor cells in hiPSCs despite cellular reprogramming, with a 
resultant skewed propensity to differentiate towards the cell-type of origin (Kim et al., 2010;  
Kim et al., 2011;  Polo et al., 2010), which to date has only been partially explored in the 
differentiation of hiPSCs towards HLCs. This will be discussed in more detail in Chapter 2, 
where we also describe our contribution to this conundrum by focussing on the potential 
impact of epigenetic memory in hepatic differentiation by comparing HLCs generated from 
isogenic hPH- and human dermal fibroblast-derived hiPSCs (Figure 1.3).   
 
 
Figure 1.3 Schematic diagram of plan for comparison of isogenic hepatocyte-like cells 
generated from human primary hepatocytes and human dermal fibroblasts derived 
from the same donor. Scale bar, 100 μm. 
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1.5 microRNA 
MicroRNAs (miRs) which are small non-coding RNAs consisting of 18-24 nucleotides (nt), 
were first discovered in 1993 (Lee et al., 1993), and have since been found to play crucial 
roles in almost every facet of cellular biology and human disease (Li and Rana, 2014;  
Pritchard et al., 2012). Although there is only approximately 2500 mature miRs in humans  
(Griffiths-Jones, 2004) compared to approximately 30000 mRNAs (Pritchard, et al., 2012), 
one miR may regulate hundreds of mRNAs whilst each mRNA may in turn be regulated by 
many different miRs (Szabo and Bala, 2013). As a result, miR expression patterns convey a 
huge amount of biological information as variation in gene expression patterns can 
potentially be captured by the expression patterns of just one or a few miRs that regulate 
them. Therefore, there has been intense interest in the study of miR expression patterns for 
potential targets for manipulation as a means to influence biological functions and correct 
pathophysiological processes. Our effort in delineating the changing global miR profile of 
dedifferentiating hPHs as described in Chapter 3 of this thesis, is one example of this 
approach. 
 
1.5.1 Biogenesis and function of miRs 
Most of the miR genes lie within intronic regions of protein-coding genes and therefore the 
expression of miRs subjected to similar transcriptional control as these genes (Li and Rana, 
2014). The major mechanism governing tissue- and cell-type-specific expression of miRs 
has been suggested to be due to transcriptional regulation, although many of the factors and 
catalytic enzymes involved in miR biogenesis are also tightly regulated (Krol et al., 2010;  Li 
and Rana, 2014).  
Each miR is first transcribed by RNA polymerase II as a long primary transcript (termed as 
pri-miR), and is then processed into mature miR via canonical or non-canonical pathways 
(Figure 1.4) (Li and Rana, 2014). In the canonical pathway, the pri-miR stem-loop structure 
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is digested by an RNase III family member, Drosha into precursor miR (termed as pre-miR), 
while in the non-canonical pathway, the pre-miR is generated by the mRNA splicing 
machinery without the need for Drosha. Following the generation of the pre-miR via either 
pathway in the nucleus, it is then exported into the cytoplasm and further processed by 
another RNase III enzyme, Dicer into a double-stranded miR duplex which contains the 
mature miR strand and the passenger strand. The mature miR is then incorporated into a 
RNA-induced silencing complex (RISC) containing Argonaute 2 proteins, which function as 
key catalytic enzymes within the complex for miR-mediated post-transcriptional gene 
silencing (Chen, 2009). In most cases, the miR-RISC complex bind to their mRNA targets by 
complementary interaction between the 3’ untranslated region (UTR) of the mRNA with a 
sequence of 2-8 nt, known as the seed region, at the 5’ end of the mature miR. This miR-
mRNA interaction then results in the regulation of gene expression via translational 
repression, inhibition of translation initiation or induction of endonucleolytic cleavage of the 
target mRNAs, although the exact mechanisms involved remain unclear (Chen, 2009;  Li 
and Rana, 2014).  
 
1.5.2 Nomenclature of miRs 
The latest nomenclature of miR is widely-accepted to be based on miRBase 
(www.mirbase.org), which serves as the definitive repository of published miR sequences 
and annotation, with links to databases of predicted mRNA targets. Currently, the total 
number of listed entries of human pre-miR is 1881, while the total number of listed entries of 
mature miRs is 2588 (miRBase 21, accessed 22 August 2014). Important points to note is 
that distinct species of mature miRs can be produced from the 3’ and 5’ arms of the pre-miR 
duplex and either species could be the mature miR strand dependent on its stability in the 
double-stranded miR duplex (Szabo and Bala, 2013). In addition, sequencing studies have 
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shown that a given mature miR can vary from 15-23 nt, although the majority are of 22-23 nt, 
due to 3’ or 5’ end post-transcriptional modifications (Pritchard, et al., 2012).  
 
1.5.3 Liver-enriched miR-122 
miR-122 (denoting the mature strand of miR-122-5p) was first identified in various mouse 
tissue samples and was found to be highly-enriched in the liver (Lagos-Quintana et al., 
2002). Its seed sequence was then subsequently demonstrated to be highly conserved in 
many species (Chang et al., 2004), and are currently detected in 30 species (miRBase 21, 
accessed 22 August 2014). miR-122 has since been shown to be highly enriched and 
abundant in adult and foetal liver as well (Liu et al., 2009;  Sempere et al., 2004).  
 
1.5.3.1  The role of miR-122 in the liver 
The human miR-122 genomic locus is situated on chromosome 18 in a non-coding RNA 
exon (Jopling, 2012), with a highly conserved core promoter region containing the target site 
for the liver-enriched transcription factor, hepatic nuclear factor 4 alpha, which positively-
regulates its expression and involvement in hepatic differentiation (Laudadio et al., 2012;  Li 
et al., 2011). miR-122 have been shown to play a major role in maintaining homeostasis of 
hepatic cholesterol and lipid metabolism through studies which involved inhibition of miR-122 
using antisense oligonucleotides, although the exact pathways involved have not yet been 
delineated (Esau et al., 2006;  Krutzfeldt et al., 2005). miR-122 has also been shown to 
regulate iron homeostasis in mice via translational repression of the activators of hepcidin – 
a major regulatory hormone (Castoldi et al., 2011;  Rossi, 2005). It also appears to be a 
tumour suppressor gene as miR-122 levels were found to be reduced in human 
hepatocellular carcinoma (HCC) compared to normal liver (Kutay et al., 2006), while 
overexpression of miR-122 in HCC cell lines reduced their tumorigenic properties (Bai et al., 
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2009), and sensitised their responses to chemotherapeutic agents (Bai, et al., 2009;  Fornari 
et al., 2009).   
 
1.5.3.2  miR-122 as a biomarker of DILI 
Previous studies have also documented the presence of miRs in various forms in the plasma 
and other bodily fluids (Weber et al., 2010), although the processes underlying their release 
from the intracellular compartment and postulations regarding their role in extracellular 
communication between tissues and organs remain unclear (Szabo and Bala, 2013). Due to 
their stability in the serum and plasma (Szabo and Bala, 2013), circulating miRs are seen as 
attractive biomarkers of various diseases; including the notion of miR-122 as a potential 
marker of liver injury in general. Increased plasma/serum levels of miR-122 have been found 
in patients with liver diseases of different aetiologies, including chronic viral hepatitis C, 
hepatocellular carcinoma and non-alcoholic fatty liver disease (Cermelli et al., 2011;  Xu et 
al., 2011).  
Several studies have also demonstrated the value of circulating miR-122 as a hepatocyte-
specific biomarker of DILI in rodents and humans caused by drugs such as acetaminophen 
and heparin (Antoine et al., 2013;  Harrill et al., 2012;  Starkey Lewis et al., 2011;  Wang et 
al., 2009). The decrease in the level of miR-122 in the livers of mice administered toxic 
doses of acetaminophen (Wang, et al., 2009), added to the presumption that the liver-
enriched miR-122 was released from injured hepatocytes into the circulation, although exact 
mechanisms have yet to be reported. Additionally, as miR-122 is highly conserved across 
many species (Chang, et al., 2004), it has the potential to be used in pharmaco-toxicology 
studies as a relevant and liver-specific biomarker for extrapolation of in vivo findings from 
animal models to humans.  
Similarly, a hepatocyte-specific biomarker of hepatocyte perturbation for in vitro pharmaco-
toxicology studies that could be used to bridge in vivo and clinical studies would be 
  Chapter 1 
18 
 
invaluable. Therefore, in Chapter 4 of this thesis, we describe our evaluation of miR-122 as a 
hepatocyte-enriched in vitro marker of drug-induced hepatotoxicity using the prototypical 
hepatotoxicants acetaminophen and diclofenac. 
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Figure 1.4 Biogenesis of microRNAs. 
The microRNA (miR) gene is first transcribed by RNA polymerase II into a pri-miR stem-loop 
structure, which is then processed into a shorter precursor-miR (pre-miR) via both canonical 
and non-canonical pathways. The pre-miR molecule is then exported into the cytoplasm 
where it is further processed by Dicer into miR duplexes. The mature miR strand is then 
loaded together with Argonaute 2 (AGO2) proteins into RNA-induced silencing complexes 
(RISCs) which then bind to their target messenger RNAs causing gene silencing. The 
passenger strand meanwhile undergoes degradation. 
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1.6  AIMS OF THESIS 
Relevant and functional human hepatic models are urgently required for the mechanistic 
study and prediction of drug-induced liver injury. hiPSC-derived HLCs represent an exciting 
hepatic model with a unique potential to capture the inherent genetic polymorphisms present 
in the population for the purposes of pharmaco-toxicology evaluations. However, the 
functional limitation of HLCs remains a hindrance despite great strides being made in 
refining differentiation protocols. One potential approach to increase the functional capacity 
of HLCs is by harnessing the epigenetic memory in hiPSCs of its cell-type of origin, although 
its contribution in the propensity for hepatic differentiation of hiPSCs has not been evaluated 
fully so far.  
At the same time, understanding the process of dedifferentiation of hPHs, may help to 
enhance its functional lifespan for toxicology studies, especially in chronic toxicity of which 
there are currently no suitable models. As miR expression patterns capture a huge amount 
of biological information with potential for manipulation, studying the changing miR profile of 
hPHs may provide novel insights to reverse or prevent the detrimental process, with 
concomitant utility to enhance hepatic differentiation from hPSCs.     
On the other hand, improving the translatability of results from pre-clinical studies to the 
human cohort and vice versa, would be immensely useful for the study of DILI. One way of 
doing so would be the use of cell-type specific biomarkers in in vitro assays, as opposed to 
generic cellular markers e.g. adenosine triphosphate (ATP), used in most conventional in 
vitro toxicity assays which have limited potential to bridge in vitro and in vivo findings. miR-
122 which is also highly expressed in the liver of other species commonly used in in vivo 
studies is one example.  
Therefore, this thesis will set about addressing the following hypotheses in relation to the 
issues explained above: 
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Hypothesis 1 
 HLCs generated from hPH-derived hiPSCs display a closer resemblance to the hPH 
phenotype compared to HLCs generated from isogenic human dermal fibroblast-derived 
hiPSCs. 
 
Hypothesis 2 
 Novel insights into the process of hPH dedifferentiation can be gained by investigating 
the changing global miR profiles of hPHs in extended in vitro culture. 
 
Hypothesis 3 
 miR-122 can be utilised as a relevant in vitro marker of drug-induced hepatotoxicity in 
hepatic models expressing high levels of miR-122 
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PHENOTYPIC COMPARISON OF ISOGENIC HEPATOCYTE-LIKE 
CELLS GENERATED FROM HEPATOCYTE- AND FIBROBLAST-
DERIVED HUMAN IPSCS 
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2.1 INTRODUCTION 
Drug-induced liver injury (DILI) in humans persists as a significant cause of patient morbidity 
and mortality, and unpredicted hepatotoxicity during drug development continues to be a 
major problem for the pharmaceutical industry and the regulatory authorities (Davies et al., 
2010;  Olsen and Whalen, 2009). Due to a lack of alternative in vitro hepatic models, human 
primary hepatocytes (hPHs) remain the most relevant and the most metabolically active in 
vitro model, although a myriad of issues limit their application in the in vitro study of drug-
induced toxicity and safety screening – most notably their limited availability, large donor 
variations and their limited preservation of their functional capabilities (Godoy et al., 2013;  
Rodriguez-Antona et al., 2002;  Rowe et al., 2010;  Sison-Young et al., 2012).  
A potentially new hepatic model and an inexhaustible source of metabolically competent 
cells for the use in drug screening and the mechanistic study of DILI, is hepatocytes 
generated from human pluripotent stem cells (hPSCs), typically called hepatocyte-like cells 
(HLCs) (Baxter et al., 2010). The generation of HLCs from both human embryonic stem cells 
and human induced pluripotent stem cells (hiPSCs) have been reported using multiple 
hepatic differentiation protocols which mimic the process of hepatogenesis during human 
embryonic development (Rashid et al., 2010;  Sullivan et al., 2010;  Szkolnicka et al., 2014). 
However, the reported hepatic differentiation efficiencies in various studies were widely 
variable and the functional phenotype of HLCs in general remains limited in comparison with 
the gold standard in vitro hepatic model of hPH (Kia et al., 2013).  
This may be partially due to the variations in the differentiation propensity of hPSCs towards 
certain lineages (Bock et al., 2011;  Osafune et al., 2008;  Ramos-Mejia et al., 2010), and 
the differences in turn potentially contributed by a myriad of factors. These include the 
heterogeneous genetic background of the donors, the differences in culture conditions, and 
variations in the methods for hiPSC generation (Kajiwara et al., 2012).  
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In recent years, various studies have also shown that iPSCs retain transient epigenetic 
memories of the donor cells despite cellular reprogramming, with a resultant skewed 
propensity to differentiate towards the cell-type of origin (Kim et al., 2010;  Kim et al., 2011;  
Polo et al., 2010). The potential translational importance of these findings were then 
highlighted in a study where human iPSCs derived from pancreatic beta-cells were shown to 
have a greater propensity to differentiate back towards beta-cells when compared to 
isogenic hiPSCs derived from non-beta-cells (Bar-Nur et al., 2011).  
However, the contribution of epigenetic memory in the differentiation of hiPSCs towards 
HLCs has only been partially explored. In a mouse study, HLCs generated from mouse 
iPSCs (miPSCs) derived from hepatoblasts and hepatocytes possess a more functional 
hepatic phenotype compared to HLCs generated from isogenic foetal fibroblast-derived 
miPSCs (Lee et al., 2012), though these findings have yet to be replicated in human studies. 
Another study of human donors compared the functional phenotype of HLCs generated from 
hiPSCs derived from cell-types from all three germ layers, including hPH-derived hiPSCs, 
and found their albumin secretion capacity and cytochrome-P450 enzyme activities to be 
similar (Liu et al., 2011). However, in this study all the hiPSC lines were from different 
donors, hence the influence of genetic background was a confounding factor that was not 
controlled. Another study which did compare the functional phenotype of HLCs generated 
from isogenic hiPSC lines however did not include hPH-derived hiPSCs (Kajiwara, et al., 
2012). The paucity of studies of hepatic differentiation involving hPH-derived hiPSCs is likely 
to be related to the fact that only two reports from separate laboratories (Hansel et al., 2014;  
Liu et al., 2010) that have reported successful derivation of hiPSCs from hPHs, including the 
group that published the first study described above (Liu, et al., 2010).  
Therefore in this chapter, we aimed to investigate the hypothesis that HLCs generated from 
hPH-derived hiPSCs have a better hepatic differentiation capacity compared to HLCs 
generated from isogenic non-hPH-derived hiPSCs. To explore the contribution of epigenetic 
memory of the cell-type of origin in hiPSCs with minimal confounding factors, we used 
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genetically-matched hPHs and human dermal fibroblasts (hDFs) from the same adult 
donors. We derived hiPSCs from these starting cell types using the same reprogramming 
method and subsequently generated HLCs from them using the same differentiation protocol 
for comparison. Our comparison of HLCs generated from 1 clone of hPH-derived hiPSC 
against 3 clones of hDF-derived hiPSCs is described here. 
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2.2 MATERIALS AND METHODS 
2.2.1 Human subjects and tissue 
Human liver resections from surgical waste tissue were obtained from adult patients 
undergoing hepatobiliary surgery. For each donor, a full-thickness elliptical skin excision 
measuring about 1 – 2 cm in maximum length was also obtained by our surgical colleagues 
from the abdomen along the edge of the laparotomy incision undertaken for the hepatobiliary 
surgery. All tissue collection was undertaken with full informed consent and ethical approval 
from the relevant institutional review boards (National Research Ethics Service REC 
reference: 11/NW/0327). 
 
2.2.2 Human primary hepatocyte isolation and culture 
Human primary hepatocytes (hPHs) were isolated using a previously described method with 
minor modifications (LeCluyse et al., 2005). Briefly, liver resections were received as 
surgical waste tissue immediately post-resection (Aintree University Hospital, Liverpool, 
United Kingdom) and transferred on ice in N-(2-Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES) buffer (10 mM HEPES, 136 mM NaCl, 5 mM KCl, 0.5% (w/v) 
glucose, pH 7.6) to the laboratory. The liver resection specimens were then perfused with 
HEPES-buffered saline (HBS) followed by digestion with collagenase A (Roche) or 
collagenase IV (Sigma-Aldrich) in HBS containing calcium. The suspension containing 
isolated hepatocytes was then filtered through a nylon gauze and purified by centrifugation 
twice at 80x g for 5 minutes at 4oC, before the pellet was resuspended in an appropriate 
medium. 
hPHs used for reprogramming into hiPSCs were resuspended in Williams E medium (WEM, 
Sigma-Aldrich) containing 10-7 M dexamethasone (Sigma-Aldrich), 5% (v/v) foetal bovine 
serum (FBS, Life Technologies), 2 mM L-glutamine (Sigma-Aldrich), 15 mM HEPES solution 
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(Sigma-Aldrich), 0.4% (v/v) insulin-transferrin-selenium (from 100x stock, Life Technologies), 
1% (v/v) penicillin-streptomycin (Sigma-Aldrich), 50 ng/mL hepatocyte growth factor (HGF, 
PeproTech) and 50 ng/mL epidermal growth factor (EGF, PeproTech) before being seeded 
onto a Matrigel (hESC-Qualified matrix, Corning) -coated 6-well plate (Greiner Bio-One) and 
cultured at 5% CO2 and 37°C. hPHs used as control were resuspended in WEM 
supplemented with 1% (v/v) insulin-transferrin-selenium, 2 mM L-glutamine, 10-7 M 
dexamethasone and 1% (v/v) penicillin-streptomycin and seeded onto a collagen-I coated 
24-well plate (BD Beckinson) and cultured at 5% CO2 and 37°C.  
After 3 hours, non-attached cells were washed away and replaced with fresh medium before 
overnight incubation. The medium was replaced again the next day, and lysates and media 
for the control hPHs collected for analysis 48 hours later.   
 
2.2.3 Propagation of human dermal fibroblasts (hDFs) 
hDFs were established from the skin excisions of donors based on published methods with 
some minor modifications (Aasen and Izpisua Belmonte, 2010;  Neely et al., 2011). Briefly, 
following excision, the skin tissue was received immediately (Aintree University Hospital, 
Liverpool, United Kingdom) and transferred on ice in a 50 mL centrifuge tube (Greiner Bio-
One) containing 15 mL of Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) 
supplemented with 2 mM L-glutamine (Sigma-Aldrich), 10% (v/v) foetal bovine serum (FBS; 
Life Technologies) and 1% (v/v) penicillin-streptomycin (Sigma-Aldrich).  
The skin excisions were then transferred to a cell culture hood and rinsed with complete 
DMEM before separating the epidermis from the dermal layer using a scalpel (Fisher 
Scientific) and/or sterile scissors (Fisher Scientific). The dermis was then cut into 0.5 – 1.0 
mm pieces and a maximum of 3 pieces placed directly into a single well of a 6-well tissue 
culture plate (Corning) using tweezers. A few drops of complete DMEM were placed onto 
each piece of dermal tissue, making sure that there was adequate contact with the surface 
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of the culture well. The dermal tissue pieces were then incubated overnight at 5% CO2 and 
37°C. For the next 2-3 days, the media was carefully replaced with new drops of complete 
DMEM daily to ensure that they did not dry out completely. When the dermal tissue pieces 
have attached to the surface of the culture well, the total volume of complete DMEM was 
gradually increased from 500 μL/well to 2 ml/well. The medium was replaced every 2-3 days 
and unattached pieces were removed.  
After 7-10 days of placing the dermal tissues into the tissue culture well, outgrowths of 
fibroblasts appeared and the culture expanded for a further 7-10 days until a confluency of 
about 80% was reached. The fibroblasts were then rinsed twice with Dulbecco's Phosphate 
Buffered Saline (DPBS, Life Technologies) and then incubated with 500 μL of 0.05% trypsin-
EDTA solution (Life Technologies) at 37°C for 3-5 minutes. The trypsinisation process was 
then stopped with complete DMEM and the detached fibroblasts collected into a 15 ml 
centrifuge tube (Greiner Bio-One) before centrifugation at 1000 rpm for 5 minutes at room 
temperature. The cell pellet was then resuspended and the fibroblast culture from each well 
of a 6-well plate passaged onto a 100 mm tissue culture dish (Greiner Bio-One) for 
expansion. 
 
2.2.4 Derivation of hiPSCs from human primary hepatocytes 
Following plating of the hPHs onto Matrigel (hESC-Qualified matrix, Corning) –coated tissue 
culture wells, the hPHs were cultured for 3 days in WEM (Sigma-Aldrich) containing 10-7 M 
dexamethasone (Sigma-Aldrich), 5% (v/v) FBS (Life Technologies), 2 mM L-glutamine 
(Sigma-Aldrich), 15 mM HEPES solution (Sigma-Aldrich), 0.4% (v/v) insulin-transferrin-
selenium (from 100x stock, Life Technologies), 1% (v/v) penicillin-streptomycin (Sigma-
Aldrich), 50 ng/mL HGF (PeproTech) and 50 ng/mL EGF (PeproTech), which was replaced 
daily. This medium composition, termed as the hPH reprogramming medium, and the 
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following hPH reprogramming protocol was adapted and modified based on a previously 
reported protocol of hiPSC generation from hPHs (Liu, et al., 2010) (Figure 2.2) .  
After 3 days post-seeding (designated Day 0), the hPHs were transduced with the 
CytoTune-iPS Sendai Reprogramming Kit (Life Technologies) containing four Sendai viral-
based reprogramming vectors, each expressing one of the four Yamanaka factors (i.e. Oct4, 
Sox2, Klf4, and c-Myc) (Fusaki et al., 2009) at a multiplicity of infection (MOI) of 3 to 7, in 
WEM. After 24 hours of transduction, the medium was replaced daily with fresh hPH 
reprogramming medium until Day 3 post-transduction when the medium was replaced with 
Essential 6 (E6, Life Technologies) medium supplemented with 100 ng/mL of recombinant 
basic fibroblast growth factor (bFGF, Life Technologies). The E6 medium was then replaced 
daily and the culture closely monitored for the appearance of hiPSC colonies, typically 
around Day 25-30.  
 
2.2.4.1  Manual passaging of hPH-derived hiPSC colonies 
When the colonies were ready to be transferred, the colonies were manually picked with the 
aid of a light microscope (EVOS XL Core Cell Imaging System, Life Technologies) in the cell 
culture hood. Each colony was then cut into 8-10 pieces in a grid-like pattern using a 
disposable surgical blade (Swann-Morton), and the pieces from a single colony transferred 
using a 100 μL pipette to a well of a 24-well plate (Greiner Bio-One) prepared with 
mitotically-inactivated murine embryonic fibroblast (MEFs, CF-1 strain, GlobalStem) 
containing Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12, Life 
Technologies) supplemented with 20% (v/v) KnockOut Serum Replacement (KOSR, Life 
Technologies), 100 μM minimum essential medium non-essential amino acids (MEM NEAA, 
Life Technologies), 50 μM 2-mercaptoethanol (2-ME, Life Technologies), 4 ng/ μL bFGF 
(Life Technologies) and 0.5% (v/v) penicillin-streptomycin (Life Technologies). The MEF 
culture plate containing the picked colonies was then incubated overnight at 37°C to allow 
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attachment before replacing the medium daily with fresh complete DMEM/F12 medium. The 
reprogrammed colonies were then expanded and maintained as described in Section 2.2.6. 
 
2.2.5 Derivation of hiPSCs from human dermal fibroblasts 
The reprogramming of human dermal fibroblasts (hDFs) was performed using the CytoTune-
iPS Sendai Reprogramming Kit (Life Technologies) as per protocol. Briefly, hDFs at passage 
5 or less were plated onto a 6-well plate (Corning) and cultured for 48 hours in DMEM (Life 
Technologies) supplemented with 2 mM L-glutamine (Sigma-Aldrich), 10% (v/v) FBS 
(embryonic stem cell-qualified, Life Technologies) and 0.5% (v/v) penicillin-streptomycin (Life 
Technologies), aiming for a confluency of 80-90% and ensuring the fibroblasts have 
extended and adhered. On the day of transduction (Day 0), each well containing hDFs was 
transduced with the CytoTune-iPS Sendai Reprogramming Kit (Life Technologies) 
containing the four Sendai viral-based reprogramming vectors at a MOI of 3 to 5 in fresh 
complete DMEM. After 24 hours of viral transduction, the medium was replaced with fresh 
complete DMEM and the culture continued until Day 7 with a medium change every other 
day. The transduced fibroblasts were then trypsinised with 0.05% trypsin-EDTA (Life 
Technologies) as described in Section 2.2.3 and centrifuged at 200x g for 5 minutes. The 
cell pellet was then resuspended with fresh complete DMEM and the cell concentration 
determined using a haemocytometer. The derivation of hiPSCs from the transduced 
fibroblasts was then continued using either a feeder-dependent method or a feeder-free 
method.  
 
2.2.5.1  Feeder-dependent method of reprogramming hDFs 
For the feeder-dependent method, the transduced fibroblasts were seeded onto 100 mm 
tissue culture dishes (Greiner Bio-One) prepared with MEFs (CF-1 strain, GlobalStem) at 
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densities of 5 x 104 – 2 x 105 cells/dish and incubated at 37°C for 24 hours. At Day 8, the 
medium was then replaced with DMEM/F12 (Life Technologies) supplemented with 20% 
(v/v) KnockOut Serum Replacement (KOSR, Life Technologies), 100 μM MEM NEAA (Life 
Technologies), 100 μM 2-ME (Life Technologies), 4 ng/ μL bFGF (Life Technologies) and 
0.5% (v/v) penicillin-streptomycin (Life Technologies). The medium was then replaced daily 
and the culture closely monitored for the appearance of hiPSC colonies, typically at Day 20-
25. Colonies that were ready for transfer were manually picked as described in Section 
2.2.4.1 onto 24-well plates coated with MEFs for further expansion.  
 
2.2.5.2  Feeder-free method of reprogramming hDFs 
For the feeder-free method, the transduced fibroblasts were seeded onto a 6-well plate 
(Corning) coated with Matrigel (hESC-Qualified matrix, Corning) at densities of 2.5 x 104 - 5 
x 105 cells/well and incubated at 37°C for 24 hours. At Day 8, the medium was then replaced 
with E6 medium (Life Technologies) supplemented with 100 ng/mL of bFGF (Life 
Technologies). The medium was then replaced daily and the culture closely monitored for 
the appearance of hiPSC colonies, typically at Day 25-30. Colonies that were ready for 
transfer were manually picked as described in Section 2.2.4.1 onto 24-well plates (Corning)  
coated with Matrigel (Corning) in Essential 8 medium (E8, Life Technologies) for further 
expansion. 
 
2.2.6 Human induced pluripotent stem cell culture 
2.2.6.1   Maintenance matrices and media for hiPSCs 
The hiPSC lines were maintained on either MEFs (CF-1 strain, GlobalStem) in DMEM/F12 
(Life Technologies) supplemented with 20% (v/v) KnockOut Serum Replacement (KOSR, 
Life Technologies), 100 μM MEM NEAA (Life Technologies), 50 μM 2-ME (Life 
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Technologies), 4 ng/ μL bFGF (Life Technologies) and 0.5% (v/v) penicillin-streptomycin 
(Life Technologies), or on Matrigel (Corning) in E8 medium (Life Technologies) 
supplemented with 0.5% (v/v) penicillin-streptomycin (Life Technologies).  
 
2.2.6.2  Enzyme-free passaging of hiPSCs 
All the hiPSC lines were passaged every 4-7 days at a ratio of 1:3 to 1:6 using an enzyme-
free Gentle Cell Dissociation Reagent (GCDR, STEMCELL Technologies) based on a 
previously described protocol (Chen et al., 2011). Briefly, for each well of a 6-well format 
tissue culture plate, the confluent culture was first washed gently with 1 ml of GCDR, before 
incubation with 1 mL of fresh GCDR for 2-5 minutes at room temperature. The culture was 
observed closely under a light microscope with phase contrast (100x magnification, 
ECLIPSE TS100/100-F, Nikon) for the appearance of junctions within colonies. At this point, 
the dissociation was stopped by removing the GCDR and adding 2 mL of the appropriate 
complete hPSC medium. The colonies were gently detached with a cell scraper (Greiner 
Bio-One), and the cell aggregates transferred to a 15 mL centrifuge tube (Greiner Bio-One). 
The mixture was gently pipetted to break up the aggregates to create a uniform suspension 
of aggregates of approximately 100 μm. The aggregate mixture was allowed to stand at 
room temperature for about 1 minute to separate out larger aggregates and the dense MEF 
feeder layer which would sink faster to the bottom of the centrifuge tube. The suspension 
containing aggregates with optimal size was then added to fresh matrix-coated wells in the 
appropriate passage ratio and incubated overnight at 37°C. Once attachment of the 
aggregates to the fresh matrix-coated well was confirmed, the medium was replaced with 
fresh complete hiPSC medium.  
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2.2.6.3  Preparation of MEF feeder layers 
MEF feeder layers were prepared by seeding mitotically-inactivated MEFs (CF-1 strain, 
GlobalStem) at the recommended density by the manufacturer, onto tissue culture vessels 
pre-coated with Attachment Factor (AF, Life Technologies) in DMEM (Life Technologies) 
supplemented with 15% (v/v) FBS (embryonic stem cell-qualified, Life Technologies), 2 mM 
L-glutamine (Life Technologies) and 1% (v/v) penicillin-streptomycin (Life Technologies). 
The MEFs were then incubated overnight at 37°C, and rinsed a few times with DPBS (Life 
Technologies) before use.  
 
2.2.7 Directed hepatic differentiation of hiPSCs 
The directed differentiation of all the hiPSC lines towards hepatocyte-like cells was 
performed using a common protocol adapted from a combination of previously published 
protocols (Kajiwara, et al., 2012;  Sullivan, et al., 2010;  Szkolnicka, et al., 2014). The 
directed differentiation protocol is summarised in Figure 1. All the hiPSCs used for directed 
differentiation towards hepatocyte-like cells (HLCs) were from feeder-free cultures 
maintained on Matrigel (Corning); hence hiPSC lines maintained on MEFs were first 
transitioned to feeder-free Matrigel matrix and maintained for at least 2 passages before 
being used for differentiation towards HLCs.  
 
Figure 2.1 Protocol for directed differentiation of hiPSCs towards HLCs using growth 
factors and small molecules. 
RPMI, Roswell Park Memorial Institute; AA, activin A; Wnt-3a, wingless-type MMTV 
integration site family, member 3A; KO-DMEM, KnockOut Dulbecco’s Modified Eagle’s 
Medium; DMSO, dimethyl sulfoxide; KOSR, KnockOut Serum Replacement; HGF, 
hepatocyte growth factor; OSM, oncostatin M; hiPSCs, human induced pluripotent stem 
cells; DE, definitive endoderm; HE, hepatic endoderm; HLCs, hepatocyte-like cells. 
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2.2.7.1  Induction of hiPSCs to definitive endoderm 
For the differentiation of the hiPSCs towards definitive endoderm (DE), the feeder-free 
hiPSC cultures were first dissociated into single cell suspensions by incubating the cultures 
with Accutase (Life Technologies) at 37oC for 2-5 minutes. Once detachment of the hiPSCs 
was observed, the dissociation reaction was stopped by diluting the Accutase with complete 
E8 medium (Life Technologies) and dissociated into single cells by pipetting. The cell 
concentration of the suspension was determined using a haemocytometer, centrifuged at 
200x g for 4 minutes at room temperature, and resuspended with Roswell Park Memorial 
Institute (RPMI, Life Technologies) medium supplemented with 1% (v/v) B27 (from 50x 
stock, Life Technologies), 0.5% (v/v) penicillin-streptomycin (Life Technologies), 100 ng/mL 
activin A (AA, R&D Systems) and 50 ng/mL Wnt-3a (R&D Systems) and 10 μM of the 
selective inhibitor of Rho-associated protein kinase, InSolution Y-27632 (Merck Millipore). 
The hiPSCs were then seeded onto Matrigel (Corning) at a density of 2.5 x105 cells/cm2 and 
incubated overnight at 37°C. The medium was then replaced on the first day of 
differentiation (designated Day 0) with RPMI medium supplemented with 1% (v/v) B27, 0.5% 
(v/v) penicillin-streptomycin, 100 ng/mL AA and 50 ng/mL Wnt-3a for 72 hours, followed by a 
further 48 hours of the same medium composition but without Wnt-3a. The medium was 
replaced daily for this stage.  
 
2.2.7.2  Specification of DE to hepatic endoderm (HE) 
Hepatic specification was then carried out for seven days in KnockOut DMEM (Life 
Technologies) supplemented with 20% (v/v) KnockOut Serum Replacement (KOSR, Life 
Technologies), 1 mM L-glutamine (Sigma-Aldrich), 100 μM MEM NEAA (Life Technologies), 
200 μM beta-ME (Life Technologies), 1% (v/v) dimethyl sulfoxide (DMSO, Fisher Scientific) 
and 0.5% (v/v) penicillin-streptomycin (Life Technologies), which was changed every two 
days.  
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2.2.7.3  Maturation of HE to hepatocyte-like cells (HLCs) 
To allow for maturation, HLCs were cultured for a further seven days in Hepatozyme-SFM 
medium (Life Technologies) supplemented with 0.5% (v/v) penicillin-streptomycin (Life 
Technologies), 2 mM L-glutamine (Sigma-Aldrich), 10-7 M dexamethasone (Sigma-Aldrich), 
20 ng/mL oncostatin M (OSM, PeproTech) and 20 ng/mL hepatocyte growth factor (HGF, 
PeproTech), which was changed every two days. Cells were lysed at Days 5, 12 and 22 of 
differentiation in 700 μL of QIAzol (Qiagen) as per manufacturer’s instructions before being 
stored at -80°C.  
 
2.2.8 Embryoid body formation and spontaneous differentiation into cells of three 
germ layers 
For the embryoid formation assay, the hiPSC colonies were first dissociated using GCDR 
(STEMCELL Technologies) as described in Section 2.2.6, and the cell aggregates seeded 
on non-tissue culture treated plates (Corning) at a passaging ratio of 2:1 in differentiation 
medium consisting of DMEM/F12 (Life Technologies) supplemented with 20% (v/v) KOSR 
(Life Technologies), 2 mM L-glutamine (Sigma-Aldrich), 100 μM MEM NEAA (Life 
Technologies), 100 μM 2-ME (Life Technologies) and 0.5% (v/v) penicillin-streptomycin (Life 
Technologies). 50% of the medium was replaced with fresh medium every two days. After 
seven days, the embryoid bodies (EBs) were collected and transferred to tissue culture 
treated plates coated with 0.1% AF (Life Technologies) and cultured for another 5-7 days 
with the medium changed every two days before the cells were fixed for indirect 
immunocytochemistry analysis. Some embryoid bodies were also lysed in 700 μL of QIAzol 
(Qiagen) as per manufacturer’s instructions before being stored at -80°C.  
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2.2.9 Immunocytochemistry 
2.2.9.1  Indirect immunocytochemistry 
For indirect immunocytochemistry analysis, cells were fixed in 4% (w/v) paraformaldehyde 
(Sigma-Aldrich) for 10 minutes at room temperature followed by repeated washes in 
Dulbecco's Phosphate Buffered Saline (DPBS, with magnesium chloride and calcium 
chloride, Life Technologies). The fixed cells were then incubated in DPBS (Life 
Technologies) containing 10% (v/v) donkey serum (Sigma-Aldrich) and 0.1% (v/v) Triton X-
100 (Sigma-Aldrich) for 30 minutes followed by overnight incubation with the relevant 
primary antibody at 4°C. After three washes in DPBS (Life Technologies), the fixed cells 
were incubated with the appropriate secondary antibody for 2 hours in the dark, at room 
temperature, before the cells were washed three times again with DPBS. The cells were 
then incubated with Hoechst 33342 (1:7500, from stock solution of 1 mg/ml, Sigma–Aldrich) 
for 15 minutes at room temperature before further washes with DPBS. Primary and 
secondary antibodies were diluted in DPBS (Life Technologies) containing 10% (v/v) donkey 
serum (Sigma-Aldrich) and 0.1% (v/v) TritonX-100 (Sigma-Aldrich), which was then 
centrifuged at 13000 rpm for 6 minutes at room temperature. The following primary and 
secondary antibodies were used: rabbit anti-Oct4 (1:100, ab18976, Abcam), rabbit anti-Sox2 
(1:100, ab75627, Abcam), rabbit anti-Nanog (1:200, ab21624, Abcam), rabbit anti-albumin 
(1:20, ab135575, Abcam), rabbit anti-alpha smooth muscle actin (1:100, ab5694, Abcam), 
rabbit anti-beta-III tubulin (1:500, ab18207, Abcam), rabbit anti-alpha fetoprotein (1:100, 
A0008, Dako), goat anti-Sox17 (1:20, AF1924, R&D Systems), rabbit anti-HNF-4α (1:50, sc-
8987, Santa Cruz Biotechnology), donkey Alexa Fluor 488-anti-rabbit IgG (1:1000, A-21206, 
Life Technologies) and donkey Alexa Fluor 568-anti-goat IgG (1:1000, A-11057, Life 
Technologies). Technical control stainings without primary antibodies were performed for all 
indirect immunocytochemical stainings (data not shown).  
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2.2.9.2  Direct immunocytochemistry 
For direct immunocytochemistry analysis, the fixed cells were incubated with conjugated 
primary antibodies diluted in DPBS (Sigma-Aldrich) for 90 minutes at 37°C before repeated 
washes with DMEM/F12. The cells were then incubated with Hoechst 33342 (1:7500, from 
stock solution of 1 mg/ml, Sigma–Aldrich) for 15 minutes at 37°C before further washes with 
DMEM/F12. The following conjugated primary antibodies were used: Alexa Fluor 488-anti-
TRA-1-60 (1:10, 560173, BD Biosciences) and Alexa Fluor 555-anti-SSEA-4 (1:10, 560218, 
BD Biosciences).  
The immunocytochemical stainings were analysed using a fluorescence microscope (Axio 
Observer.Z1, Carl Zeiss), a digital camera (AxioCam MR, Carl Zeiss) and corresponding 
software (ZEN, Carl Zeiss).  
 
2.2.10 Flow cytometry 
For flow cytometric analysis of albumin-positive cells in hPH cultures, the hPHs were first 
dissociated into a cell suspension using TrypLE Select Enzyme (Life Technologies) as per 
manufacturer’s protocol. The cells were then fixed and permeabilised using the 
Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) as per 
manufacturer’s protocol, before being labelled with rabbit anti-albumin (1:20, ab135575, 
Abcam) in a volume of 100 μL on ice for 30 minutes. The cell was then pelleted and labelled 
with donkey Alexa Fluor 488-anti-rabbit IgG (1:2000, A-21206, Life Technologies) on ice for 
20 minutes. A minimum of 10000 cells were analysed by flow cytometry using the BD 
FACSCanto II (BD Biosciences) cell analyser and the data analysed using Cyflogic (CyFlo). 
Technical controls using unlabelled hPHs and hPHs labelled with the secondary antibody 
only were also used. The technical assistance of Dr. Lee Faulkner (University of Liverpool) 
with the flow cytometric analysis is gratefully acknowledged.  
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2.2.11 Real-time quantitative RT-PCR (qRT-PCR) 
2.2.11.1  Purification of total RNA 
The purification of total RNA from cellular lysates was performed using the miRNeasy mini 
kit (Qiagen), as per the manufacturer's instructions. Briefly, each lysate was thawed at room 
temperature and thoroughly mixed before the addition of 140 μL of chloroform. The samples 
were then mixed vigorously for 15 seconds and left at room temperature for 3 minutes. The 
homogenates were then centrifuged at 12000x g for 15 minutes at 4°C. 350 μL of the upper 
aqueous phase and 525 μL of 100% ethanol were then mixed thoroughly in a new collection 
tube before transferring to a miRNeasy Mini spin column. The column was then sequentially 
centrifuged and washed with supplied buffers at room temperature, before the column was 
placed into a new collection tube. 30 μL of RNase-free water was then added directly onto 
the column membrane and centrifuged for 1 minute at 10000x g to elute the total RNA which 
also contained the small RNA fraction. Quantification and the quality of the total RNA 
extracts was then analysed using the NanoDrop spectrophotometer (Thermo Scientific).  
 
2.2.11.2  Gene expression analysis 
For the analysis of mRNA expression, first strand complementary DNA (cDNA) was 
synthesized from equal amounts of total RNA with ImProm-II Reverse Transcription System 
(Promega) as per manufacturer’s instructions. Briefly, a total RNA and primer mixture was 
first prepared as instructed in a total volume of 25 μL and incubated for 5 minutes at 70°C 
before being chilled on ice for at least 5 minutes. A reverse transcription (RT) reaction 
mixture was then prepared as instructed and added to the 25 μL of the total RNA and primer 
mixture for complementary DNA (cDNA) synthesis in a total volume of 50 μL, before being 
heated sequentially in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) 
for 5 minutes at 25°C, 60 minutes at 42°C and 15 minutes at 70°C. The cDNA was then 
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chilled at 4°C before storage at -20°C or proceeding to real-time quantitative RT-PCR (qRT-
PCR) which was performed using SYBRGreen JumpStart Taq ReadyMix (Sigma-Aldrich) as 
per manufacturer’s instructions. Briefly, 5 μL of cDNA was mixed with a PCR mixture 
containing 10 μM of PCR primers in a total volume of 25 μL. PCR amplification was then 
performed in duplicates with the ABI Prism 7000 or ViiA 7 Real-Time PCR instruments 
(Applied Biosystems) using a 2-step thermal cycling protocol of 95°C for 10 minutes followed 
by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Ct values were determined 
using the fluorescent signal produced from the SYBR Green I dye. The gene expression was 
normalized against the reference gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), and fold changes were calculated using a calibrator sample using the relative 
quantification method. 
 
2.2.11.4  Design of real-time qRT-PCR primers 
Primers for real-time qRT-PCR analysis of mRNA expression were designed using Primer-
BLAST with their default parameters (Ye et al., 2012). The mRNA targets were based on the 
latest NCBI RefSeq annotations and the specificity of primers checked against the RefSeq 
human mRNA database. All the designed primers span an exon-exon junction to exclude the 
possibility of genomic DNA amplification. The primers were also assessed for the likelihood 
for self-complementarity, hairpin and primer-dimer formations using OligoCalc (Kibbe, 2007). 
The primer sequences used for qRT-PCR analysis of mRNA expression reported in this 
chapter are listed in Table 1.  
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Table 1.1 Primer sequences for real-time qRT-PCR.  
For gene name abbreviations, please see http://www.ncbi.nlm.nih.gov/gene/. Commonly 
known aliases are listed in parentheses. 
 
Gene 
 
 
Real-time 
qRT-PCR primers 
 
 
Sequence (5’ – 3’) 
 
   
ALB ALB mRNA-F CCTGTTGCCAAAGCTCGATG 
 ALB mRNA-R ATCTCCATGGCAGCATTCCG 
   
SERPINA1 
(A1AT) 
A1AT mRNA-F TCCGATAACTGGGGTGACCT 
A1AT mRNA-R AGACGGCATTGTCGATTCACT 
   
CYP3A4 CYP3A4 mRNA-F AGAAATCTGAGGCGGGAAGC 
 CYP3A4 mRNA-R GGAATGGAAAGACTGTTATTGAGAG 
   
KRT18 
(CK18) 
CK18 mRNA-F ACATCCGGGCCCAATATGAC 
CK18 mRNA-R GGTGCTCTCCTCAATCTGCT 
   
GAPDH GAPDH mRNA-F CTATAAATTGAGCCCGCAGCC 
 GAPDH mRNA-R GCCCAATACGACCAAATCCGT 
   
HNF4A HNF4A mRNA-F GTTGACGATGGGCAATGACAC 
 HNF4A mRNA-R TCTTTGTCCACCACGCACTG 
   
AFP AFP mRNA-F GCGGCCTCTTCCAGAAACTA 
 AFP mRNA-R AATAATGTCAGCCGCTCCCT 
   
SOX17 SOX17 mRNA-F GGATACGCCAGTGACGACCA 
 SOX17 mRNA-R GACTTGCCCAGCATCTTGCTC 
   
NANOG NANOG mRNA-F GGCTCTGTTTTGCTATATCCCCTAAA 
 NANOG mRNA-R CATTACGATGCAGCAAATACGAGA 
   
 
 
2.2.12  Enzyme-linked immunosorbent assay (ELISA) for albumin detection 
For the measurement of albumin secretion, the culture media of HLCs and hPHs were 
collected and stored at -80°C until further analysis using the Human Albumin ELISA 
Quantitation Set (Bethyl Laboratories) as per manufacturer’s protocol. Briefly, 96-well format 
plates were first coated with supplied goat anti-human albumin antibody and prepared 
according to instructions. A standard curve was also prepared using recommended dilutions 
of supplied human reference serum. Diluted media samples in a total volume of 100 μL were 
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then loaded in duplicates and incubated at room temperature for 1 hour. The plates were 
then washed five times with a wash buffer, and incubated with the supplied goat HRP-
conjugated anti-human albumin detection antibody for a further 1 hour. Following washes, 
the supplied 3,3′,5,5′-Tetramethylbenzidine (TMB) Substrate Solution was then added, and 
the colour enzymatic reaction allowed to develop at room temperature in the dark for 15 
minutes. The reaction was then stopped using 0.18M of sulphuric acid and its absorbance 
measured using the MRXe Microplate Reader (Dynex Technologies) at 450 nm. The albumin 
concentration in the samples was then estimated using values obtained from the prepared 
standard curve.   
 
2.2.13 Phase contrast microscopy 
Cell morphology was analysed by light microscopy using a phase contrast microscope 
(ECLIPSE TS100/100-F, Nikon), and photographs captured using a digital camera head 
(DS-Vi1, Nikon) and a stand-alone controller and display unit (DS-L3, Nikon). 
 
2.2.13 Statistical analysis 
For pairwise comparisons between HLCs generated from different hiPSC lines, the unpaired 
t-test was used. For all tests, p < 0.05 was considered significant. Statistical analyses were 
performed using GraphPad Prism 6 (GraphPad Software). 
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2.3  RESULTS 
2.3.1 Isogenic hiPSC lines were successfully derived from hepatocytes and 
fibroblasts using Sendai viral vectors encoding the Yamanaka pluripotency factors 
Corresponding sets of isogenic human iPSC lines (hiPSCs) were derived from human 
primary hepatocytes (hPHs) and human dermal fibroblasts (hDFs) originating from the same 
patients, using commercially-available Sendai episomal viral vectors encoding the 
Yamanaka pluripotency factors i.e. Oct4, Sox2, Klf4 and c-Myc (Fusaki, et al., 2009;  
Takahashi et al., 2007). The demographic and clinical details of the adult donor from which 
the tissues were obtained from are shown in Table 2.2 
 
Table 2.2 Demographic and clinical details of the adult donor of hPHs and hDFs 
 DONOR 1 DONOR 2 
Age at surgery 66 63 
   
BMI 27.9 31.2 
   
Sex Male Female 
   
Diagnosis Colorectal carcinoma  
with liver metastases 
Colorectal carcinoma  
with liver metastases 
   
Co-morbidity Type II diabetes mellitus Hypertension 
Chronic liver disease 
Type II diabetes mellitus 
   
 
 
2.3.1.1  Derivation of hiPSCs from adult human primary hepatocytes 
The reprogramming of hPHs from adult donors was performed using the protocol described 
in Section 2.2.4, and summarised in Figure 2.2. The purity of the hPH culture in terms of 
cells expressing the hepatic marker albumin was also assessed using cultures of hPHs 
isolated from both donors. Following plating of the hPHs and prior to the reprogramming of 
the culture at Day 0, the hPH cultures were analysed using immunocytochemical (n = 2 
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donors) and flow cytometric methods (n = 1 donor). Using immunocytochemistry, we 
estimated that >90% of the plated hPHs were positive for albumin, while flow cytometric 
quantification showed that 85.1% of the cells were positive (Figure 2.3). The cell viability of 
hPHs isolated from both donors was >80%. 
The morphology of the hPH culture in the medium containing hepatocyte growth factor 
(HGF) and epidermal growth factor (EGF) was also noted to change prior to reprogramming 
from its initial typical cuboidal shape with distinct borders to flattened cells with multiple 
projections (Figure 2.4A and 2.4B). Following transduction of the plated hPHs, the culture 
was monitored closely for the appearance of nascent hiPSC colonies with daily replacement 
of the medium. At Day 2, the morphology of the culture was noted to have changed further 
with the presence of apoptotic cells, presumably due to the SeV transduction, and also the 
presence of cells which were noted to be smaller than a typical hPH which has lost its 
distinct borders (Figure 2.5A and 2.5B). Whether these latter cells were transduced hPHs 
undergoing early reprogramming or hPHs merely transformed by the presence of SeV is 
unclear. The number of cells present in the culture continued to noticeably decrease until 
about Day 7, before the eventual emergence and expansion of homogenous colonies of 
epithelial-like cells (Figure 2.5C and 2.5D). By about Day 18, the morphology of some these 
homogenous colonies was also noted to change and distinct cells with a high ratio of 
nucleus to cytoplasm resembling human embryonic stem cells (hESCs), started to emerge 
within these homogeneous colonies (Figure 2.5E and 2.5F). Concomitantly, there were also 
colonies of cells resembling typical hESC-like colonies which appeared separate from the 
homogeneous colonies of flat small cells and typically appeared later during the 
reprogramming process (Figure 2.5G, 2.5H and 2.5I). hiPSC lines were successfully 
established from both types of colonies containing hESC-like cells. There were also 
numerous colonies which were non-hESC-like and most probably represent incompletely 
reprogrammed cells. Between Day 25 to Day 40, the hESC-like colonies of sufficient size 
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were then manually passaged separately onto either Matrigel-coated wells or MEF feeder 
layers for expansion.  
The manually picked colonies were then expanded as described in Section 2.2.6. However, 
only colonies which were plated onto MEF feeder layers were successfully established as 
hiPSC lines (Figure 2.6A and 2.6B). Details of successful hiPSC derivation from hPHs 
obtained from the 2 adult donors are shown in Table 2.3. 
Overall, from our experience of reprogramming hPHs (n = 4 separate donors of hPHs), we 
found that the optimal conditions required to successfully derive hiPSC lines include using a 
multiplicity of infection (MOI) of 5-7, avoiding the use of thawed SeV particles, the use of 
feeder layers to support picked colonies and using a starting cell density of at least 2 x105 
cells/well of a 6-well plate format to obtain adequate hESC-like colonies for isolation. 
 
 
 
 
Figure 2.2 Protocol of reprogramming hPHs into hiPSCs. 
WEM, Williams E medium; FBS, foetal bovine serum; HGF, hepatocyte growth factor; EGF, 
epidermal growth factor; E6, essential 6; bFGF, basic fibroblast growth factor; SeV, Sendai 
virus; hiPSC, human induced pluripotent stem cell. 
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Figure 2.3 Characterisation of the hPH cultures for ALB-positive cells  
Representative results for hPHs obtained from Donor 1: (A) Immunocytochemical analysis of 
ALB in combination with Hoescht 33342 (nuclear stain in blue) for hPHs at Day 0. 
Magnification: 200x; scale bar, 100 μm. (B) ALB expression of cells from the hPH culture at 
Day 0, analysed using flow cytometry. 
 
 
Figure 2.4 Morphological changes of the hPH culture before reprogramming. 
Phase contrast microscopy showing morphology of plated hPHs pre-transduction at (A) Day 
-3, and (B) Day 0. Magnification: 100x; scale bar, 100 μm. 
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Figure 2.5 Morphological changes of the hPH culture during reprogramming. 
Phase contrast microscopy showing morphology of plated hPHs at Day 2, imaged with 
magnification of (A) 40x; scale bar, 500 μm and (B) 100x; scale bar, 100 μm. Appearance of 
a typical homogeneous colony of small flat cells with high ratio of nucleus to cytoplasm at 
Day 13, imaged with magnification of (C) 40x; scale bar, 500 μm and (D) 100x; scale bar, 
100 μm. Typical morphology of hESC-like cells emerging within the homogenous colony of 
small cells observed at Day 23, imaged with magnification of (E) 40x; scale bar, 500 μm and 
(F) 100x; scale bar, 100 μm. A typical hESC-like colony observed at Day 36, imaged with 
magnification of (G) 40x; scale bar, 500 μm, (H) 100x; scale bar, 100 μm and (I) 200x; scale 
bar, 100 μm. hESC, human embryonic stem cell.
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Figure 2.6 Representative established hiPSC lines derived from hPHs of 2 different 
adult donors 
Phase contrast microscopy showing morphology of (A) Liv4HJ derived from hPHs of Donor 1 
and (B) Liv6HD derived from hPHs of Donor 2. Magnification: 100x; scale bar, 100 μm. 
 
 
 
Table 2.3 Details of hiPSC derivation from adult donors of hPHs.  
* Reprogramming efficiency for each donor-batch of hPH was calculated as: (number of 
hiPSC lines established/total number of hPHs seeded) x100%. 
     
Donor Number of  hPHs seeded 
hESC-like 
colonies picked 
hiPSC lines 
established 
Reprogramming 
efficiency (%)* 
     
     
1 2.0 x 105 8 1 0.0005 
2 4.0 x 105 7 5 0.00125 
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2.3.1.2  Derivation of hiPSCs from adult human dermal fibroblasts 
hDFs from the corresponding adult donors of hPHs were first propagated from the skin 
excisions (Figure 2.7) and reprogrammed only when at least one hiPSC line was 
successfully derived from hPHs isolated from the donor. The hDFs used for reprogramming 
were passaged less than four times from initial propagation from the dermal tissue pieces.  
The derivation of hiPSCs from hDFs of Donors 1 and 2 were both performed using the same 
SeV vectors encoding the Yamanaka pluripotency factors (Figure 2.8). The hDFs were 
reprogrammed as per manufacturer’s protocol and as previously described (Fusaki, et al., 
2009), with the main difference compared to the protocol used for reprogramming hPHs 
being that the culture of transduced hDFs was split and replated at Day 7 to prevent the 
culture from being too confluent due to the proliferation of the hDFs (Figure 2.8C).  
The transduced hDFs were then transferred onto MEF feeder layers or Matrigel and the 
cultures monitored for the emergence of nascent hiPSC colonies (Figure 2.8D). hESC-like 
colonies were seen from Day 15 onwards and the colonies manually passaged onto fresh 
MEF feeder layer or Matrigel respectively between Day 25 to Day 35. In contrast to hiPSCs 
derived from hPHs, hiPSC lines derived from hDFs were successfully established on both 
feeder-dependent and feeder-free cultures (Figure 2.9). The reprogramming efficiency of 
hDFs was notably much higher than hPHs, as there were many other colonies in the 
reprogramming cultures with typical hESC-like appearances which were not picked as we 
only manually isolated enough colonies (>10 per donor-batch of hDFs from both feeder- 
dependent and feeder-free cultures) to ensure successful establishment of at least 3 hDF-
derived hiPSC lines.     
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Figure 2.7 Propagation of hDFs from skin excisions. 
(A) Close-up view of pieces of dermis placed in a single well of a 6-well tissue culture plate. 
Phase contrast microscopy showing (B) a piece of dermal tissue on the surface of the tissue-
culture plate, imaged with magnification of 40x; scale bar, 500 μm. Appearance of hDFs 
growing out from the edge of the dermal tissue 17 days after initial propagation, imaged with 
(C) magnification of 40x; scale bar, 500 μm, and (D) magnification of 100x; scale bar, 100 
μm. 
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Figure 2.8 Morphological changes of the hDF culture during reprogramming. 
Phase contrast microscopy showing (A) plated hDFs at Day 0 prior to transduction of SeV 
vectors, seen with magnification of 40x; scale bar, 500 μm.  Morphology of transduced hDFs 
at (B) Day 4 and (C) Day 7 prior to splitting of the culture, both seen with magnification of 
40x; scale bar, 500 μm. (D) Appearance of hESC-like colony observed at Day 16 for the 
culture of transduced hDFs transferred onto a MEF feeder layer, seen with magnification of 
40x; scale bar, 500 μm. Typical appearance of a hiPSC colony ready for manual passaging, 
observed at Day 31, seen with magnification of (E) 40x; scale bar, 500 μm and (F) 100x; 
scale bar, 100 μm. 
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Figure 2.9 Representative established hiPSC lines derived from hDFs of 2 different 
adult donors. 
Phase contrast microscopy showing morphology of (A) Liv4FA and (B) Liv4FB derived from 
hDFs of Donor 1; (C) Liv6FP and (B) Liv6FC derived from hDFs of Donor 2.  Magnification 
for all images: 100x; scale bar, 100 μm. 
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2.3.2 Characterisation of isogenic hiPSC lines derived from hepatocytes and dermal 
fibroblasts 
At the time of preparation for the thesis, only HLCs differentiated from hiPSC lines derived 
from Donor 1 was available for comparison. Therefore, the rest of the following chapter will 
only describe the characterisation of the hiPSC lines derived from Donor 1 and also the 
respective HLCs generated from these lines. 
 
2.3.1.1 Derived hiPSC lines express pluripotency markers 
All the hiPSC lines derived from both hPHs and hDFs which were used for subsequent 
directed differentiation towards HLCs were confirmed for their pluripotency using 
immunocytochemistry with antibodies against a panel of pluripotency markers: octamer-
binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2), NANOG, 
TRA-1-60 and stage-specific embryonic antigen-4 (SSEA-4) (Figure 2.10). The hiPSC lines 
were cultured as monolayers and maintained their undifferentiated state, as observed by 
their morphology.  
 
2.3.1.2 Derived hiPSC lines spontaneously differentiate into cells of three germ layers  
All the hiPSC lines were also assessed for their ability to spontaneously differentiate in vitro 
into cells of all three germ layers using the embryoid body formation assay (Figure 2.11). 
After 7 days in suspension culture, the embryoid bodies were plated onto gelatin-coated 
plates and culture continued for a further 5-7 days. The attached cells showed various 
morphology when analysed using phase contrast microscopy, and immunocytochemistry 
detected cells positive for beta-III tubulin (marker of ectodermal cells), alpha smooth muscle 
actin (α-SMA, marker of mesodermal cells) and alpha fetoprotein (AFP, marker of 
 Chapter 2 
54 
 
endodermal cells) in all the hiPSC lines assessed (Figure 2.12). This confirmed that the 
hiPSCs could spontaneously differentiate into cells from all three germ layers in vitro.  
 Chapter 2 
55 
 
 
Figure 2.10 Immunocytochemistry for pluripotency markers in isogenic hiPSCs derived from hPHs and hDFs.  
For all the ICC images (coloured panels), the nuclei were counterstained with Hoescht 33342 (blue) and imaged with magnification of 200x; 
scale bar, 100 μm. The left panel shows corresponding phase contrast microscopy images of the hiPSC colonies, imaged with magnification of 
40x; scale bar 500 μm. 
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Figure 2.11 Embryoid body formation from hiPSCs. 
Representative phase contrast microscopy images of embryoid bodies of various sizes 
formed from Liv4HJ (A, B) and Liv4FA (C, D) in suspension culture. Magnification of (A, B) 
40x; scale bar 500 μm and (C, D) 100x; scale bar 100 μm. 
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Figure 2.12 Immunocytochemistry for multi-lineage markers of spontaneously 
differentiated cells from embryoid bodies formed from isogenic hiPSCs derived from 
hPHs and hDFs. 
The ICC images show cells positive (green) for β-III tubulin (left column), alpha-smooth 
muscle actin (α-SMA, middle column) and alpha fetoprotein (AFP, right column) with the 
nuclei counterstained with Hoescht 33342 (blue), imaged with magnification of 200x; scale 
bar, 100 μm. The images were representative of cells spontaneously differentiated from both 
hPH-derived hiPSCs (Liv4HJ, first row) and hDF-derived hiPSCs (Liv4FA, second row; 
Liv4FB, third row; and Liv4FC, fourth row).   
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2.3.3 HLCs generated from multiple hepatocyte- and fibroblast-derived hiPSC lines 
using a modified multistage hepatic differentiation protocol 
To examine the potential contribution of epigenetic memory inherent in the hiPSC lines 
towards the propensity for hepatic differentiation, we generated HLCs from all the hiPSC 
lines which were at the early-passage stage (passaged less than 10 times) to avoid the 
abrogation of epigenetic memory in late-passage hiPSCs as previously reported  (Kim, et al., 
2011;  Polo, et al., 2010). We also applied the same directed hepatic differentiation protocol 
to all the hiPSC lines examined and used a modified protocol (Figure 2.1) adapted from 
previously reported ones which were shown to allow for effective hepatic differentiation for 
multiple hiPSC lines (Kajiwara, et al., 2012;  Sullivan, et al., 2010;  Szkolnicka, et al., 2014).  
All the hiPSC lines were able to undergo hepatic differentiation towards HLCs using the 
three-step protocol. Briefly, all the hiPSCs were initially dissociated into single cells to allow 
for greater reproducibility of the cellular responses to growth factors and cell-cell to 
interactions as opposed to the more conventional method of hepatic differentiation using 
hiPSC clusters of variable and undefined sizes (Kajiwara, et al., 2012). The induction of 
hiPSCs into definitive endodermal (DE) cells was confirmed by immunocytochemistry using 
the DE marker, sex determining region Y-box 17 (SOX17) (Cai et al., 2007;  Yasunaga et al., 
2005) while hepatic nuclear factor 4 alpha (HNF4A) and albumin was used as hepatic 
markers at the hepatic endodermal (Day 12, denoting 12 days after the start of 
differentiation) and mature stages (Day 22) of the differentiation process respectively (Figure 
2.13) (Cai, et al., 2007;  Hay et al., 2008;  Hengstler et al., 2005). There were also sequential 
morphological changes during the differentiation process and the HLCs at Day 22 generally 
assumed a polyglonal shape though the resemblance to hPHs was more pronounced with 
Liv4HJ- and Liv4FB-derived HLCs (Figure 2.13).  
The hepatic differentiation of the hiPSCs was also confirmed using real-time qRT-PCR to 
analyse the expression of the hepatic markers SOX17 and AFP. There was a temporal up-
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regulation of the DE marker SOX17 for all the hiPSC lines at Day 5, compared to their 
respective undifferentiated hiPSC counterparts (Figure 2.14A), while the expression of AFP,  
gradually increased for all the hiPSC lines and peaked at the HLC stage (Figure 2.14B). 
Concomitantly, all the hiPSC lines also had down-regulation of the pluripotency marker 
NANOG during the differentiation process (Figure 2.14C).  
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Figure 2.13 Immunocytochemistry for protein markers of key stages of the hepatic differentiation of hiPSCs.  
The representative ICC images (right panel of each column) show cells positive (magenta for Sox17, green for HNF4α and albumin) with the 
nuclei counterstained with Hoescht 33342 (blue), imaged with magnification of 200x; scale bar, 100 μm. The images were representative of 
cells differentiated from both hPH-derived hiPSCs (Liv4HJ, first row) and hDF-derived hiPSCs (Liv4FA, second row; Liv4FB, third row; and 
Liv4FC, fourth row). Phase contrast microscopy images of the cells in corresponding stages of hepatic differentiation are shown in the left panel 
of each column – magnification: 200x; scale bar, 100 μm. 
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Figure 2.14 Real-time qRT-PCR gene expression analyses of hepatic markers and the 
pluripotency marker NANOG during hepatic differentiation.  
Data is presented as the mean fold change of gene expression relative to H-hiPSC. The 
error bars for the endodermal derivatives represent the standard error of the mean (SEM) for 
three individual replicate cultures performed in parallel for each hiPSC line. For each 
sample, the real-time qRT-PCR reactions were performed in duplicates. DE, definitive 
endoderm; HE, hepatic endoderm; HLC, hepatocyte-like cell; SOX17, sex determining 
region Y-box 17; AFP, alpha fetoprotein. 
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2.3.3 Comparison of liver-related gene expression between isogenic HLCs  
Following successful generation of HLCs from all the hiPSC lines derived from both primary 
hepatocytes and dermal fibroblasts, we then quantitatively compared their expression of 
commonly accepted hepatocyte-specific genes (Cai, et al., 2007;  Hay, et al., 2008;  
Hengstler, et al., 2005). For this comparison, we used the same donor’s hPHs as the ideal 
comparator to exclude the effect of genetic variability in the expression of liver-related genes 
between different donors. 
Overall, we found that the gene expression profile of the HLCs generated from hPH-derived 
hiPSCs was largely similar to the HLCs generated from hDF-derived hiPSCs (Figure 2.15). 
In fact, it was HLCs generated from one of the hDF-derived hiPSC line (Liv4FA) that had the 
highest gene expression of albumin (ALB) and alpha-1 antitrypsin (A1AT), hepatic markers 
that are frequently used to denote the differentiation efficiency of HLC cultures (Kia, et al., 
2013). There were also no significant differences in the expression of the liver-enriched 
transcription factor HNF4A and the most abundant cytochrome-P450 enzyme in the human 
liver CYP3A4 (Rodriguez-Antona, et al., 2002), between the HLCs generated from the 
examined hiPSC lines. The HLCs generated from the hPH-derived hiPSC line also 
expressed significantly higher levels of ALB, A1AT and the hepatocyte lineage marker 
keratin-18 (CK18) compared to HLCs generated from of the hDF-derived hiPSC line 
(Liv4FC). There were also differences in the expression of the hepatic genes between the 
HLCs generated from the various hDF-derived hiPSC lines.  
Therefore, based on these results obtained using hiPSC lines derived from a single donor, 
there did not seem to be a higher propensity of HLCs generated from hPH-derived hiPSCs 
to express a hepatic transcription profile comparable to hPHs, and differences in the hepatic 
gene expression profile was also seen between HLCs generated from hiPSCs derived from 
the same tissue type, in this case hDFs. 
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Figure 2.15 Real-time qRT-PCR gene expression analyses of hepatic markers in 
isogenic HLCs generated from hPH- and hDF-derived hiPSCs of the same adult donor.   
Data is presented as the mean fold change of gene expression relative to the donor’s hPHs. 
The error bars for the HLCs represent the standard error of the mean (SEM) for three 
individual replicate cultures performed in parallel for each hiPSC line. For each sample, the 
real-time qRT-PCR reactions were performed in duplicates. The unpaired t-test was used to 
compare the statistical significance of the mean fold change of each gene for the hDF-
derived hiPSC lines (F-hiPSC1, F-hiPSCS2 and F-hiPSCS3) against the hPH-derived hiPSC 
line (H-hiPSC). * denotes p < 0.05. For gene name abbreviations, please see 
http://www.ncbi.nlm.nih.gov/gene/. Commonly known aliases are listed in parentheses. 
Selected descriptions of gene name abbreviations: SERPINA1 (A1AT), serpin peptidase 
inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1; CYP3A4, cytochrome 
P450, family 3, subfamily A, polypeptide 4; KRT18 (CK18), keratin-18.   
 Chapter 2 
64 
 
2.3.4 Comparison of albumin secretion capacity between isogenic HLCs    
We then chose to examine the functional phenotype of the HLC cultures by examining the 
amount of albumin secreted into the media. Hepatocytes are the only cell-type that secretes 
albumin (Hengstler, et al., 2005) and the capacity for albumin secretion in HLCs is frequently 
used as a surrogate for quantitative comparison of “maturity” of their phenotype (Hay, et al., 
2008;  Kajiwara, et al., 2012;  Shan et al., 2013)  
The media was collected serially from the same well of the respective cultures of HLCs and 
the concentration of albumin measured. In parallel to the ALB expression data shown in 
(Figure 2.15), the HLC cultures generated from Liv4FA, a hDF-derived hiPSC line, had the 
highest amount of albumin in the media, while the culture of HLCs generated from Liv4FC 
which had the lowest relative expression of ALB, had the least albumin in the media (Figure 
2.16A).  
When the mean concentration of albumin in the media of the respective cultures at Day 22 
was normalised to the amount of total protein of HLCs from the same wells of cultures used 
as a surrogate for cell count, the mean concentration of albumin in the media of HLC 
cultures generated from Liv4FA was 16-fold higher than that of the HLCs generated from the 
hPH-derived Liv4HJ, and about 2-fold lower than that in the media of the donor’s primary 
hepatocytes which has been plated for 48 hours (Figure 2.16B). Again, based on the 
comparison of albumin secretion, HLCs generated from hPH-derived hiPSCs did not result in 
a better functional phenotype compared to HLCs generated from hDF-derived hiPSCs, with 
variable albumin secretion seen also between HLCs generated from different hiPSC lines 
derived from hDFs.   
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Figure 2.16 Comparison of albumin secretion between isogenic HLCs generated from hPH- and hDF-derived hiPSCs of the same 
adult donor. 
DAY 22 OF 
DIFFERENTIATION 
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(A) Data is presented as the mean secretion of albumin into the media of HLCs per 24 hours and the error bars represent the standard error of 
the mean (SEM) for three individual replicate cultures performed in parallel for each hiPSC line. The trend of albumin secretion for each culture 
of HLC was analysed using serial media samples from each respective well. (B) Data is presented as the mean secretion of albumin into the 
media per 24 hours normalised to the amount of total protein of the culture, and the error bars represent the standard error of the mean (SEM) 
for three individual replicate cultures performed in parallel for each hiPSC line and hPHs. The media used for comparison was collected at Day 
22 for the HLCs and at 48 hours post-plating for the hPHs. For each media sample, the ELISA reactions were performed in duplicates. The 
unpaired t-test was used to compare the statistical significance of the mean albumin secretion for the hDF-derived hiPSC lines (F-hiPSC1, F-
hiPSCS2 and F-hiPSCS3) against the hPH-derived hiPSC line (H-hiPSC). * denotes p < 0.05, ** denotes p < 0.01. 
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2.4 DISCUSSION 
To investigate our hypothesis in this chapter, we first had to derive hiPSCs from hPHs which 
had previously only been reported twice in the literature (Hansel, et al., 2014;  Liu, et al., 
2010). Both reports were contrasting in their experience with reprogramming hPHs though 
the methods used were not directly comparable. Liu et al. reported rapid and efficient 
reprogramming of hPHs using retroviral delivery of the Yamanaka factors, in contrast to 
Hansel et al. who reported a very low reprogramming efficiency of hepatocytes from 
children. The latter group managed to derive three hiPSC lines from a 13-month-old and 12-
year-old donor, while reprogramming attempts of hPHs from 12 other donors including adults 
failed to generate any hESC-like colonies. They also required delivery using lentiviral vectors 
of two additional reprogramming factors (Lin-28 and Nanog) in addition to the conventional 
Yamanaka factors used in our study (Hansel, et al., 2014). Therefore, as successful 
derivation of hiPSC lines from adult hPH donors would be the critical component in our 
study, we therefore adapted our own reprogramming protocol largely based on the 
experience reported by Liu et al (Figure 2.2).   
For this study, we chose to use the Sendai viral (SeV) vectors to deliver the transcription 
factors for two main reasons: 1. The vectors are non-integrative - they replicate as negative 
single-stranded RNA in the cytoplasm of infected cells and do not integrate into the host 
genome, unlike retroviral or lentiviral vectors which result in viral transgene insertions into 
the host genome that may affect terminal differentiating potential (Bitzer et al., 2003;  
Macarthur et al., 2012;  Okita et al., 2007); and  2. They are efficient in delivering foreign 
genes into a wide spectrum of host cells (Bitzer, et al., 2003;  Tokusumi et al., 2002) – an 
important factor in the design of the study, as a standardised method of efficient 
reprogramming both hPHs and hDFs with minimal variation was required to minimise 
confounding factors that influence the phenotype of hiPSCs and subsequent differentiated 
HLCs. Although efficient reprogramming of hDFs and blood cells using the SeV vectors 
encoding the Yamanaka pluripotency factors have been reported (Fusaki, et al., 2009;  Seki 
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et al., 2012), the application of SeV vectors in reprogramming hepatocytes have not been 
reported until now. Therefore, we show that the use of SeV vectors is a robust and 
reproducible non-integrative method for reprogramming adult hPHs.  
To explore the contribution of epigenetic memory of the cell-type of origin in hiPSCs with 
minimal confounding factors, we also generated HLCs from multiple hiPSC lines using the 
same differentiation protocol for comparison (Figure 2.2). Despite successful generation of 
HLCs from multiple hiPSC lines for comparison, the differentiation efficiency was not high, 
ranging from an estimated 20-40% as determined by immunocytochemistry for albumin-
positive cells at the end of differentiation (data not shown). Furthermore, as we only used the 
described protocol to ensure a standardised approach to generating HLCs from multiple 
hiPSC lines, it is possible that a different differentiation protocol may yield different 
efficiencies and propensities of the various hiPSC lines towards hepatic differentiation. 
However, we feel that our choice of protocol was justifiable as it was adapted from 
previously published protocols that were shown to be robust in generating HLCs from 
various hiPSC clones derived from multiple cell-types (Kajiwara, et al., 2012;  Sullivan, et al., 
2010;  Szkolnicka et al., 2013).  
Our results stemming from the comparison of HLCs generated from hepatocyte- and 
fibroblast-derived hiPSC lines of a single donor suggest that there is no advantage in the use 
of hPHs as the starting cell-type for deriving hiPSCs to generate functional HLCs. However, 
there are caveats to our provisional results which require further exploration.  
Firstly, the comparison between the HLCs was made using only a single hiPSC line derived 
from hPHs of Donor 1. This single clone may not be truly representative of the effect of 
epigenetic memory as clonal variations in the propensity for hepatic differentiation has been 
reported in sibling hiPSC clones derived from non-hPH cell-types of origin (Kajiwara, et al., 
2012). In fact, analysis of the expression of SOX17 among the three hDF-derived hiPSC 
lines (Figure 2.14) suggests that clonal differences may be manifested early in the 
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differentiation process as the hDF-derived hiPSC lines demonstrated variable response to 
induction towards definitive endoderm which also loosely correlated with their corresponding 
albumin secretion capacity. Therefore, future comparisons using at least 3 of the 5 
established hPH-derived hiPSC lines from Donor 2 should help to clarify this limitation.  
Secondly, the influence of donor differences in ultimately being of more importance in 
generating functional HLCs cannot be discounted. This specific issue was addressed 
partially by Kajiwara et al., where they showed that the variations in the hepatic 
differentiation of isogenic peripheral blood-derived and hDF-derived hiPSC lines were small 
in contrast to larger variations seen between hiPSC lines derived from different donors 
(Kajiwara, et al., 2012). However, to truly answer the relative contribution of epigenetic 
memory of the cell-type of origin in isogenic hiPSC lines and donor differences towards 
hepatic differentiation, the inclusion of hPH-derived hiPSC lines is vital. Therefore, further 
comparisons using corresponding sets of hPH- and hDF-derived hiPSC lines from Donor 2 
and future donors will hopefully clarify this question.  
Thirdly, the HLCs generated in this study were still relatively “immature” with limited 
expression of most hepatocyte-specific genes including CYP3A4 as well as albumin 
secretion compared to the donor hPHs (Figure 2.15 and 2.16B). There were also high levels 
of expression of AFP, a prototypical marker of hepatoblasts and foetal hepatocytes 
undergoing maturation (Figure 2.14) (Kuhlmann and Peschke, 2006). Overall, this 
characterisation data is not dissimilar to the phenotype of HLCs reported by various groups 
in the literature using different protocols (Kia, et al., 2013). However, it is possible that the 
potential advantage of using hiPSC lines derived from hPHs to generate functional HLCs 
may never be fully evaluated pending  the availability of a robust and validated hepatic 
differentiation protocol to generate HLCs with a functional phenotype more akin to a freshly-
isolated hPH phenotype.    
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In summary, this chapter describes our attempt to evaluate the contribution of epigenetic 
memory towards hepatic differentiation. Our results using hiPSC lines derived from a single 
donor suggests that our null hypothesis of HLCs generated from hPH-derived hiPSC line is 
more functional compared to HLCs generated from non-hPH-derived hiPSC is false, 
although comparison using hiPSC lines derived from other donors are required to be 
conclusive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3 
71 
 
 
 
 
CHAPTER 3 
 
 
THE GLOBAL MICRORNA PROFILES OF HUMAN PRIMARY 
HEPATOCYTES IN EXTENDED IN VITRO CULTURE 
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3.1 INTRODUCTION 
Despite longstanding efforts to develop novel in vitro hepatic models which are functional 
and relevant for mechanistic studies of drug-induced liver injury, freshly-isolated human 
primary hepatocytes (hPHs) remain largely unsurpassed as the gold standard in vitro model 
(LeCluyse, 2001), though Szkolnicka et al. had recently showed that hESC-derived HLCs 
has  equivalence with cryopreserved hPHs, albeit not tested with hepatotoxicants 
(Szkolnicka, 2014). hPHs maintain a level of functionality during short-term cultures and are 
thus widely used for in vitro studies on drug metabolism and acute toxicity (Godoy et al., 
2013). However, they rapidly lose their in vivo phenotype during extended in vitro culture, 
including the capacity for xenobiotic biotransformation, thereby preventing its use for the 
study of chronic toxicity which commonly precedes clinical presentations of idiosyncratic 
drug-induced liver injury (Rodriguez-Antona et al., 2002;  Rowe et al., 2013;  Verma and 
Kaplowitz, 2009). This detrimental process, termed as “dedifferentiation”, results in a short 
duration of optimal hepatocyte function which limits the utility of the hPH model to acute 
toxicity studies only, and compromises their use in mechanistic studies of DILI which often 
occurs following prolonged exposure to drugs (Guguen-Guillouzo and Guillouzo, 2010;  
Kalgutkar and Soglia, 2005;  LeCluyse, 2001). Therefore, reversal or prevention of the 
dedifferentiation process would result in a more relevant hepatic model for pharmaco-
toxicology studies. Furthermore, it is hoped that by better understanding the mechanisms 
involved in hPH dedifferentiation, new insights can be gained to improve the differentiation 
process of human pluripotent stem cells towards hepatocyte-like cells.    
Dedifferentiation of hPHs has been described to begin during the isolation procedure, and is 
shown to be a consequence of the activation of proliferative and inflammatory signalling 
pathways, resulting in a shift of the isolated hepatocytes towards a “proliferation-primed 
state” in expense of its functional phenotype (Paine and Andreakos, 2004;  Vinken et al., 
2006). Various strategies employed to prevent or reverse hepatocyte dedifferentiation, 
include the modification of the in vitro culture systems  (Fraczek et al., 2013), overexpression 
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of liver-enriched transcription factors  (Naiki et al., 2004) and manipulation of the epigenetic 
mechanisms to counter the underlying gene expression changes (Bolleyn et al., 2011). 
However, the existence of fully functional hPHs in long-term in vitro culture remains elusive.   
MicroRNAs (miRs), a group of endogenous non-coding RNAs which has been shown to play 
an important role in post-transcriptional gene silencing by either inhibiting protein translation 
or facilitating protein degradation of their target messenger RNAs (mRNAs) (Bartel, 2004), 
have also been recently investigated for its role in the dedifferentiation process in rat primary 
hepatocytes (Bolleyn, et al., 2011). Currently, more than 2500 mature miRs have been 
described in humans in the latest version of the miRBase database (miRBase 21) of 
published miR sequences and annotation (Griffiths-Jones, 2004), and about 50% of human 
mRNAs were estimated to be miR targets (Lewis et al., 2005). As each miR may regulate 
hundreds of mRNAs, substantial effects on the gene expression pattern may result from the 
change of expression of just a few miRs that regulate them. Indeed, miRs have been 
demonstrated to play a role in all basic biological processes including metabolism (Krutzfeldt 
and Stoffel, 2006), cell proliferation (Bueno et al., 2008) and tissue differentiation (Shi et al., 
2006). Similarly, altered miR expression was also implicated in various human diseases 
(Jiang et al., 2009), including in hepatocellular carcinoma (HCC) (Fornari et al., 2008). This 
realisation has prompted intense research into therapeutic targeting of miRs using various 
approaches particularly antisense oligonucleotides (ASOs) that target miRs directly (Li and 
Rana, 2014). In fact, there are currently many miR-targeting ASOs that are in clinical and 
preclinical trials (Li and Rana, 2014), with promising early results in the treatment of chronic 
hepatitis C virus infection and hypercholesterolaemia (Lindow and Kauppinen, 2012; Li and 
Rana, 2014). On the other hand, a miR-34 mimic as replacement therapy to normalise its 
reduced levels in patients with HCC or metastatic cancer involving the liver, has also entered 
a Phase I clinical trial (Bouchie, 2013).   
Genome-wide or global unbiased miR expression profiling using high-throughput platforms 
have further enriched our understanding of the role of miRs in biological and pathological 
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processes, for example, through the identification of a set of differentially-expressed miRs 
involved in the differentiation of human embryonic stem cells towards hepatocyte-like cells 
(Kim et al., 2011) and in the dedifferentiation of rat hepatocytes (Bolleyn, et al., 2011). 
Therefore, it is conceivable that similar global miR profiling studies could help in further 
delineating the process of dedifferentiation in hPHs. However, miR profiling studies have 
never been performed in isolated hPHs previously, although various studies using human 
adult and foetal liver tissue have been reported (Barad et al., 2004;  Fu et al., 2005;  
Landgraf et al., 2007). Therefore, we hypothesised that by investigating the miR profiles of 
freshly-isolated hPHs in extended in vitro culture, potential miRs as targets for modulation 
may be identified, and fresh insights may be gained into the complex molecular cascades 
involved.  
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3.2 MATERIALS AND METHODS 
3.2.1 Human subjects and tissue 
Human liver resections from surgical waste tissue were obtained from adult patients 
undergoing hepatobiliary surgery with full informed consent and ethical approval from the 
relevant institutional review boards (National Research Ethics Service REC reference: 
11/NW/0327). 
 
3.2.2 Human primary hepatocyte isolation 
Human primary hepatocytes (hPHs) were isolated using a previously described method with 
minor modifications (LeCluyse et al., 2005). Briefly, liver resections were received as 
surgical waste tissue immediately post-resection (Aintree University Hospital, Liverpool, 
United Kingdom) and transferred on ice in N-(2-Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES) buffer (10 mM HEPES, 136 mM NaCl, 5 mM KCl, 0.5% (w/v) 
glucose, pH 7.6) to the laboratory. The liver resection specimens were then perfused with 
HEPES-buffered saline (HBS) followed by digestion with collagenase A (Roche) or 
collagenase IV (Sigma-Aldrich) in HBS containing calcium. The suspension containing 
isolated hepatocytes was then filtered through a nylon gauze and purified by centrifugation 
twice at 80x g for 5 minutes at 4oC, before the pellet was resuspended in Williams E medium 
(Sigma-Aldrich). The hPHs were then seeded onto collagen-I coated 24-well plates (BD 
Beckinson) at 2.5 x 105 cells/cm2 and cultured in Williams E medium supplemented with 1% 
(v/v) insulin-transferrin-selenium (from 100x stock, Life Technologies), 2 mM L-glutamine 
(Sigma-Aldrich), 10-7 M dexamethasone (Sigma-Aldrich) and 1% (v/v) penicillin-streptomycin 
(Sigma-Aldrich) at 5% CO2 and 37°C. After 3 hours, non-attached cells were washed away 
and replaced with fresh Williams E medium before overnight incubation. The medium was 
replaced again the next day at the start of the experiments.  
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3.2.3 Human primary hepatocyte culture 
The plated hPHs were cultured in Williams E medium supplemented with 1% (v/v) insulin-
transferrin-selenium (from 100x stock, Life Technologies), 2 mM L-glutamine (Sigma-
Aldrich), 10-7 M dexamethasone (Sigma-Aldrich) and 1% (v/v) penicillin-streptomycin (Sigma-
Aldrich) up to seven days without any additional matrix overlay to promote dedifferentiation 
(Rowe, et al., 2013). The media was changed daily for the duration of the study, and the 
cells were lysed in QIAzol (Qiagen) according to the manufacturer’s protocol at 24 hours, 48 
hours and 168 hours post-plating. Pellets of freshly-isolated hPHs were also lysed in QIAzol 
(Qiagen) as baseline reference samples. The lysates were stored immediately in -80°C.    
 
3.2.4 Total RNA extraction 
The purification of total RNA containing the miR fraction from media or lysate samples was 
performed using the miRNeasy mini kit (Qiagen), as per the manufacturer's instructions. 
Briefly, each lysate was thawed at room temperature and thoroughly mixed before the 
addition of 140 μL of chloroform. The samples were then mixed vigorously for 15 seconds 
and left at room temperature for 3 minutes. The homogenates were then centrifuged at 
12000x g for 15 minutes at 4°C. 350 μL of the upper aqueous phase and 525 μL of 100% 
ethanol were then mixed thoroughly in a new collection tube before transferring to a 
miRNeasy Mini spin column. The column was then sequentially centrifuged and washed with 
supplied buffers at room temperature, before the column was placed into a new collection 
tube. 30 μL of RNase-free water was then added directly onto the column membrane and 
centrifuged for 1 minute at 10000x g to elute the total RNA containing the small RNA 
fraction.  
To ensure removal of residual organic solvent contamination which may result in inaccurate 
quantification of the total RNA, each total RNA elute was further purified using additional 
chloroform extractions as recommended by the microarray system manufacturer (Agilent 
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Technologies). Briefly, 100 μL of a 1:1 mixture of acid phenol (Sigma-Aldrich) and 
chloroform (Sigma-Aldrich) was added to the total RNA elute and thoroughly mixed before 
being centrifuged at maximum speed for 15 minutes at 4°C. The aqueous phase was then 
collected in a new tube. 100 μL of RNase-free water was added to the remaining acid 
phenol/chloroform mixture, thoroughly mixed and centrifuged as before, and the aqueous 
phase added to the previously recovered portion. 1 μL of glycogen (20 μg/μL stock solution, 
Life Technologies), 10% (v/v) of 3M sodium acetate (pH 5.2, Sigma-Aldrich) and 500 μL of a 
2:1 mixture of ethanol and isopropanol was then added to the total volume of recovered 
aqueous phase, and the mixture incubated overnight at -20°C, before being centrifuged for 
15 minutes at maximum speed at 4°C. The supernatant was discarded and the pellet rinsed 
with cold 75% ethanol. The pellet was spun down at 7500x g for 5 minutes before the 
supernatant was again discarded and air-dried at room temperature for 10 minutes. The total 
RNA precipitate was then dissolved in an appropriate amount of RNase-free water. 
Quantification and the quality of the total RNA extracts was analysed using the NanoDrop 
spectrophotometer (Thermo Scientific) and Agilent 2100 bioanalyser (using the RNA 6000 
Nano kit, Agilent Technologies) respectively. Only samples which had a RNA Integrity 
Number (RIN) of > 7 were used as input samples for microarray analysis. 
 
3.2.5 MicroRNA microarray analysis 
MicroRNA (miR) microarray analysis was performed using the miRNA Complete Labeling 
and Hyb kit (Agilent Technologies) according to the manufacturer’s protocol. Briefly, 100 ng 
of total RNA was incubated with calf intestinal alkaline phosphatase (CIP) reaction mixture 
consisting of 0.4 µL 10x CIP buffer, 0.5 µL CIP and 1.1 µL labelling spike-in solution, at 37°C 
for 30 minutes to dephosphorylate the RNA. The samples were then denatured with 2.8 µL 
of DMSO at 100°C for 5 min. A ligation master mixture consisting of 3 µL of Cyanine3-pCp, 1 
µL of 10x T4 RNA ligase buffer and 0.5 µL of T4 RNA ligase was then added to each sample 
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and incubated at 16°C for 2 hours. The labelled RNA was then purified using Micro Bio-Spin 
6 columns (Bio-Rad), according to the manufacturer’s protocol. Briefly, each sample was 
transferred into the column and centrifuged at 1000x g at room temperature for 4 minutes. 
The RNA samples were then dried for 1 hour using a DNA SpeedVac (Thermo Scientific), 
before being resuspended in a mixture consisting of 17 µL of RNase-free water, 22.5 µL of 
2x Hi-RPM hybridisation buffer, 4.5 µL of 10x blocking agent and 1 µL of hybridisation spike-
in solution. The samples were then incubated at 100°C for 5 minutes before being chilled on 
ice. The samples were then loaded onto the human miRNA Microarray Release 16.0, 8x60k 
microarrays (G4872A-031181, Agilent Technologies), of which 1347 human miRs were 
represented based on miRBase 16 (http://www.mirbase.org/). The hybridisation step was 
performed at 55°C for a minimum of 20 hours in a rotating chamber at 20 rpm. The 
hybridized miR arrays were then washed using proprietary buffers and according to protocol, 
and the hybridized images scanned using a G2505C Agilent Microarray Scanner (scan 
control version A.8.4.1, Agilent Technologies). 
 
3.2.6 Data pre-processing and statistical analysis of microRNA microarray data 
The images provided by the scanner were analysed using the Agilent Feature Extraction 
(AFE) software (version 10.7.3.1, Agilent Technologies) with default settings, of which a 
quality control report was produced for each scanned image. All microarrays used for 
downstream analysis passed the defined quality control parameters. The AFE algorithms 
estimated a summarised signal for each miR termed as the total gene signal (TGS) which 
was then used by the bioinformatics tool AgiMicroRna (open-source software available from 
the Bioconducter project - http://www.bioconductor.org ) for further pre-processing and 
differential expression analysis of the microRNA microarray data (Lopez-Romero, 2011).  
The AFE-processed TGS was first normalised between microarrays using the quantile 
method integrated in AgiMicroRna and the default filtering algorithm applied to remove 
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control features and genes not detected in any of the samples in the study. The limma 
package was used to fit a linear model to each miR (Smyth, 2004), to analyse statistically 
significant differential expression between the samples collected at various time-points in 
comparison to baseline. Using this model, the differential expressions were calculated using 
moderated t-test (Bayesian approach) and miRs exhibiting a significant fold change (p value 
of < 0.05) were selected for further analysis. For each time-point of sample collection, 4-6 
biological replicates from different donors were used for this study (i.e. 4 donors had 
corresponding samples with RIN > 7 for all time-points, while 2 donors had corresponding 
samples with RIN > 7 for only the baseline and 48-hour time-points).  
 
3.2.7 MicroRNA target prediction  
The miR targets of the differentially-expressed miRs (see criteria above) were analysed 
using the MicroRNA Target Filter module of Ingenuity Pathway Analysis (IPA; Qiagen, 
Redwood City, CA, www.qiagen.com/ingenuity) which enabled identification of 
experimentally validated and predicted messenger RNA (mRNA) targets. The databases 
referred to by this IPA module were Tarbase5.0 (Vergoulis et al., 2012),  miRecords (Xiao et 
al., 2009), TargetScan (Friedman et al., 2009) and the Ingenuity manually curated database 
(available through IPA). For the predicted miR-mRNA target interactions, only predictions 
with high confidence as deemed by TargetScan were included for further analyses of 
functional term enrichment and canonical pathway involvement using the Core Analysis 
module of IPA. In the analyses of mRNA targets of liver-enriched transcription factors and 
genes associated with liver-specific functions, predicted miR-mRNA target interactions with 
moderate confidence as deemed by TargetScan were also included. The sequence of all the 
detected mature miR were mapped to the annotations used in miRBase 19 (latest version 
available during the commencement of the study, www.mirbase.org/index.shtml).   
 
 Chapter 3 
80 
 
3.2.8 Real-time quantitative RT-PCR (qRT-PCR) 
The level of expression of selected differentially-expressed miRs as analysed by microarray 
analysis (Section 3.2.5 and 3.2.6) were determined via a multiplexed reverse transcriptase 
(RT) step followed by real-time PCR reactions using the TaqMan miRNA assays (Applied 
Biosystems) according to the manufacturer’s protocol. The TaqMan MicroRNA Assays used 
were for hsa-miR-122-5p (assay ID: 002245), hsa-miR-4284 (assay ID: 241828_mat), hsa-
miR-21-5p (assay ID: 000397), hsa-miR-885-5p (assay ID: 002296) and U6 (assay ID: 
001973). 
Briefly, a RT primer pool consisting of each individual 5x RT primer was mixed with 1x TE 
Buffer (Sigma-Aldrich) to a final volume of 1 ml. The RT reaction mix is then prepared using 
the TaqMan MicroRNA RT Kit (Applied Biosystems) with an appropriate volume of the RT 
primer pool. 12 µL of the RT reaction mix was then added to each well of a 96-well plate 
before 3 µL of total RNA (350 ng per reaction) extracted from the samples used for the 
microarray analysis was added, prior to incubation on ice for 5 minutes. Reverse 
transcription was then performed using the GeneAmp PCR System 9700 thermal cycler 
(Applied Biosystems) using the recommended thermal-cycling conditions.  
For the real-time PCR reaction, the PCR reaction mix was first prepared by mixing the 
TaqMan Universal Master Mix II, No AmpErase UNG (2X) (Applied Biosystems) with the 
appropriate volume of 20x TaqMan MicroRNA Assay (Applied Biosystems), the relevant RT 
product and nuclease-free water (Qiagen) as per the manufacturer’s instructions. 10 µL of 
the PCR reaction mix was then added to each well of a 384-well plate before being sealed 
with an adhesive film and briefly centrifuged. Real-time PCR was then performed in 
duplicates with the ViiA 7 Real-Time PCR instruments (Applied Biosystems) using a 2-step 
thermal cycling protocol of 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 60 seconds. Ct values were determined using the fluorescent signal produced 
from the TaqMan probes. U6 snRNA was used as endogenous control for normalisation and 
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the fold change of expression of the respective miR relative to baseline expression at the 0 
hour time-point were calculated using the 2-ΔΔCt method (Livak and Schmittgen, 2001). The 
expression of each miR at each time-point was expressed as the mean fold change +/- 
standard deviation of three biological replicates (n =3 ). The real-time qRT-PCR experiments 
were analysed with the unpaired t-test using GraphPad Prism 6 (GraphPad Software), with p 
< 0.05 considered significant.  
 
3.2.9 Cell morphology 
Cell morphology was analysed by light microscopy using a phase contrast microscope 
(ECLIPSE TS100/100-F, Nikon), and photographs captured using a digital camera head 
(DS-Vi1, Nikon) and a stand-alone controller and display unit (DS-L3, Nikon). 
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3.3 RESULTS 
3.3.1 Morphological changes of human primary hepatocytes during in vitro culture 
During the extended culture of plated human primary hepatocytes (hPHs) on collagen-
coated plates, the cell morphology was noted to change (Figure 3.1). Following overnight 
incubation post-seeding, the confluent cultures of attached hPHs were noted to display a 
cuboidal shape with distinct borders and bile canaliculi were observed. However, following in 
vitro culture up to 7 days, the hPH cultures were noted to progressively lose their distinct 
cuboidal shapes, appeared generally more disorganised and flattened with the presence of 
more cellular projections, with the loss of distinct bile canaliculi. These morphological 
changes were most noticeable after 48 hours of in vitro culture, and were most pronounced 
at the end of the study. The above changes were generally similar for hPH cultures from 
multiple human donors, with no obvious increase in cell detachment, cell death or 
proliferation during in vitro culture of up to 168 hours in this study, although these processes 
were not formally assessed using cell viability and cell proliferation assays.  
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Figure 3.1 Morphological changes of collagen-plated hPHs over time in culture.  
The series of pictures above were hPHs isolated from a single donor and representative of 
typical changes in 6 different donors, as analysed by phase contrast microscopy 
(magnification: 200x; scale bar, 100 μm). 
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3.3.2 Global microRNA expression profile of freshly-isolated human primary 
hepatocytes 
The global miR expression profile of freshly-isolated hPHs in isolation from the other non-
parenchymal cell counterparts present in the human liver, have not been previously 
reported. Using data from the miR microarray analysis of freshly-isolated hPHs (n = 6 
different donors), 117 unique human miRs were detected. Each miR was considered present 
only if it was detected in at least 3 individual donors.  
Enrichment analysis of the most abundantly expressed miRs in hPHs was performed using 
the normalised intensity values of the detected miRs of which the 30 most abundantly 
expressed miRs are shown in Figure 3.2. Based on the analysis of the mean normalised 
intensity values of all detected miRs, the most enriched miR in hPHs were miR-122-5p, 
which is estimated to constitute around 21% of all detected miRs in hPHs, while the 5 most 
abundant miRs constitute 56% of the total miR content in hPHs.   
Overall, the miR profile consisting of 117 detected miRs in our series of hPHs isolated from 6 
different donors, represent the first characterisation of the “miR-ome” of the hPH.  
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Figure 3.2 Enriched miRs in freshly-isolated human primary hepatocytes.  
Data is presented as the mean normalised intensity value of the 30 most abundant miRs obtained from individual microarray analysis of human 
primary hepatocytes isolated from 6 different donors. Error bars represent the standard deviation of the mean for each data point. Each miR 
was included in analysis only if detected in 3 individual donors or more. 
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3.3.3 The global microRNA expression profiles of human primary hepatocytes in 
extended in vitro culture 
We then investigated the miR profiles of the hPHs during conventional in vitro culture by 
analysing their global profiles using microarray analysis at 24 hours, 48 hours and 168 hours 
post-plating, in comparison with freshly-isolated hepatocytes. We specifically chose to 
culture the hPHs without any additional extracellular matrix overlay to promote hepatocyte 
dedifferentiation (Fraczek, et al., 2013) and hypothesised that the miR expression profile 
changes over time during extended in vitro culture.  
For the fold-change analysis, we included all miRs which were detected (defined as miRs 
detected from at least 3 individual adult hPH donors) at all time-points of the study. The 
results are summarised as a heatmap showing the mean log fold-change of each analysed 
miR at each time-point in comparison to the baseline levels in freshly-isolated hepatocyte 
samples, defined as 0 hours in culture (Figure 3.3A). We also separately analysed a set of 
miRs which were detected at baseline (definition of detected miR as above) but were 
otherwise not detected at all time-points during extended in vitro culture (Figure 3.3B). In 
general, most of the miRs showed a trend of either increasing up- or down-regulation of their 
expression over time, with the notable exception of the let-7 family of miRs of which their 
expression was generally unchanged (Figures 3.3A and 3.3B). The number of miRs which 
were differentially-expressed also increased with the duration of culture (Table 3.1).  
Using linear modelling and moderated t-test (Bayesian approach), the differential expression 
of miRs at each time-point in comparison to baseline was analysed for significance. All miRs 
which exhibited a significant fold change (p value of < 0.05) at each time-point are shown in 
Table 3.1, of which 22 out of 117 detected miRs were found to be differentially-expressed 
compared to the baseline samples of freshly-isolated hPHs (Table 3.1 and Figure 3.4). This 
list also included miR-122-3p which is recognised as the inactive counterpart of miR-122-5p, 
or more precisely the passenger strand of their RNA complex (Chen, 2009;  Jopling, 2012), 
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and has no predicted targets according to the databases used in this study (Section 3.2.7). 
The magnitude of change of expression of these miRs over time in culture were also 
analysed in Figure 3.4.  
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Figure 3.3 Heatmap showing change of expression of miRs in extended in vitro culture of hPHs.  
Data is presented as mean log
2
 fold change of normalised intensity value of each detected miR in hPHs, compared to baseline (freshly-isolated 
hepatocytes at 0 hours), at 24 hours, 48 hours, and 168 hours in culture respectively. Each row represents a miR detected and the fold 
changes in the expression of miRs are represented by red colour for up-regulation compared to baseline (0 hours in culture), green colour for 
down-regulation and grey colour for non-detection. (A) miRs which were detected in samples from 3 donors or more in every time-point (n = 
100 individual miRs), and (B) miRs which were detected in samples from 3 donors or more at baseline, but not in every time-point (n = 17 
individual miRs).  
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Table 3.1 Differentially-expressed miRs at each time-point of extended in vitro culture 
of hPHs, compared to baseline at 0 hours. 
All mean fold-change (FC) between 0 and 1 were transposed to a range of -1 until -infinity. 
The direction of change of expression is indicated by the symbol + for up-regulation, and – 
for down-regulation.  
miRNA Up / down  regulation Mean FC p-value 
24 h compared to 0 h 
    
miR-1246 + 4.37 1.44E-02 
miR-21-5p + 2.13 1.16E-02 
miR-29b-3p + 1.73 4.00E-02 
48 h compared to 0 h       
    
miR-21-5p + 2.83 2.27E-04 
miR-193b-3p + 1.53 7.72E-03 
miR-223-3p - 4.74 9.14E-03 
miR-4284 - 1.77 1.91E-02 
miR-4286 - 1.65 1.48E-02 
miR-122-3p - 1.41 4.64E-02 
168 h compared to 0 h       
    
miR-21-5p + 4.53 2.30E-05 
miR-3665 + 3.76 1.81E-02 
miR-1246 + 3.21 2.67E-02 
miR-762 + 3.00 2.72E-02 
miR-3195 + 2.57 4.37E-02 
miR-29b-3p + 2.19 9.32E-03 
miR-24-3p + 2.11 1.29E-02 
miR-34a-5p + 2.03 9.08E-03 
miR-1260b + 1.97 2.97E-02 
miR-193a-3p + 1.94 3.58E-03 
miR-16-5p + 1.69 1.47E-02 
miR-885-5p - 3.94 3.12E-02 
miR-192-5p - 2.24 3.59E-02 
miR-4286 - 2.15 1.19E-02 
miR-30c-5p - 1.98 4.50E-02 
miR-148a-3p - 1.92 1.37E-02 
miR-4284 - 1.89 5.50E-03 
miR-19b-3p - 1.55 4.23E-03 
miR-122-5p - 1.53 8.80E-03 
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Figure 3.4 Fold-change of differentially-expressed miRs at each time-point of extended in vitro culture of hPHs, compared to baseline 
at 0 hours.  
Data is presented as the mean log2 fold change of normalised intensity value of each miR compared to baseline (freshly-isolated hepatocytes 
at 0 h), at 24 hours, 48 hours, and 168 hours in culture respectively, from 6 individual donors of hPHs. For each miR, a time-point was included 
in analysis only if detected in 3 donors or more. Error bars represent the standard deviation of the mean log2 fold-change for each data point. * 
denotes p < 0.05, † denotes p < 0.01, ‡ denotes p < 0.001, # denotes P < 0.0001.  
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3.3.4 Real-time quantitative RT-PCR (qRT-PCR) validation of microarray microRNA 
expression profiles 
To verify the miR expression profiles of hPHs obtained from the microarray analysis, qRT-
PCR analysis on selected differentially-expressed miRs identified from the microarray 
analysis was performed. The expression profiles of four selected miRs were analysed further 
by qRT-PCR using the same samples of donor hPHs used in the microarray analysis. For 
this purpose, samples of extracted total RNA from three of the four donors which had 
corresponding RIN > 7 for all the time-points, as determined by the Agilent 2100 bioanalyser 
(using the RNA 6000 Nano kit, Agilent Technologies), were analysed. 
The rationale for the selection of the four miRs for validation using qRT-PCR were as 
follows: miR-122-5p as it was the most abundantly-expressed miR in freshly-isolated hPHs 
(Figure 3.2); miR-4284 as it was the second most abundantly-expressed miR in freshly-
isolated hPHs and was not previously detected in adult liver tissue (Figure 3.2); miR-21-5p 
as it was the most up-regulated miR at the 168 hour time-point (Table 3.1); and miR-885-5p 
as it was the most down-regulated miR at the 168 hour time-point (Table 3.1).  A fold-change 
analysis of the selected miRs was then performed at each time-point in comparison to the 
baseline levels in freshly-isolated hepatocyte samples for each individual miR, similar to the 
fold-change analysis done for all the miRs detected in hPHs from the microarray analysis 
(Figure 3.3, Table 3.1, Figure 3.4).  
As shown in Figure 3.5, similar expression profiles of all the selected miRs compared to the 
microarray analysis were seen with a matching trend towards up- or down-regulation 
compared to baseline at the 168 hour time-points, with similar magnitude of mean fold 
changes. All the time-points with significant difference to the baseline values for each miR 
when analysed by microarray analysis, were also similarly observed with the same trend of 
expression when analysed by the qRT-PCR method, apart from the 48 hour time-point for 
miR-4284 which had no significant difference. Therefore, we concluded that the global miR 
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expression profiles of human primary hepatocytes in extended in vitro culture as analysed by 
the microarray platform, were robust and reliable for further detailed analyses. 
 Chapter 3 
93 
 
 
Figure 3.5 Comparison of expression profiles of selected miRs of hPHs in extended in vitro culture as analysed by microarray 
analysis and real-time quantitative RT-PCR 
Data is presented as the mean log2 fold change of expression for each miR compared to baseline (freshly-isolated hepatocytes at 0 h), at 24 
hours, 48 hours, and 168 hours in culture respectively, as per (left panel) microarray analysis, and (right panel) real-time quantitative RT-PCR. 
Error bars represent the standard deviation of the mean log2 fold-change for each data point. * denotes p < 0.05, † denotes p < 0.01, ‡ denotes 
p < 0.001, # denotes P < 0.0001.
 Chapter 3 
94 
 
3.3.5 Perturbed biological functions and canonical pathways of human primary 
hepatocytes in extended in vitro culture 
The target mRNAs of the differentially-expressed miRs were then identified, and subsequent 
analyses of their involvement in biological functions and canonical pathways were performed 
for each set of differentially-expressed miRs at each time-point, using Ingenuity Pathway 
Analysis (IPA; Qiagen).  
In general, as early as 24 hours after plating of hPHs, many biological functions were 
significantly affected via the targeting of specific genes by the differentially-expressed miRs 
(Figure 3.6). More detailed analysis of the processes involved with each perturbed biological 
function was also interrogated by analysing the function annotation terms for the gene 
targets, which gave more biological insight into the changes that occur in hPHs during 
extended in vitro culture (Tables 3.2A, 3.2B and 3.2C).  
We found that the most significantly perturbed biological function at each time-point was 
related to gene expression (Figure 3.6). Biological functions relating to cell motility, cellular 
proliferation, cellular organisation and cytoskeletal integrity were also perturbed throughout 
extended in vitro culture, with increasing significance and number of mRNAs targeted by 
differentially-expressed miRs at the 168 hour time-point (Tables 3.2A, 3.2B and 3.2C), which 
supports the morphological changes seen with the hPH cultures (Figure 3.1). Processes 
involved in cell death and survival such as apoptosis and necrosis were also among the five 
most significantly perturbed functions after 48 hours of culture (Table 3.2B and 3.2C) while 
processes involved in cell cycle were also more significantly perturbed at the 168 hour time-
point (Figure 3.6). At 7 days post-plating of the hPHs, functions relating to metabolism and 
environmental information processing were also noted to have higher significance values 
compared to earlier time-points of in vitro culture (Figure 3.6).   
The canonical pathways that were significantly perturbed during the process of hepatocyte 
dedifferentiation were also examined (Figure 3.7). 
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Figure 3.6 Heatmap showing the high-level functional category enrichment for gene targets of differentially-expressed miRs at each 
time-point of extended in vitro culture of hPHs, compared to baseline at 0 hours.  
Data is presented as the significance value of the most relevant function for each high-level category, which indicates the probability of 
association between the dataset of predicted mRNA targets of differentially-expressed miRs at each time-point, and the function is due to 
random chance alone. The categories are ranked according to the highest values at 48 hours. The significance is expressed as the negative 
exponent of the p-value (–log
10 
p-value) as calculated by Fisher’s exact test right tailed. Red and yellow colour denotes high and low 
significance levels respectively, while grey colour denotes non-significant values (p > 0.05). 
 Chapter 3 
96 
 
Table 3.2 Analysis of function annotation term enrichment for gene targets of differentially-expressed miRs at (A) 24 hours, (B) 48 
hours and (C) 168 hours, compared to baseline at 0 hours.  
Differentially-expressed miRs were analysed with IPA using the microRNA Target Filter module, and the predicted gene targets were analysed 
with the IPA Core Analysis module. The top 5 most significantly perturbed categories of molecular and cellular function denoted by their 
representative function annotations are shown below with their corresponding p-value (calculated by Fisher’s exact test right tailed) and number 
of predicted mRNA targets. 
(A) 24 hours 
Category Representative function p-value  Number of 
  annotations (with multiple testing correction) mRNA targets 
        
GENE EXPRESSION Transcription of RNA 2.02E-13 186 
  Transcription of DNA 4.99E-09 135 
  Activation of DNA endogenous promoter 1.06E-05 86 
  Binding of DNA 7.76E-04 45 
        
    CELLULAR MOVEMENT Cell movement 5.86E-10 167 
 Migration of cells 8.67E-08 144 
            
CELLULAR GROWTH  
AND PROLIFERATION 
Proliferation of cells 9.44E-09 302 
Cytostasis 6.09E-06 33 
        
    CELLULAR ORGANISATION  
AND MAINTENANCE 
Development of cytoplasm 3.08E-07 40 
Formation of filaments 5.45E-07 37 
 Formation of cytoskeleton 2.71E-06 33 
            
CELL MORPHOLOGY Morphology of cells 7.05E-06 64 
Necrosis 3.10E-04 16 
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(B) 48 hours 
Category Representative function p-value  Number of 
  annotations (with multiple testing correction) mRNA targets 
        
GENE EXPRESSION Transcription of RNA 2.69E-17 200 
  Transcription of DNA 1.48E-11 145 
  Activation of DNA endogenous promoter 4.28E-07 92 
  Transactivation of RNA 2.78E-06 62 
  Binding of DNA 3.76E-05 50 
        
    CELL DEATH AND SURVIVAL Apoptosis 1.23E-07 211 
 Necrosis 5.47E-07 223 
 
          
CELL MORPHOLOGY Morphology of cells 1.29E-07 70 
Autophagy 9.34E-04 29 
        
    CELULAR MOVEMENT Cell movement 6.42E-07 155 
Migration of cells 2.90E-05 133 
            
CELLULAR ORGANISATION  
AND MAINTENANCE 
Development of cytoplasm 1.06E-06 39 
Quantity of lipid droplets 1.14E-05 13 
Formation of cytoskeleton 5.96E-05 30 
  Depolarization of mitochondrial 
membrane 
1.86E-04 7 
  Remodelling of chromatin 6.34E-04 9 
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(C) 168 hours 
Category Representative function p-value  Number of 
  annotations (with multiple testing correction) mRNA targets 
        
GENE EXPRESSION Transcription of RNA 9.74E-30 698 
  Transcription of DNA 5.37E-23 526 
  Transactivation of RNA 8.59E-15 231 
  Activation of DNA endogenous promoter 5.87E-12 331 
  Repression of RNA 1.52E-06 51 
  Binding of DNA 6.67E-06 165 
  Binding of protein binding site 9.87E-05 81 
        
    CELLULAR MOVEMENT Cell movement 4.46E-22 642 
 Migration of cells 6.92E-17 560 
 
          
CELLULAR GROWTH  
AND PROLIFERATION 
Proliferation of cells 1.60E-19 1230 
Colony formation of cells 8.72E-09 185 
  Arrest in growth of cells 1.67E-06 65 
        
    CELLULAR DEVELOPMENT Differentiation of cells 2.80E-16 379 
Epithelial-mesenchymal transition 9.99E-07 66 
 Immortalization 3.22E-04 13 
            
CELL DEATH AND SURVIVAL Apoptosis 3.30E-15 832 
Necrosis 2.22E-14 893 
  Cell viability 1.87E-11 456 
  Anoikis 6.92E-05 37 
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CANONICAL PATHWAY 24 h 48 h 168 h 
Molecular Mechanisms of Cancer    
IGF-1 Signaling    
PI3K/AKT Signaling    
Myc Mediated Apoptosis Signaling    
HGF Signaling    
PTEN Signaling    
Wnt/β-catenin Signaling    
ERK5 Signaling    
Telomerase Signaling    
STAT3 Pathway    
Aryl Hydrocarbon Receptor Signaling    
Cell Cycle: G1/S Checkpoint Regulation    
Insulin Receptor Signaling    
Regulation of Epithelial-Mesenchymal Transition    
Protein Kinase A Signaling    
Glucocorticoid Receptor Signaling    
Apoptosis Signaling    
SAPK/JNK Signaling    
PPARα/RXRα Activation    
PXR/RXR Activation    
NF-κB Signaling    
Gap Junction Signaling    
Calcium Signaling    
p53 Signaling    
IL-1 Signaling    
Death Receptor Signaling    
Cyclins and Cell Cycle Regulation    
TGF-β Signaling    
Actin Cytoskeleton Signaling    
Phospholipase C Signaling    
G Beta Gamma Signaling    
eNOS Signaling    
EGF Signaling    
Oncostatin M Signaling    
FGF Signaling    
FAK Signaling    
Sonic Hedgehog Signaling    
Growth Hormone Signaling    
RAN Signaling    
IL-6 Signaling    
ERK/MAPK Signaling    
Gα12/13 Signaling    
NRF2-mediated Oxidative Stress Response    
Estrogen-mediated S-phase Entry    
Docosahexaenoic Acid (DHA) Signaling    
Role of JAK2 in Hormone-like Cytokine Signaling    
BMP signaling pathway    
Rac Signaling    
RAR Activation    
ErbB Signaling     
 
Figure 3.7 Heatmap showing the most significantly perturbed canonical pathways at 
each time-point of extended in vitro culture of hPHs, compared to baseline at 0 hours.  
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Data is presented as the significance value of the canonical pathway, which indicates the 
probability of association between the dataset of mRNA targets of differentially-expressed 
miRs at each time-point with the canonical pathway is due to random chance alone. The top 
50 pathways are ranked according to the highest values at 48 hours. The significance is 
expressed as the negative exponent of the p-value (–log
10 
p-value) as calculated by Fisher’s 
exact test right tailed. Red and yellow colour denotes high and low significance levels 
respectively, while grey colour denotes non-significant values (p > 0.05).  
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3.3.6 Targets of up-regulated microRNAs in dedifferentiating hPHs include liver-
specific genes and liver-enriched transcription factors  
During extended in vitro culture of hPHs, liver-specific features progressively decline (Elaut 
et al., 2006), and the reduction of the mRNA levels of phase I/II xenobiotic biotransformation 
enzymes and drug transporters as well as liver-enriched transcription factors have been 
shown to occur during hepatocyte dedifferentiation (Elaut, et al., 2006;  Mizuguchi et al., 
1998;  Padgham et al., 1993;  Rodriguez-Antona, et al., 2002).  
In this study, we found that the targets of many of the up-regulated miRs include genes 
involved in all phases of xenobiotic biotransformation (Table 3.3). Some of these genes were 
targeted by both up- and down-regulated miRs, though interestingly for the phase I enzymes 
including the cytochrome-P450s, they were almost exclusively targeted by miRs which were 
up-regulated during extended in vitro culture (Table 3.3). Three liver-enriched transcription 
factors (LETFs) and two nuclear factors that play important roles in the transcriptional control 
of liver-specific gene expression were also found to be targets of up-regulated miRs (Tables 
3.4 and 3.5). Corresponding fold-change values for down-regulated miRs which target the 
listed factors were also included to provide a more balanced picture, though the overall net 
effect of all the associated miRs on the function of each factor is unknown.   
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Table 3.3 Selected genes that are important for xenobiotic biotransformation which are 
targeted by up-regulated miRs.  
Liver-specific 
function Liver-specific genes 
miRs targeting liver-
specific genes 
Up / down 
regulation 
Mean FC 
at 168 h 
          
Phase I xenobiotic 
biotransformation 
ALDH1A1 miR-21-5p + 4.53 
CYP1A2 miR-762 + 3.00 
    miR-4284 - 1.89 
  CYP1B1 miR-1260b + 1.97 
    miR-16-5p + 1.69 
  CYP2B6 miR-29b-3p + 2.19 
  CYP2C18 miR-3665 + 3.76 
  CYP2C8 miR-3665 + 3.76 
  CYP3A4 miR-762 + 3.00 
  CYP3A5 miR-21-5p + 4.53 
  DPYD miR-34a-5p + 2.03 
  PTGS2 (COX2) miR-16-5p + 1.69 
       
     
Phase II xenobiotic 
biotransformation 
COMT miR-3665 + 3.76 
 miR-762 + 3.00 
  miR-16-5p + 1.69 
  miR-30c-5p - 1.98 
 NQO1 miR-34a-5p + 2.03 
 SULT1A1 miR-1260b + 1.97 
 SULT1C2 miR-1260b + 1.97 
  miR-148a-3p - 1.92 
 SULT4A1 miR-29b-3p + 2.19 
  miR-34a-5p + 2.03 
  *miR-193a-3p + 1.94 
     
          
Phase III xenobiotic 
biotransformation 
ABCB6 miR-29b-3p + 2.19 
ABCC6 (MRP6) miR-762 + 3.00 
    miR-122-5p - 1.53 
  
  
SLC15A1 *miR-193a-3p + 1.94 
  miR-122-5p - 1.53 
SLC22A7 (OAT2) miR-29b-3p + 2.19 
  SLC22A9 (OAT4) miR-24-3p + 2.11 
    miR-4284 - 1.89 
  SLCO2B1 (OATP2B1) miR-762 + 3.00 
    miR-4284 - 1.89 
         
For gene name abbreviations, please see http://www.ncbi.nlm.nih.gov/gene/. Commonly 
known aliases are listed in parentheses. Selected descriptions of gene name abbreviations: 
ALDH1A1, aldehyde dehydrogenase 1 family, member A1; DPYD, dihydropyrimidine 
dehydrogenase; PTGS2 (COX2), prostaglandin-endoperoxide synthase 2 (cyclooxygenase 2; 
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COMT, catechol-O-methyltransferase; NQO1, NAD(P)H dehydrogenase, quinone 1; 
SLC15A1, solute carrier family 15, member 1; OAT2, organic anion transporter 2; SLCO2B1 
(OATP2B1), solute carrier organic anion transporter family, member 2B1 (organic anion 
transporting polypeptide, member 2B1). miRs highlighted in bold represent miR-mRNA 
interaction that have been experimentally observed, miRs in normal font represent predicted 
miR-mRNA interaction with high confidence (as defined by TargetScan) and miRs in italics 
represent predicted miR-mRNA interaction with moderate confidence (as defined by 
TargetScan).The mean fold change (FC) of miRs which were between 0 and 1 at 168 hours, 
compared to baseline at 0 hours, was transposed to a range of -1 until -infinity. The direction 
of change of expression for all miRs listed is indicated by the symbol + for up-regulation, and 
– for down-regulation. * miR-193a-3p and miR-193b-3p share the same seed sequence of 
ACUGGCC used for downstream analysis of mRNA targets.  
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Table 3.4 Liver-enriched transcription factors (LETFs) targeted by up-regulated miRs, and their roles in liver-specific functions.  
LETF Liver-specific function Liver-specific genes regulated by LETF 
miRs targeting 
LETF 
Up / down 
regulation 
Mean FC 
at 168 h 
            HNF1A Xenobiotic biotransformation 
CYP1A2, CYP2C11, CYP2E1, CYP7A1, miR-34a-5p + 2.03   GSTA2, SULT2A1, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7,            UGT2B1, UGT2B7, UGT2B17                     Carbohydrate and lipid metabolism 
PCK2 (PEPCK), ALDOB, APOA1, APOB                               Protein synthesis ALB, AFP, TTR, SERPINA1 (A1AT)                         
HNF4A Xenobiotic biotransformation 
CYP2A6, CYP2C2, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, miR-34a-5p + 2.03  UGT1A9          
 Carbohydrate and 
lipid metabolism 
ALDH2, APOA1, APOC3         
      
 Protein synthesis 
and urea cycle 
TTR, TF, SERPINA1 (AAT), OTC         
      
            CEBPA Xenobiotic biotransformation 
CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4 miR-762 + 3.00   GSTA1, UGT2B1, UGT2B7                     Carbohydrate and lipid metabolism 
PCK2 (PEPCK), ALDOB, APOB                               Protein synthesis ALB, AFP, TTR, TF, SERPINA1 (A1AT)                   For gene name abbreviations, please see http://www.ncbi.nlm.nih.gov/gene/. Commonly known aliases are listed in parentheses. Selected 
descriptions of gene name abbreviations: HNF1A, hepatocyte nuclear factor 1, alpha; PCK2 (PEPCK), phosphoenolpyruvate carboxykinase 2; 
ALDOB, aldolase B, fructose-bisphosphate; APOA1, apolipoprotein A-1; APOB, apolipoprotein B; ALB, albumin; AFP, alpha-fetoprotein; TTR, 
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transthryretin; SERPINA1 (A1AT), serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1; ALDH2, aldehyde 
dehydrogenase 2 family; APOC3, apolipoprotein C-III; OTC, ornithine transcarbamoyltransferase; TF, transferrin; CEBPA, CCAAT/enhancer 
binding protein (C/EBP), alpha. miRs in normal font represent predicted miR-mRNA interaction with high confidence (as defined by 
TargetScan) and miRs in italics represent predicted miR-mRNA interaction with moderate confidence (as defined by TargetScan). The 
direction of change of expression for all miRs listed is indicated by the symbol + for up-regulation, and – for down-regulation. References for 
the associated genes regulated by the LETFs are listed in Fraczek et al., 2013. 
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Table 3.5 Nuclear receptors (NRs) targeted by up-regulated miRs, and their roles in liver-specific functions.  
NR Liver-specific function Associated genes regulated by nuclear receptor
‡ miRs targeting 
NR 
Up / down 
regulation 
Mean FC 
at 168 h 
            
NR1I2 
(PXR) 
Xenobiotic 
biotransformation 
CYP2B, CYP3A4, UGT1A1, UGT1A6, ABCC2  miR-34a-5p + 2.03 
  miR-148a-3p - 1.92 
  Bile acid 
homeostasis 
CYP7A1, ABCC2, SLC21A6    
         
           
      
PPARA Carbohydrate and 
lipid metabolism 
CPT1A, ACOX1, HMGCS1 miR-21-5p + 4.53 
 GPD1, GPD2, GK miR-24-3p + 2.11 
   miR-16-5p + 1.69 
   miR-19b-3p - 1.55 
   miR-223-3p - 4.74* 
       
For gene name abbreviations, please see http://www.ncbi.nlm.nih.gov/gene/. Selected descriptions of gene name abbreviations: NR1I2 (PXR), 
nuclear receptor subfamily 1, group I, member 2 (also known as pregnane X receptor); PPARA, peroxisome proliferator-activated receptor 
alpha; CPT1A, carnitine palmitoyltransferase 1A ; ACOX1, acyl-CoA oxidase 1, palmitoyl; HMGCS1, 3-hydroxy-3-methylglutaryl-CoA synthase 
1; GPD1, glycerol-3-phosphate dehydrogenase 1; GK, glycerol kinase. miRs highlighted in bold represent miR-mRNA interaction that have 
been experimentally observed, miRs in normal font represent predicted miR-mRNA interaction with high confidence (as defined by TargetScan) 
and miRs in italics represent predicted miR-mRNA interaction with moderate confidence (as defined by TargetScan).The mean fold change 
(FC) of miRs which were between 0 and 1 at 168 hours, compared to baseline at 0 hours, was transposed to a range of -1 until -infinity. The 
direction of change of expression for all miRs listed is indicated by the symbol + for up-regulation, and – for down-regulation. * The mean FC 
shown for miR-223-3p was at 48 hours post-plating, as it was not detected at 168 hours post-plating. ‡ References for the associated genes 
regulated by the NRs: (Jigorel et al., 2006;  Kakizaki et al., 2011;  Lefebvre et al., 2006;  Staudinger et al., 2003;  Takagi et al., 2008)  
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3.4 DISCUSSION 
Dedifferentiation of hPHs, which are currently used as the gold standard in vitro hepatic 
model (LeCluyse, 2001), remains a major limitation of its application in pharmaco-toxicology 
studies, especially in chronic toxicity studies that aim to mimic the clinical presentations of 
DILI which often occurs following prolonged exposure to drugs (Guguen-Guillouzo and 
Guillouzo, 2010;  Kalgutkar and Soglia, 2005;  LeCluyse, 2001). Therefore, better 
understanding of the dedifferentiation process is vitally important to develop a more relevant 
hepatic model of drug-induced hepatotoxicity and could additionally reveal novel insights for 
better hepatic differentiation of human pluripotent stem cells towards hepatocyte-like cells.  
The global miR profile of human primary hepatocytes (hPHs) has not been previously 
reported, although the global miR expression of liver tissue has been updated over the years 
with newly-discovered mature miRs being included as part of the repertoire of miRs 
detectable by high-throughput platforms. However, as up to 40% of hepatic cells consist of 
many other cell-types including non-parenchymal cells such as endothelial cells, stellate 
cells, Kupffer cells, biliary epithelial cells and lymphoid cells (Godoy, et al., 2013), the miR 
expression profile of the liver tissue actually represents the composite miR profiles of all the 
above cell-types. For the purposes of understanding the process of dedifferentiation of 
hPHs, the distinct global miR expression of a human hepatocyte is more relevant as 
opposed to the profile of the liver tissue.  
Using samples of freshly-isolated hPHs from six different adult donors, we found that in 
general, the global miR profile of a typical hPH include previously identified enriched miRs 
(miR-122-5p, miR-21-5p, miR-22-3p, miR-125b-5p, miR-27b-3p and the let-7 family of miRs) 
in earlier studies using human liver tissue profiled using small RNA library sequencing 
(Landgraf, et al., 2007) and oligonucleotide microarray techniques (Barad, et al., 2004) 
(Figure 3.2). Our list of enriched miRs in hPHs also includes some miRs (miR-1260a, miR-
4286, miR-30b-5p and miR-223-3p) reported in the latest study which included a list of all 
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detected miRs in healthy liver tissue using PCR arrays capable of detecting 372 pre-chosen 
miRs (Ward et al., 2014).  
Similar to human liver tissue, miR-122-5p was the most abundant in isolated hPHs (Figure 
3.2), which is not surprising given that hepatocytes constitute 81% of the total liver cell mass 
(Kmiec, 2001;  Landgraf, et al., 2007). However, based on the analysis of the mean 
normalised intensity values of all detected miRs in this study, the relative abundance of miR-
122-5p was estimated to constitute around 21% of all detected miRs in hPHs. This is a 
striking contrast to the often-quoted figure of approximately 70% relative abundance of miR-
122-5p in mouse liver tissue (Jopling, 2012;  Lagos-Quintana et al., 2002), although many 
methodological differences between our studies prevent any conclusive direct comparisons.  
The study by Lagos-Quintana et al., which was based on the identification of miRs which 
were cloned and sequenced, only detected 11 distinct miR sequences in the mouse liver 
tissue, including 2 other less common sequence variants of miR-122-5p which were also 
included in the estimation of the relative abundance of miR-122-5p. In addition, only less 
than 100 miRs were previously reported in the literature at the time of that study. 
Furthermore, if only the sequence of miR-122-5p with the highest mean number of reads per 
million was used for estimation, the relative abundance of miR-122-5p from that study would 
be lower at 45%. Nevertheless, further quantitative estimation of miR-122-5p in the human 
liver in comparison to isolated hPHs would be interesting to exclude the possibility of 
significant change with its level during the process of isolation, which may be related to early 
events in the dedifferentiation process. 
There were also differences between the global miR profile of an isolated hPH delineated in 
our study in comparison to previously published miR profiles of human liver tissue. Firstly, 
within the list of the 30 most abundant miRs detected (Figure 3.2), there were novel miRs 
(miR-494-3p, miR-4284, miR-4281, and miR-4299) which were not previously reported in 
adult liver tissue. The discovery of the latter three miRs were only first reported in 2009 in 
human embryonic stem cells and neural precursors (Goff et al., 2009), following the 
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publication of the earlier studies (Barad, et al., 2004;  Landgraf, et al., 2007) and these miRs 
were also not included as part of the analysis in the latest study using human liver tissue 
(Ward, et al., 2014).  
Furthermore, there were also differences with the relative abundance of the miRs detected in 
hPHs and human liver tissue (Table 3.6). The latest published study using normal liver tissue 
was used for comparison against results from our study as it used a list of miR assays which 
were most comparable to our study, although caution should be applied due to the different 
methods used for miR analysis (PCR array versus oligonucleotide microarray) and the 
coverage of miRs detectable (372 versus 1204). Nevertheless, this comparison allows for 
unique contextual analysis of the miR profile of isolated hPHs. 13 of the top 30 most 
abundant miRs detected in hPHs were also detected in the top 30 most abundant miRs in 
human liver tissue, though conversely, 15 of the top 30 most abundant miRs detected in 
human liver tissue were found to be of much lower abundance in hPHs, outwith the top 30 
most abundant miRs. Therefore, it is quite possible that many of the miRs detected at much 
higher abundance in the liver tissue compared to hPHs are miRs which are more enriched in 
non-parenchymal cells, and the list of top 30 most abundant miRs in hPHs shown in Figure 
3.2 represents the first unencumbered definition of human hepatocyte-enriched miRs.  
However, it is currently unclear if the miR profile of the isolated hPH reported in this study is 
truly representative of the hPH residing in the in vivo liver niche, and whether the “true” miR 
profile was altered by the isolation process. Therefore, further validation studies by other 
groups using freshly-isolated hPHs and possibly parallel global analysis of hPHs 
microdissected from liver tissue will be required to confirm our findings.     
To specifically study the role of miRs in the dedifferentiation process of hPHs, the miR 
profiles were analysed using hPHs which were maintained as two-dimensional monolayer 
culture in conventional conditions up to 168 hours (termed Day 7). The combined effect of 
these differentially-expressed miRs was then interrogated by the analyses of the perturbed 
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biological functions (Figure 3.6) and canonical pathways (Figure 3.7). Strikingly, gene 
expression was the most significantly perturbed function identified at every time-point of the 
study (Figure 3.6) with the number of mRNAs targeted by differentially-expressed miRs 
increasing by more than 3-fold at Day 7 compared to Day 1 (Table 3.2A and 3.2C).  
Further analysis of the function annotations related to gene expression suggested that 
during extended in vitro culture the gene expression hPHs was perturbed at both the pre- 
and post-transcriptional levels due to dysfunction to the processes of binding of protein 
binding sites, transactivation of RNA, binding of DNA and activation of DNA endogenous 
promoter (Table 3.2C). Therefore, delineating in more detail the additional mechanisms of 
how the differentially-expressed miRs can regulate the global regulators of gene expression 
in dedifferentiating hPHs, may provide new approaches to counter hepatocyte 
dedifferentiation. 
Besides its widely studied role in the translational repression of protein-coding genes via 
direct binding to the 3′ untranslated region (UTR) of target mRNAs (Bartel, 2004), miRs have 
also been found to regulate gene expression by binding to and disrupting the function of 
RNA-binding proteins (RBPs), which have been suggested recently to be the main drivers of 
gene expression (Kechavarzi and Janga, 2014) by acting as transcriptional activators or 
repressors (Beitzinger and Meister, 2010). With this in mind, we found that 4 out of 10 RBPs 
with the highest gene expression values reported in human liver tissue (Kechavarzi and 
Janga, 2014), were targeted by 6 of the differentially-expressed miRs in our study (Table 
3.7). Further comprehensive analysis of the 850 genes experimentally characterised as 
RBPs in the human genome (Castello et al., 2012) may of course yield more potential 
targets. Furthermore, there is evidence that miRs target directly and indirectly effectors of 
the epigenetic machinery. Increased expression of the miR-29 family, including miR-29b-3p 
which was upregulated in our study (Table 3.1), was shown to directly and indirectly target 
the family members of DNA methyltransferases (DNMTs; DNMT1, 3A and 3B) (Fabbri et al., 
2007;  Garzon et al., 2009), which play important roles in maintaining the cell and tissue-
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specific epigenetic fingerprint of their methylation pattern (Cheng and Blumenthal, 2008), 
resulting in a global reduction of DNA methylation. Similarly, overexpression of miR-21-5p, 
which was also up-regulated in our study, was also shown to result in the down-regulation of 
DNMT1 (Pan et al., 2010). In addition, many of the histone deacetylases (HDACs), which 
are typically associated with transcriptional repression by their role in the reconstitution of a 
dense chromatin (Eberharter and Becker, 2002), were also noted to be targets of our set of 
differentially-expressed miRs (Table 3.8). These included HDAC-1 and HDAC-4 targeted by 
the up-regulated miR-34a-5p and miR-29b-3p respectively, of which the interactions were 
experimentally observed (Winbanks et al., 2011;  Zhao et al., 2013). Therefore, our findings 
add a further dimension to the increasing recognition that the modulation of epigenetic 
mechanisms using HDAC and DNMT inhibitors may be a promising strategy to prevent or 
restore the dedifferentiated phenotype (Fraczek, et al., 2013). However, targeting all of the 
HDAC and DNMT isozymes with a broad spectrum inhibitor may not be ideal, as our current 
knowledge of their individual roles in specific hepatocellular processes are still lacking 
(Fraczek, et al., 2013). Perhaps by modulating the differentially-expressed miRs either in 
isolation or in a considered combinatorial approach that target individual isozymes of HDACs 
and DNMTs as well as RBPs, a more targeted assessment of the contribution of 
dysregulated effectors of gene expression towards hepatic dedifferentiation could be 
evaluated.  
Dedifferentiation of hepatocytes has been described to begin during the hepatocyte isolation 
process partly due to the proliferative response, mediated by the mitogen-activated protein 
kinase (MAPK) pathway (Elaut, et al., 2006;  Fraczek, et al., 2013). Adult hepatocytes are 
usually highly differentiated and mitotically quiescent at the G0 phase, though they retain the 
potential for high proliferative capacity (Fausto, 2001;  Fraczek, et al., 2013). However, 
following the isolation process, the hepatocytes were reported to rapidly and synchronously 
re-enter the G1 phase of the cell cycle and primed to respond to growth signals, with a 
consequent negative effect on the expression of liver-specific genes, particularly those 
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related to phase I and II xenobiotic transformation and the liver-enriched transcription factors 
(LETFs) (Beigel et al., 2008;  de Longueville et al., 2003;  Fraczek, et al., 2013;  Paine and 
Andreakos, 2004). In our study, two of the most significantly perturbed pathways associated 
with the differentially-expressed miRs at the 48 hour time-point, were the extracellular signal-
regulated kinases (ERK)/MAPK signalling pathway and the pathway governing cyclins and 
cell cycle regulation (Figure 3.7), which suggests that miRs also play an early and important 
role in hepatocytes entering the “proliferation-primed state”. Cellular proliferation was also 
noted to be a significantly perturbed biological function from Day 1 (Figure 3.6). Therefore, 
another approach to prevent the occurrence of hepatocyte dedifferentiation could be the 
early modulation of differentially-expressed miRs associated with cellular proliferation at the 
early time-points. Indeed, miR-21-5p which was up-regulated from Day 1 and was the most 
up-regulated miR at Day 2 and Day 7 (Table 3.1), similar to the findings in a dedifferentiating 
rat hepatocyte model (Bolleyn, et al., 2011), was also previously shown to be up-regulated 
during the proliferative phase of liver regeneration in rat and mice models (Castro et al., 
2010;  Marquez et al., 2010). miR-1246 which was the most  up-regulated miR at Day 1 and 
remaining significantly up-regulated at Day 7 (Table 3.1), was previously reported to promote 
cell proliferation and migration in a human cervical cancer cell line (Chen et al., 2014). 
Meanwhile, miR-885-5p which was the most down-regulated miR at Day 7 (Table 3.1), was 
shown to inhibit proliferation of neuroblastoma cell lines through the activation of the p53 
pathway (Afanasyeva et al., 2011). Modulation of the miRs that target components of the 
MAPK pathway could also be considered.  
In addition, many of the pathways that were previously reported to be involved in the process 
of hepatocyte dedifferentiation (Elaut, et al., 2006;  Fraczek, et al., 2013) such as the 
phosphoinositide-3-kinase–protein kinase B/Akt (PI3K/AKT) pathway, apoptosis signalling 
pathways, the signal transducer and activator of transcription 3 (STAT3) pathway and the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸβ) pathway, were also 
noted to be perturbed in our study (Figure 3.7). By modulating a small set of miRs that target 
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multiple components of a pathway as exemplified in the STAT3 pathway (Figure 3.8), which 
play a major role in the expression of liver-specific genes (Kyriakis and Avruch, 2001), the 
negative consequences of the perturbation of a specific pathway may be nullified.  
One of the major hallmark of a dedifferentiated hPH in in vitro culture is the reduction in the 
expression of genes and associated proteins involved in xenobiotic biotransformation (Rowe, 
et al., 2013;  Ulvestad et al., 2013), as well as liver-enriched transcription factors (LETFs) 
(Rodriguez-Antona, et al., 2002) which play crucial roles in the transcriptional regulation of a 
myriad of liver-specific genes (Elaut, et al., 2006;  Fraczek, et al., 2013). Therefore, it is 
interesting to note from our study that many of these genes and LETFs, are direct targets of 
the up-regulated miRs (Table 3.3 and 3.4). The nuclear receptor, pregnane X receptor 
(PXR), which regulates the expression of enzymes involved in phase I-III drug metabolism 
and transport (Elaut, et al., 2006), was also a target (Table 3.5). Therefore, one further anti-
dedifferentiating strategy to produce a relevant human hepatic in vitro model for the 
purposes of pharmaco-toxicology where drug metabolising capability is important, could be 
selective inhibition of the identified differentially-expressed miRs that target the genes 
involved in xenobiotic biotransformation and LETFs.  
In summary, we have shown that our hypothesis of using a global approach in identifying the 
changing miR profiles of dedifferentiating hPHs to gain novel insights is valid. We have 
shown that differentially-expressed miRs in dedifferentiating hPHs were associated with 
many of the previously delineated perturbed pathways, biological functions and genes, and 
highlighted a potential major effect of miRs in the dedifferentiation process via perturbation 
of gene expression at the pre- and post-transcriptional levels. However, validation 
experiments are now required to confirm our findings from the bioinformatics analyses, and it 
still remains to be answered whether miRs are mere silent observers or active participants in 
the process of hepatic dedifferentiation. Nevertheless, our study added to the ongoing efforts 
in overcoming the dedifferentiation of hPHs in in vitro culture by providing a narrow list of 
targets for manipulation in the form of the differentially-expressed miRs, which could in turn 
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result in simultaneous manipulation of numerous biological processes and pathways 
governed by these miRs.  
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Table 3.6 Comparison of the top 30 most abundant miRs in human primary 
hepatocytes with human liver tissue. 
* The miRs were ranked according to the mean normalised intensity value obtained from 
individual microarray analysis of hPHs isolated from 6 different donors. ‡ The miRs were 
ranked according to raw CT values as reported in Ward, et al., 2014, excluding miRs which 
were considered tRNA fragments, from 3 healthy donors. The slash denotes miRs which 
were not assayed, while blank values represent miRs which were detected but not within the 
top 30 most abundant miRs.    
microRNA 
Top 30 most abundant  
miRs in hPHs*  
(values denote rank) 
Top 30 most abundant  
miRs in human liver tissue‡ 
(values denote rank) 
   
miR-122-5p 1 1 
miR-4284 2 / 
miR-4286 3 4 
miR-1260a 4 2 
miR-21-5p 5 7 
let-7a-5p 6 
miR-192-5p 7 16 
miR-148a-3p 8 15 
let-7f-5p 9 
let-7b-5p 10 
miR-494-3p 11 / 
miR-22-3p 12 9 
miR-19b-3p 13 
miR-29a-3p 14 17 
miR-1260b 15 
miR-4281 16 / 
miR-27b-3p 17 
miR-122-3p 18 / 
miR-23b-3p 19 
miR-194-5p 20 11 
miR-125b-5p 21 14 
miR-451a 22 5 
let-7g-5p 23 
miR-29c-3p 24 8 
miR-4299 25 / 
miR-30b-5p 26 
miR-16-5p 27 12 
miR-223-3p 28 
let-7c 29 
miR-885-5p 30 
miR-4454 / 3 
miR-4516 / 6 
miR-126-3p 10 
miR-26a-5p 13 
miR-4301 18 
miR-195-5p 19 
miR-99a-5p 20 
miR-100-5p 21 
miR-101-3p 22 
miR-30e-5p 23 
miR-24-3p 24 
miR-148b-3p 25 
miR-30a-5p 26 
miR-145-5p 27 
miR-27a-3p 28 
miR-20a-5p 29 
miR-199a-5p 30 
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Table 3.7 Selection of RNA-binding proteins (RBPs) and differentially-expressed miRs 
in dedifferentiating hPHs that target their mRNA.  
The 10 most highly expressed genes classified as RBPs in human liver tissue as reported by 
Kechavarzi et al., 2014, were analysed as potential targets of differentially-expressed miRs 
detected in our study. miRs in normal font represent predicted miR-mRNA interaction with 
high confidence (as defined by TargetScan) and miRs in italics represent predicted miR-
mRNA interaction with moderate confidence (as defined by TargetScan).The mean fold 
change (FC) of miRs which were between 0 and 1 at 168 hours, compared to baseline at 0 
hours, was transposed to a range of -1 until -infinity. The direction of change of expression 
for all miRs listed is indicated by the symbol + for up-regulation, and – for down-regulation. 
RNA-binding protein (RBP) miRs targeting RBP 
Up / down 
regulation 
Mean FC 
at 168 h 
     
EEF1A1 (eukaryotic translation elongation 
factor 1 alpha 1) 
  
miR-3665 + 3.76 
miR-30c-5p - 1.98 
     
    PDIA3 (protein disulfide isomerase family 
A, member 3) miR-148a-3p - 1.92 
         
CANX (calnexin) miR-29b-3p + 2.19 
  miR-148a-3p - 1.92 
  miR-122-5p - 1.53 
     
    P4HB (prolyl 4-hydroxylase, beta 
polypeptide) 
miR-762 + 3.00 
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Table 3.8 Histone deacetylases (HDACs) and differentially-expressed miRs in 
dedifferentiating hPHs that target their mRNA.  
miRs highlighted in bold represent miR-mRNA interaction that have been experimentally 
observed, miRs in normal font represent predicted miR-mRNA interaction with high 
confidence (as defined by TargetScan) and miRs in italics represent predicted miR-mRNA 
interaction with moderate confidence (as defined by TargetScan).The mean fold change 
(FC) of miRs which were between 0 and 1 at 168 hours, compared to baseline at 0 hours, 
was transposed to a range of -1 until -infinity. The direction of change of expression for all 
miRs listed is indicated by the symbol + for up-regulation, and – for down-regulation. * The 
mean FC shown for miR-223-3p was at 48 hours post-plating, as it was not detected at 168 
hours post-plating. 
Class HDAC miRs targeting HDAC 
Up / down 
regulation 
Mean FC 
at 168 h 
          
I HDAC-1 miR-34a-5p + 2.03 
    miR-4284 - 1.89 
  HDAC-2 miR-24-3p + 2.11 
    miR-192-5p - 2.24 
  HDAC-8 miR-1260b + 1.97 
       
     IIa HDAC-4 miR-29b-3p + 2.19 
  miR-19b-3p - 1.55 
  miR-223-3p - 4.74* 
 HDAC-5 miR-762 + 3.00 
  miR-30c-5p - 1.98 
 HDAC-7 miR-19b-3p - 1.55 
  miR-4286 - 2.15 
 HDAC-9 miR-30c-5p - 1.98 
            
IIb HDAC-6 miR-762 + 3.00 
       
     IV HDAC-11 miR-762 + 3.00 
  
miR-1260b + 1.97 
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Pathway miRNA Up / down regulation 
Mean FC 
at 48 h mRNA targets 
     STAT3  miR-21-5p + 2.8 BCL2, BMPR2, CDC25A, CDKN1A, 
MAPK10, SOCS5, SOCS6, STAT3, TGFBR2    
 miR-193b-3p + 1.5 KRAS, MAPK10, TGFBR3 
 miR-223-3p - 4.7 FGFR2, IGF1R, RRAS2, TGFBR3 
 miR-4284 - 1.8 MAP3K9 
 miR-4286 - 1.6 PIM1 
          
     Figure 3.8 (A) Schematic representation of the STAT3 pathway, with constituents of 
which the mRNAs are targeted (outlined in purple) by differentially-expressed miRs at 
48 hours of hPH culture, compared to baseline at 0 hours. (B) Pathway mRNA targets 
of differentially-expressed miRs at 48 hours of hPH culture.  
mRNA targets highlighted in bold represent miR-mRNA interaction that have been 
experimentally observed and mRNA targets in normal font represent predicted miR-mRNA 
interaction with high confidence (as defined by TargetScan). All mean fold change (FC) of 
miRs between 0 and 1 were transposed to a range of -1 until -infinity. The direction of 
change of expression is indicated by the symbol + for up-regulation, and – for down-
regulation. For gene name abbreviations, please see http://www.ncbi.nlm.nih.gov/gene/. 
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MICRORNA-122: A NOVEL HEPATOCYTE-ENRICHED IN VITRO 
MARKER OF DRUG-INDUCED HEPATOTOXICITY 
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4.1 INTRODUCTION 
Despite the development of various hepatic models for use in screening for adverse effects 
of new drugs and to aid mechanistic understanding of hepatotoxicity, drug-induced liver 
injury (DILI) in humans remains a significant cause of patient morbidity and mortality, and 
confers a major burden to the pharmaceutical industry and the regulatory authorities (Davies 
et al., 2010;  Olsen and Whalen, 2009). This is partly due to the major limitations of currently 
available hepatic models in recapitulating in vivo functional and metabolic capabilities of the 
human hepatocyte, most notably the expression of drug metabolising proteins such as 
cytochrome-P450 (CYP) enzymes, and drug transporters which are important for a 
mechanistic understanding of drug-induced toxicity (Godoy et al., 2013). The most 
metabolically active in vitro hepatic model is freshly-isolated human primary hepatocytes, 
although a myriad of issues limit their application in the in vitro study of drug-induced toxicity 
and safety screening (Kia et al., 2013). Human primary hepatocytes are not readily available, 
they are expensive, exhibit large donor variations, and rapidly lose their functional phenotype 
over time in in vitro culture, leading to reduced expression of the majority of CYP enzymes 
(Godoy, et al., 2013;  Rodriguez-Antona et al., 2002;  Rowe et al., 2010).  
A potential new hepatic model is the use of human pluripotent stem cells to generate 
hepatocytes in vitro (Baxter et al., 2010;  Bone et al., 2011;  Brolen et al., 2010). Directed 
differentiation of human pluripotent stem cells into hepatocytes, typically called hepatocyte-
like cells (HLCs),  with a mature functional phenotype, could in theory provide a readily 
available source of metabolically competent cells for use in drug screening (Greenhough et 
al., 2010;  Yildirimman et al., 2011). However, the differentiation efficiency of HLCs from 
human pluripotent stem cells can be variable, which is believed to be mainly due to 
differences of the differentiation protocols being employed and the propensity of the selected 
pluripotent stem cell line to differentiate towards a hepatic lineage (Baxter, et al., 2010;  Bock 
et al., 2011). The differentiation efficiency of HLCs from a starting culture of undifferentiated 
pluripotent stem cells can range from 9-90%, as determined by the percentage of cells in the 
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culture that express the hepatocyte protein marker albumin (Hay et al., 2008;  Rashid et al., 
2010;  Shiraki et al., 2008). Therefore, for the application of HLCs as an in vitro model for 
drug screening and toxicology, this heterogeneity of maturity needs to be accounted for.  
Another approach taken to develop a relevant and functional hepatic model includes efforts 
to better emulate the in vivo liver tissue environment that mimics complex multicellular and 
cell-matrix interactions. Examples include the co-culture of primary hepatocytes with non-
parenchymal cells such as hepatic sinusoidal endothelial cells and fibroblasts, in either 
conventional two dimensional (2D) platforms or as three dimensional (3D) spheroids (Bader 
et al., 1996;  Bhatia et al., 1999). More recently, a complex 3D quasi-liver “bud” was also 
successfully engineered from a co-culture of human pluripotent stem cell-derived HLCs with 
non-hepatocyte cell lines, and this showed promising functional improvement of the HLCs 
compared to conventional 2D culture (Takebe et al., 2013).  
However, for the application of HLC cultures with heterogeneous maturity and complex 
hepatic co-culture models in the study of drug-induced toxicity, a hepatocyte-specific marker 
of hepatocyte perturbation is needed to discriminate non-specific cellular toxicity contributed 
by non-hepatocyte cell types present within the model. This is currently lacking as the 
cytotoxicity assays routinely used in in vitro toxicology research depend on intracellular 
molecules which are ubiquitously present in all eukaryotic cell types.  Parameters commonly 
used in cytotoxicity assays include the release of the stable cytoplasmic molecule lactate 
dehydrogenase (LDH) from necrotic cells, or change in the metabolic activity of viable cells, 
by either relative quantification of intracellular adenosine triphosphate (ATP), or reduction of 
substrates such as tetrazolium salts by cellular oxidoreductase enzymes using the MTT or 
MTS colorimetric assays (Lappalainen et al., 1994;  Mosmann, 1983;  Slater, 2001). These 
intracellular molecules and enzymes that are used in these assays are not cell-specific, and 
therefore the parameters described above to measure toxicity and cell viability can only be 
applied accurately in models incorporating homogeneous cultures. Therefore, in the 
emerging models of DILI which take the field beyond assaying simple single hepatocytes or 
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HLCs, current toxicological endpoints largely reflect the global toxicity of the different cell 
types in the culture, and are not able to specifically measure only the perturbation of the 
hepatocytes or HLCs. 
In this chapter, the concept of using microRNA-122 (miR-122) as a potential hepatocyte-
enriched marker of toxicity was explored. MicroRNAs (miRs) are highly-conserved small 
non-coding RNAs responsible for translational regulation of messenger RNAs (Chen and 
Rajewsky, 2007;  Lagos-Quintana et al., 2001). Some miR species demonstrate high tissue 
enrichment, with miR-122 shown to be highly enriched and abundant in adult and foetal liver 
(Liu et al., 2009;  Sempere et al., 2004), constituting approximately 70% of the total mouse 
liver miR content in one of the earliest studies (Lagos-Quintana et al., 2002). miR-122 is 
involved in hepatic differentiation via a feedback loop with the liver-enriched transcription 
factor network (Laudadio et al., 2012), and is also highly upregulated in human embryonic 
stem cell-derived hepatocytes compared to undifferentiated stem cells and early endodermal 
lineage cells (Kim et al., 2011). For these reasons, several studies have evaluated miR-122 
in the plasma as a circulating hepatocyte-specific biomarker of various liver injuries, 
including DILI in rodents and humans caused by drugs such as acetaminophen and heparin 
(Antoine et al., 2013;  Harrill et al., 2012;  Starkey Lewis et al., 2011;  Wang et al., 2009). 
Therefore, miR-122 could potentially be used as a bridging biomarker to translate findings 
from in vitro experiments to in vivo experiments and the clinical setting. However, to date, 
the utility of miR-122 as an in vitro hepatocyte-enriched marker of drug-induced toxicity has 
not been explored.  
To explore the potential application of miR-122 as a hepatocyte-enriched biomarker in 
hepatic models, the prototypical hepatotoxicants acetaminophen and diclofenac were 
chosen as model compounds. Acetaminophen overdose which causes centrilobular hepatic 
necrosis (Prescott, 1980) remains a major clinical cause of acute liver failure (Lee, 2004;  
Litovitz et al., 2002). When ingested, acetaminophen typically undergoes phase II drug 
metabolism to produce non-toxic conjugates which are then eliminated (James et al., 2003). 
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However, acetaminophen-induced hepatotoxicity has been shown to be caused by reactive 
metabolites due to concomitant bioactivation of the analgesic by phase I cytochrome-P450 
(CYP) enzymes, rather than direct effects of the parent compound (James, et al., 2003;  
Mitchell et al., 1973). The reactive metabolite has been identified as N-acetyl-p-
benzoquinone imine (NAPQI) and is produced from the oxidation of acetaminophen by 
CYP2E1, 1A2, 3A4 and 2A6 (Chen et al., 1998;  Patten et al., 1993;  Thummel et al., 1993). 
In cases of acetaminophen overdose, the hepatic reserve of glutathione which detoxifies 
NAPQI, is rapidly depleted, resulting in formation of acetaminophen-protein adducts which 
are then postulated to perturb key cellular proteins (Nelson, 1990). In contrast, diclofenac 
has been linked to rare, but clinically-relevant idiosyncratic hepatotoxicity with a 
predominantly hepatocellular pattern of injury (Banks et al., 1995;  de Abajo et al., 2004). 
Similar to acetaminophen, metabolic activation of diclofenac resulting in reactive metabolites 
and protein adducts which subsequently lead to diclofenac-induced liver injury is likely to be 
a factor (Aithal, 2011). The parent drug is metabolised by CYP2C9, 2C8, 3A4 and 2C19 
while the accumulation of the reactive metabolites is also affected by the expression of the 
phase III efflux transporter multidrug resistance protein 2 (Aithal, 2011;  Yan et al., 2005). As 
acetaminophen and diclofenac-induced toxicity largely occurs in the event of bioactivation by 
drug metabolising enzymes which are predominantly expressed in hepatic tissue, both 
compounds have been widely adopted as model hepatotoxicants to evaluate the functional 
relevance of preclinical hepatic models being developed for drug-induced toxicity (Brolen, et 
al., 2010;  Leite et al., 2012;  Szkolnicka et al., 2014). 
Therefore, the hypothesis to be addressed in this chapter is that miR-122 can be utilised as 
a hepatocyte-enriched in vitro marker of drug-induced toxicity. We aimed to address this 
using human primary hepatocytes and human pluripotent stem cell-derived hepatocytes – 
hepatic models with high levels of intracellular miR-122, treated with the model 
hepatotoxicants and aimed to compare the sensitivity of the miR-122 toxicity assay in 
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comparison with conventional cytotoxicity assays in detecting drug-induced hepatocyte 
perturbation.  
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4.2 MATERIALS AND METHODS 
4.2.1 Human subjects and tissue 
Human liver resections from surgical waste tissue were obtained from adult patients 
undergoing hepatobiliary surgery with full informed consent and ethical approval from the 
relevant institutional review boards (National Research Ethics Service REC reference: 
11/NW/0327).  
 
4.2.2 Human primary hepatocyte isolation and culture 
This work was and is an ongoing collaborative effort within the MRC Centre for Drug Safety 
Science, University of Liverpool. Human primary hepatocytes were isolated using a 
previously described method with minor modifications (LeCluyse et al., 2005). Briefly, liver 
resections were received as surgical waste tissue immediately post-resection (Aintree 
University Hospital, Liverpool, United Kingdom) and transferred on ice in N-(2-
Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES) buffer (10 mM HEPES, 136 
mM NaCl, 5 mM KCl, 0.5% (w/v) glucose, pH 7.6) to the laboratory. The liver resection 
specimens were then perfused with HEPES-buffered saline (HBS) followed by digestion with 
collagenase A (Roche) or collagenase IV (Sigma-Aldrich) in HBS containing calcium. The 
suspension containing isolated hepatocytes was then filtered through a nylon gauze and 
purified by centrifugation twice at 80x g for 5 minutes at 4oC, before the pellet was 
resuspended in Williams E medium (Sigma-Aldrich). The hepatocytes were then seeded 
onto collagen-I coated 24-well plates (BD Beckinson) at 2.5 x 105 cells/cm2 and cultured in 
Williams E medium supplemented with 1% (v/v) insulin-transferrin-selenium (from 100x 
stock, Life Technologies), 2 mM L-glutamine (Sigma-Aldrich), 10-7 M dexamethasone 
(Sigma-Aldrich) and 1% (v/v) penicillin-streptomycin (Sigma-Aldrich) at 5% CO2 and 37°C. 
After 3 hours, non-attached cells were washed away and overlaid with fresh ice-cold medium 
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containing 0.25 mg/ml of Matrigel (BD Beckinson). The media was replaced the next day at 
the start of the experiments.  
 
4.2.3 Human cancer cell line culture 
The human hepatoma cell lines (HepG2 and HuH7) and the pancreatic cancer cell line (Suit-
2) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM 
L-glutamine (Sigma-Aldrich), 10% (v/v) foetal bovine serum (FBS; Life Technologies) and 
1% (v/v) penicillin-streptomycin (Sigma-Aldrich) at 5% CO2 and 37°C.   
 
4.2.4 Human pluripotent stem cell (hPSC) culture 
The hESC line HUES7 was maintained on mitotically-inactivated murine embryonic 
fibroblasts (MEFs) as previously reported (Baxter et al., 2009), in KnockOut DMEM (KO-
DMEM; Life Technologies) supplemented with 20% (v/v) KnockOut Serum Replacement 
(KOSR; Life Technologies), 0.1 mM non-essential amino acids (NEAA), 2 mM L-glutamine 
(Life Technologies), 1% (v/v) penicillin-streptomycin (Life Technologies), 1% (v/v) insulin-
transferrin-selenium (from 100x stock, ITS; Life Technologies), 0.1 mM beta-
mercaptoethanol (Life Technologies) and 4 ng/ml fibroblast growth factor 2 (FGF2; 
PeproTech). HUES7 hESCs in 96-well plate format were kindly gifted by Professor Hanley, 
University of Manchester as part of collaboration within the Stem Cells for Safer Medicines 
(SC4SM) consortium.  
The human embryonic stem cell line (hESCs) Shef-3 was maintained on embryonic stem 
cell-qualified Matrigel (BD Beckinson) -coated plates as previously reported (Bone, et al., 
2011), in mTeSR1 (STEMCELL Technologies). Shef-3 hESCs in 96-well plate format were 
kindly gifted by Professor Tosh, University of Bath as part of collaboration within the Stem 
Cells for Safer Medicines (SC4SM) consortium. 
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Cell suspensions of human induced pluripotent stem cells, ChiPSC-18 (DEF-hiPSC™, 
Cellectis AB) were purchased and plated at a density of 70000 cells/cm2 onto a proprietary 
matrix as per protocol, and maintained using a proprietary feeder-free and defined culture 
system, DEF-CS 500 (Cellectis AB). ChiPSC-18 were generated using polycistronic 
retrovirus technology (Edsbagge, 2014 – personal communication) based on the 
transduction of the transcription factors Oct3/4, Sox2, Klf4 and c-Myc (Takahashi et al., 
2007). 
 
4.2.5 Differentiation of hPSCs into hepatocyte-like cells (HLCs) 
4.2.5.1  Directed differentiation of HUES7 towards HLCs 
The differentiation of HUES7 hESCs towards definitive endoderm was commenced 3-4 days 
post-passage onto fresh MEFs in Roswell Park Memorial Institute (RPMI) media (Sigma-
Aldrich) supplemented with 0.5% (v/v) FBS (Life Technologies), 100 ng/ml activin A (AA, 
PeproTech) and 25 ng/ml Wnt-3a (R&D Systems) for 48 hours, followed by 0.5% (v/v) FBS 
(Life Technologies) and 100 ng/ml AA (PeproTech) without Wnt-3a for a further 48 hours. 
Hepatic specification was then carried out for 6 days in Hepatocyte Culture Medium (HCM; 
Lonza) supplemented with 20 ng/ml bone morphogenetic protein 2 (BMP2; R&D Systems) 
and 30 ng/ml fibroblast growth factor 2 (PeproTech). For the hepatocyte maturation stage, 
the HLCs were cultured in HCM supplemented with 20 ng/ml hepatocyte growth factor (HGF, 
PeproTech) for 5 days followed by HCM supplemented with 10 ng/ml oncostatin M (R&D 
Systems) and 10-7 M dexamethasone (Sigma-Aldrich) for a further 15 days. Differentiation of 
HUES7-derived HLCs in 96-well plate format were performed in the laboratory of Professor 
Hanley, University of Manchester, who kindly gifted us the material as part of collaboration 
within the Stem Cells for Safer Medicines (SC4SM) consortium. 
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4.2.5.2  Directed differentiation of Shef-3 towards HLCs 
The differentiation of Shef-3 hESCs towards hepatocyte-like cells (HLCs) was performed 
using a 3-stage differentiation protocol. Briefly, to induce differentiation to definitive 
endoderm (DE), Shef-3 hESCs were cultured in RPMI media (Life Technologies) containing 
100 ng/ml AA (PeproTech) and 2 μM 1m for 24 hours, followed by 100 ng/ml AA and 0.2% 
(v/v) HyClone FBS (Fisher Scientific) for 48 hours. DE cells were then passaged as single 
cells with Accutase (STEMCELL Technologies) onto Matrigel (BD Beckinson) -coated 96-
well plates at a density of 18,000 cells/well. Hepatic specification was carried out for 7 days 
in KO-DMEM supplemented with L-glutamine (Life Technologies), 0.5% (v/v) penicillin-
streptomycin (Life Technologies), 1 mM NEAA (Life Technologies), 2% (v/v) KnockOut 
Serum Replacement (Life Technologies), 10 ng/ml HGF (PeproTech) and 10 ng/ml fibroblast 
growth factor 4 (FGF4; PeproTech). To allow for maturation, HLCs were cultured for 14 days 
in Williams E medium supplemented with L-glutamine (Life Technologies), 0.5% (v/v) 
penicillin-streptomycin, 1% (v/v) ITS (from 100x stock, Life Technologies), 10 ng/ml 
oncostatin M (PeproTech), 10 ng/ml HGF (PeproTech), 10 ng/ml FGF4 (PeproTech), 10 
ng/ml epidermal growth factor (PeproTech) and 10-7 M dexamethasone (Sigma-Aldrich). 
During hepatic induction and maturation, medium was replenished every other day. 
Differentiation of Shef-3-derived HLCs in 96-well plate format were performed in the 
laboratory of Professor Tosh, University of Bath, who kindly gifted us the material as part of 
collaboration within the Stem Cells for Safer Medicines (SC4SM) consortium. 
 
4.2.5.3  Commercially-sourced HLCs 
ChiPSC-18-derived HLCs were purchased in plated 96-well plate formats (HEP-104-0096, 
Cellectis AB) which was received at Day 23 of differentiation and maintained with proprietary 
media, HEP-104-SUP (Cellectis AB).  
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4.2.6 Cytotoxicity assays 
Human primary hepatocytes, HLCs and undifferentiated human pluripotent stem cells were 
treated for up to 24 hours with acetaminophen (0 mM – 30 mM, Sigma-Aldrich) and 
diclofenac (0 mM – 1 mM, Sigma-Aldrich), which were dissolved and diluted to the final test 
concentrations in the appropriate culture media. The range of concentrations used in the 
cytotoxicity assays were chosen to incorporate the concentration of 30 times the reported 
efficacious concentration (Cmax) for each compound in humans, which was suggested to be 
the optimal drug concentration for in vitro prediction of human toxicity (O'Brien et al., 2006).  
The human primary hepatocytes and the hiPSCs (ChiPSC-18) were treated with the test 
compounds 24 hours after seeding, while for the ChiPSC-18-derived HLCs, cytotoxicity 
assays were started on Day 31 of differentiation.  
 
4.2.6.1  LDH activity assay 
For the human primary hepatocyte samples, both the cellular lysates and media at the end 
of the experiments were collected and assayed separately for LDH using the Cytotoxicity 
Detection Kit (Roche). Briefly, the media was first collected and the cells lysed in medium 
containing 2% (v/v) Triton X-100 (Sigma-Aldrich). Both the media and cellular lysate were 
then stored in -80°C immediately. The level of LDH activity (a surrogate for the quantity of 
LDH molecules) in each sample was determined separately as per the manufacturer’s 
instructions and the percentage of LDH activity in the media was expressed as a percentage 
of the combined total intracellular and extracellular LDH activity in the well. 
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4.2.6.2  Intracellular ATP assay 
The quantification of intracellular ATP in HLCs and undifferentiated human pluripotent stem 
cells was performed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). 
Following dosing of the cells with acetaminophen and diclofenac for 24 hours, the media was 
collected first for miR-122 analysis and the remaining adherent cells used for ATP 
measurement. Briefly, 50 μL of Dulbecco's Phosphate Buffered Saline (Life Technologies) 
was added to each well followed by 50 μL of CellTiter-Glo reagent which was prepared 
according to the manufacturer’s protocol. The contents were mixed in a plate shaker for 2 
minutes to induce cell lysis and then incubated for 10 minutes at room temperature. The 
cellular lysate was then transferred to an opaque 96-well plate and the luminescent signal 
measured using a Varioskan Flash spectral scanning multimode reader (Thermo Scientific). 
 
4.2.7 Total RNA extraction 
The purification of total RNA containing the miR fraction from media or lysate samples was 
performed using the miRNeasy mini kit (Qiagen), as per the manufacturer's instructions, with 
some modifications. Briefly, a typical 40 μL of media or lysate diluted in RNAse-free water up 
to a total volume of 200 μL was used for RNA purification in each experiment. Following 
addition of 700 μL of QIAzol (Qiagen) to the diluted media or lysate, and incubation at room 
temperature for 10 minutes, 5 μL of a 5 fM solution of cel-lin-4 (Integrated DNA 
Technologies) was added as a spiked-in exogenous non-human miR to monitor for the 
efficiency of the miR extraction process by evaluation of the amount of recovered cel-lin-4 in 
each sample. 140 μL of chloroform was then added and the rest of the protocol was as per 
the manufacturer’s instruction. The total RNA containing the miR fraction was eluted with 
RNase-free water and quantification performed using the NanoDrop spectrophotometer 
(Thermo Scientific). The fully automated platform QIAcube (Qiagen) was used in the 
extraction of total RNA containing miRs in the HLC media samples.   
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4.2.8 Real-time quantitative RT-PCR (qRT-PCR) analysis of miR-122 
MiR-122 levels in each sample were determined using the TaqMan gene expression assay 
(Applied Biosystems) according to the manufacturer’s protocol. Briefly, a reverse 
transcription (RT) cocktail mixture containing specific stem-loop RT primers for each target 
miR species (Applied Biosystems) was prepared as instructed and added to 5 μL of the total 
RNA elute for complementary DNA (cDNA) synthesis in a total volume of 15 μL using the 
GeneAmp PCR System 9700 thermal cycler (Applied Biosystems). 1.33 μL of cDNA was 
then mixed with a PCR mixture containing specific stem-loop PCR primers in a total volume 
of 20 μL. Real-time PCR was then performed in duplicates with the ABI Prism 7000 or ViiA 7 
Real-Time PCR instruments (Applied Biosystems) using a 2-step thermal cycling protocol of 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. 
Ct values were determined using the fluorescent signal produced from the TaqMan probes. 
The number of copies of miR-122 in each PCR reaction was quantified using the absolute 
quantification method with a standard curve of cel-lin-4 cDNA used as a surrogate for miR-
122 cDNA, due to its similar nucleotide length and to avoid contamination of PCR reactions 
with synthetic miR-122. The total number of copies of miR-122 in each sample was then 
extrapolated from this figure. For the human primary hepatocyte samples, both the total 
copies of miR-122 in the cellular and media components were determined separately, and 
the percentage of miR-122 in the media was expressed as a percentage of the combined 
total of intracellular and extracellular miR-122 copies in the well, analogous to the LDH 
cytotoxicity assay. 
 
4.2.9 Statistical analysis 
For comparison of the intracellular miR-122 level between models, the mean and the 
standard error of the mean of each model was determined. For comparisons between each 
model with human primary hepatocytes, the Mann-Whitney non-parametric test was used, 
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while the Dunn’s multiple comparison test was used for comparison of more than two 
models. For the cytotoxicity assays, the unpaired t-test was used for pairwise comparisons, 
while correlation analyses were performed using the Pearson correlation test. For all tests, p 
< 0.05 was considered significant. Statistical analyses were performed using GraphPad 
Prism 6 (GraphPad Software). 
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4.3 RESULTS 
4.3.1 Intracellular miR-122 levels reflect the physiological relevance of human 
hepatic models 
Freshly-isolated human primary hepatocytes are currently considered to be the most 
physiologically-relevant single cell in vitro hepatic model, particularly due to their functional 
recapitulation of the in vivo metabolic processes such as phase I and II enzyme activities, 
glucose metabolism and ammonia detoxification (Godoy, et al., 2013;  Kia, et al., 2013). 
Therefore, to investigate the relevance of miR-122 as a potential biomarker in in vitro hepatic 
models, we first performed quantification of the intracellular level of miR-122 among the 
commonly used hepatic models of liver cancer cell lines (HepG2 and HuH7) and human 
pluripotent stem cell-derived HLCs in direct comparison to freshly-isolated and plated human 
primary hepatocytes from adult donors.  
We found that the mean intracellular miR-122 level normalised to the amount of total RNA 
used for qRT-PCR, is the highest in human primary hepatocytes, with a 9- to 41-fold lower 
expression in hPSC-derived HLCs, 410-fold lower in HepG2 and 2600-fold lower in HuH7 
(Figure 4.1). Human primary hepatocytes also expressed significantly more miR-122 
compared to undifferentiated hPSCs (3900- to 78000-fold lower) and the pancreatic cancer 
cell line Suit2 (17000-fold lower), which was included as part of the comparison as a 
negative control for non-hepatic cells of the endodermal lineage.  
Overall, the results in Figure 4.1 confirm that miR-122 is highly enriched in human primary 
hepatocytes and provide a quantitative comparison of intracellular miR-122 among the most 
relevant human hepatic in vitro models currently used.  
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Figure 4.1 Quantitative comparison of intracellular miR-122 between human hepatic 
models. 
Data is presented as the mean total number of copies of intracellular miR-122 per µg of total 
RNA +/- standard error of the mean (SEM) for human primary hepatocytes, hPH (n = 6 
different donors), HLCs differentiated from HUES7 and Shef-3 hESC lines (n = 3 separate 
differentiation experiments each), HLCs differentiated from ChiPSC-18 hiPSC line (n = 3 
separate differentiation experiments), HepG2 (n = 4 independent experiments), HuH7 (n = 3 
biological replicates from one experiment), Suit2 (n = 3 biological replicates from one 
experiment) and undifferentiated human pluripotent stem cell (hPSC) lines (n = 3 
independent experiments each). * denotes p < 0.05, ** denotes p < 0.01, ns denotes non-
significance.  
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4.3.2 miR-122 expression increases during directed differentiation of hESCs and 
hiPSCs towards HLCs 
The mean fold increase of miR-122 in HLCs differentiated from their respective hESC lines 
was similar (420- and 430- fold change respectively), in contrast to the varying basal levels 
of miR-122 in the undifferentiated hESCs, while in the HLCs differentiated from the hiPSC 
line (ChiPSC-18), the mean miR-122 level was 3500-fold higher (Figure 4.1). There was also 
no significant difference between the mean intracellular miR-122 levels among the HLCs 
derived from the two hESC lines and ChiPSC-18, or between the low levels of mean 
intracellular miR-122 detected in the undifferentiated pluripotent stem cell lines. 
 
4.3.3 The relative level of miR-122 detected in the media correlates with the 
extracellular release of LDH in drug-induced toxicity of human primary hepatocytes 
To explore the potential of miR-122 as an in vitro marker of drug-induced cellular 
perturbation, we first compared its performance against the conventional marker of cellular 
necrosis, LDH, using human primary hepatocytes. We chose to validate miR-122 against 
LDH, as the levels of LDH and miR-122 can be readily measured in both the cellular lysate 
and media component, which allows for direct comparison of the sensitivity of both markers 
in detecting drug-induced toxicity. 
Dose-response experiments using human primary hepatocytes treated with the known 
hepatotoxicants acetaminophen and diclofenac (Figure 4.2A and 4.2B) were performed. The 
LDH activity in the media and cellular fraction of each well were separately measured to 
calculate the relative percentage of total LDH activity in the media. In parallel experiments, 
using the same donor-batch of human primary hepatocytes, we also quantified the number 
of copies of miR-122 in the media and cellular fraction in response to acetaminophen and 
diclofenac, and calculated the relative percentage of total miR-122 in the media (Figure 4.2A 
and 4.2B). We found that the level of miR-122 increased in the media with increasing 
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concentrations of acetaminophen and diclofenac, which paralleled the extracellular release 
of intracellular LDH, with significant levels of both molecules detected in the media at the 
maximal concentrations of acetaminophen and diclofenac used in this study (Figure 4.2A 
and 4.2B). By plotting the paired values of each biomarker obtained from the experiments 
using various concentrations of acetaminophen and diclofenac in a scatter graph, we 
confirmed that there was a high positive correlation between the levels of LDH and miR-122 
in the media (Pearson’s correlation coefficient, r = 0.993, p < 0.0001, 95% CI 0.974 to 0.998) 
(Figure 4.2C). This suggests that using the model of human primary hepatocytes, miR-122 is 
equivalent to LDH when used as an in vitro biomarker of drug-induced toxicity.  
We also performed a time-course experiment on the hepatocytes treated with diclofenac 
over 24 hours and observed comparable trends in both biomarkers in the media with a 
concentration of 1 mM (Figure 4.3A and 4.3B). Increased levels of both biomarkers were 
detected in the media after 2 hours, although significant levels were only detected at 24 
hours using either biomarker (Figure 4.3A and 4.3B). This suggests miR-122 is as sensitive 
as LDH when used as a toxicity marker for human primary hepatocytes but the time-course 
experiments using diclofenac as the test compound, did not point towards the possibility of 
miR-122 providing an earlier signal of hepatocyte perturbation compared to LDH. 
We also observed that the miR-122 level in the media has a wider dynamic range compared 
to LDH. In both sets of dose-response experiments, the untreated human primary 
hepatocytes showed a baseline mean percentage of total LDH in the media at 24 hours of 
6.4% and 6.9% respectively, compared to a baseline mean percentage of total miR-122 of 
1.8% and 1.4% (Figure 4.2A and 4.2B). When a toxic concentration of 30 mM 
acetaminophen was used, the mean increase over baseline of LDH in the media was 6.8-
fold compared to a higher mean increase of 25-fold for miR-122 (Figure 4.2A). Similarly, 
human primary hepatocytes treated with 1 mM diclofenac showed a mean increase over 
baseline of LDH in the media of only 8.9-fold compared to a higher mean increase of 53-fold 
for miR-122 (Figure 4.2B).  
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We then sought to simplify the miR-122 assay further and observed that the estimation of 
the total copies of miR-122 in the media alone is sufficiently predictive of the relative 
percentage of total miR-122 in the media. It has a wide dynamic range and the denominator 
of the total number of copies of miR-122 in both the cellular lysates and the media 
component remained fairly constant throughout the various validation experiments (Figure 
4.4 and Figure 4.5). Using the experimental values obtained from the dose-response 
experiments of hepatocytes treated with various concentrations of acetaminophen and 
diclofenac, we found a high positive correlation between the mean percentage of total miR-
122 and the mean number of copies of miR-122 in the media (Pearson’s correlation 
coefficient, r = 0.967, p < 0.0001, 95% CI 0.882 to 0.991) (Figure 4.6A). There was also a 
similarly high positive correlation between the mean percentage of total LDH activity and the 
mean number of copies of miR-122 in the media (Pearson’s correlation coefficient, r = 0.945, 
p < 0.0001, 95% CI 0.810 to 0.985) (Figure 4.6B). Therefore, by absolute quantification of 
the number of copies of miR-122 in the media alone, the miR-122 assay as a biomarker of 
toxicity is made simpler without the need to measure the miR-122 level in the cell lysate 
component. Drug-induced perturbation of the hepatic models can be evaluated using only 
the media component by relative comparison with the baseline levels of miR-122 in the 
media.  
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Figure 4.2 Dose-response of human primary hepatocytes after treatment with 
acetaminophen and diclofenac. 
Percentage of total LDH and miR-122 in the media of human primary hepatocytes at 24 
hours post-treatment with (A) acetaminophen and (B) diclofenac. Data is presented as the 
mean +/- SEM from 3 independent experiments using different donors of human primary 
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hepatocytes. For each donor batch of hepatocytes, parallel experiments were performed in 
duplicates to compare the sensitivity of LDH and miR-122 as biomarkers. The unpaired t-test 
was used to compare the statistical significance of the dose-response as measured by the 
percentage of total marker in the media for each concentration of hepatotoxicant against the 
respective untreated controls. * denotes p < 0.05, ** denotes p < 0.01, † denotes p < 0.0001. 
(C) Correlation of the percentage of total LDH in the media against the percentage of total 
miR-122 in the media, using paired mean values for each condition obtained from 
experimental results summarised in Figures 2A and 2B. r denotes Pearson’s correlation 
coefficient, CI denotes the confidence interval of r. 
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Figure 4.3 Hepatotoxicity of human primary hepatocytes treated with diclofenac up to 
24 hours.  
Time-course experiment of human primary hepatocytes treated with diclofenac up to 24 
hours as measured by (A) percentage of total LDH in the media and (B) percentage of total 
miR-122 in the media. Data is presented as the mean +/- SEM from 3 independent 
experiments using different donors of human primary hepatocytes. For each donor batch of 
hepatocytes, parallel experiments were performed in duplicates to compare the sensitivity of 
LDH and miR-122 as biomarkers. The unpaired t-test was used to compare the statistical 
significance of the percentage of total marker in the media at each timepoint compared to 
untreated controls. * denotes p < 0.05 
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Figure 4.4 Analysis of the change in the number of copies of miR-122 in the lysate and 
media components of human primary hepatocyte cultures treated with 
acetaminophen and diclofenac.   
Data is presented as the mean +/- SEM of the number of copies of miR-122 in the lysate 
and/or media components of the dose-response experiments of human primary hepatocytes 
treated with (A) acetaminophen and (B) diclofenac, from 3 independent experiments using 
different donors of human hepatocytes. The number of copies of miR-122 estimated in the 
media and lysates were normalised to the number of hepatocytes in the culture to allow for a 
direct comparison of absolute quantities of miR-122 in the media with other cell types used 
for similar cytotoxicity assays. The cytotoxicity assays were performed on hepatocytes 
plated in 24-well plates at a density of 5 x 105 hepatocytes per well. The same raw values 
from these graphs were used to calculate the percentage of total miR-122 in the media 
shown in Figure 4.2. 
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Figure 4.5 Analysis of the change in the number of copies of miR-122 over time in the 
lysate and media components of human primary hepatocyte cultures treated with 
non-toxic and toxic concentrations of diclofenac. 
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Data is presented as the mean number of copies of miR-122 in the lysate and/or media 
components of the time-course experiments of (A) Untreated human primary hepatocytes, 
and hepatocytes treated with (B) non-toxic concentration of 0.1 mM diclofenac and (C) toxic 
concentration of 1 mM diclofenac. Error bars indicate the SEM from 3 independent 
experiments using different donors of human primary hepatocytes. The same raw values 
from these graphs were used to calculate the percentage of total miR-122 in the media 
shown in Figure 4.3. 
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Figure 4.6 Correlation between absolute quantification of miR-122 copies in the media 
and the relative percentage levels of miR-122 and LDH in the media of human primary 
hepatocytes treated with acetaminophen and diclofenac 
Experimental values from the dose-response experiments of human primary hepatocytes 
treated with acetaminophen and diclofenac for 24 hours (Figure 4.2) were used to examine 
the correlation of mean number of copies of miR-122 with (A) mean percentage of total miR-
122 and (B) mean percentage of total LDH, in the media. r denotes Pearson’s correlation 
coefficient, CI denotes the confidence interval of r. 
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4.3.4 The level of miR-122 in the media reflects hepatocyte-specific drug-induced 
toxicity in hiPSC-derived HLCs  
We then explored the use of miR-122 in complex human hepatic models which may not be 
homogeneous such as cultures of HLCs, where the differentiation efficiency can be variable 
and not 100% predictable (Baxter, et al., 2010;  Kia, et al., 2013). We hypothesised that the 
hepatocyte-enriched expression of miR-122 could be used to detect selectively drug-induced 
perturbation of the HLCs, without concomitant measurement of cellular toxicity of other non-
hepatocyte cells present in the culture, as is the case with other simple cellular markers of 
toxicity such as LDH and ATP, and others used in multiparametric high content screening 
platforms (Rausch, 2006). 
The use of miR-122 as an in vitro biomarker in hiPSC-derived HLCs (ChiPSC-18-derived 
HLCs) was explored using the same hepatotoxicants (acetaminophen and diclofenac), and 
compared against the sensitivity of intracellular ATP quantification by multiplexing both 
assays in the same experiments. We chose to use the intracellular ATP assay instead of the 
LDH activity assay to compare against the miR-122 assay for the cytotoxicity experiments 
utilising HLCs, as the much smaller volume of media available for each culture of HLCs (100 
uL total volume per well in a 96-well plate format) did not allow for sufficient material for both 
extraction of miRs and quantification of the LDH activity in the media. However, the 
intracellular ATP assay has been separately validated by our group for assessment of drug-
induced hepatocyte perturbation, using different donors of freshly-isolated adult human 
primary hepatocytes treated with a similar dose range of acetaminophen and diclofenac (n = 
8 and n = 6 respectively). The endpoint of change in intracellular ATP level was confirmed to 
significantly correlate with the percentage of total LDH activity in the media, percentage of 
total miR-122 in the media and the number of copies of miR-122 per million cells in the 
media (unpublished data).      
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In parallel experiments, we also used the undifferentiated hiPSCs (ChiPSC-18) from which 
the HLCs were derived from, as a surrogate for poorly differentiated cells present in HLC 
cultures that do not possess a hepatic phenotype and express a very low level of 
intracellular miR-122 relative to hepatic cells, to examine the hepatic specificity of miR-122 
as an in vitro marker of toxicity. Each batch of HLCs or hiPSCs were treated with 
acetaminophen or diclofenac over 24 hours, and the lysate was used for the ATP assay, 
whilst the media from the same well was collected in order to estimate the number of copies 
of miR-122 (Figure 4.7A to 4.7D). Using the ATP assay, perturbation of the HLCs was 
detected, with a mean reduction of ATP of 35% and 33% respectively at 24 hours, when the 
cells were treated with the highest concentrations of acetaminophen and diclofenac (Figure 
4.7A and 4.7B). However, the non-hepatocyte model of hiPSCs displayed a higher reduction 
in ATP levels, with lower concentrations of acetaminophen (56% with 10 mM and 99% with 
30 mM), confirming ATP as a generic and non-cell-type specific marker of cellular 
perturbation (Figure 4.7A). In contrast, the hiPSCs, when treated with diclofenac, displayed 
increased ATP levels of up to 196% of baseline (Figure 4.7B).  
Using miR-122 as a marker for drug-induced toxicity in the same experiments, a trend 
towards an increase in the number of copies of miR-122 in the media of HLCs was noted 
with acetaminophen and diclofenac, with a mean 4-fold and 6-fold increase from baseline 
respectively, at the highest concentrations used in these experiments (Figure 4.7C and 
4.7D). This suggested that when the miR-122 assay was used as a toxicity assay for the 
HLCs, its performance was as sensitive as the ATP assay. This was confirmed by a 
correlation analysis using the paired values of both assays from the experiments using HLCs 
treated with acetaminophen and diclofenac at various concentrations (Figure 4.8A). By 
plotting the values in a scatter graph, a significant negative correlation was found (Pearson’s 
correlation coefficient, r = -0.862, p < 0.001, 95% CI -0.961 to -0.571).  
However, in contrast to the varying intracellular ATP profile seen in the hiPSCs treated with 
acetaminophen and diclofenac (Figure 4.7A and 4.7B), the miR-122 level in the media did 
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not display any increasing trend and was fairly constant throughout the range of 
concentrations of the hepatotoxicants (Figure 4.7C and 4.7D). Analysis utilising the paired 
values of both biomarkers from the experiments using hiPSCs described above, also 
showed no correlation between the levels of miR-122 in the media and the change in 
intracellular ATP levels in the hiPSCs (Pearson’s correlation coefficient, r = 0.041, p = 0.901, 
95% CI -0.546 to 0.601) (Figure 4.8B).  
The total number of copies of miR-122 expressed by an equivalent number of hiPSCs was 
also at least 78-fold less than that expressed by the HLCs, and therefore the potential 
contributory effect of miR-122 from the non-hepatocyte cells in HLC cultures towards the 
total number of copies of miR-122 measured in the media was negligible. More importantly, 
at the toxic concentrations of acetaminophen and diclofenac, where a reduction of 
intracellular ATP level and an increase in miR-122 in the media of treated HLCs was 
detected (Figure 4.7A to 4.7D), the corresponding miR-122 level in the media of hiPSCs 
treated with the same concentrations remained unchanged. This meant that the source of 
increased level of miR-122 in a heterogeneous culture such as HLCs treated with toxic 
concentrations of hepatotoxicants was likely to be from hepatic cells with a high level of 
intracellular miR-122 – in this case well-differentiated HLCs. 
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Figure 4.7 Dose-response of hepatocyte-like cells (ChiPSC-18-derived HLCs) and 
undifferentiated human induced pluripotent stem cells (ChiPSC-18) after treatment 
with acetaminophen and diclofenac. 
(A, B) Intracellular ATP level (expressed as percentage of vehicle control) and (C, D) 
number of copies of miR-122 per million cells in the media of hiPSC-derived HLCs and 
undifferentiated hiPSCs treated with acetaminophen and diclofenac for 24 hours. Data is 
presented as the mean +/- SEM from 3 independent experiments. For the HLCs, each 
independent experiment represented HLCs from separate differentiation experiments, while 
for the hiPSCs, each independent experiment represented separate batches of hiPSCs 
plated on different days. The cytotoxicity assays were performed in at least two replicates on 
HLCs and hiPSCs cultured in 96-well plates. The number of copies of miR-122 estimated in 
the media was normalised to the number of cells estimated to be present in the HLC and 
hiPSC cultures to allow for a direct comparison of absolute quantities of miR-122 in the 
media. The density of HLCs present in a single well was estimated to be about 1 x 105 
cells/cm2 when the HLC culture was fixed and stained with the nuclear stain 4',6-diamidino-
2-phenylindole (DAPI) (data not shown). As the total cell culture surface per well was 0.32 
cm2, a total number of 3.2 x 104 HLCs per well was obtained. For the hiPSCs, a total number 
of 2.2 x 104 hiPSCs per well was obtained using the plating density of 7 x 105 cells/cm2. 
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Figure 4.8 Correlation of intracellular ATP activity with miR-122 level in the media. 
Correlation between intracellular ATP activity (expressed as percentage of vehicle control) 
and number of copies of miR-122 per million cells in the media of (A) hiPSC-derived HLCs 
and (B) undifferentiated hiPSCs, treated with acetaminophen and diclofenac over 24 hours 
using paired mean values obtained from experimental results summarised in Figure 4. r 
denotes Pearson’s correlation coefficient, CI denotes the confidence interval of r. 
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4.4 DISCUSSION 
MicroRNA-122 has been shown to be a liver-enriched and -abundant miR, which could be 
useful as a bridging biomarker of drug-induced hepatotoxicity to translate findings from in 
vitro experiments to in vivo experiments and the clinical setting.   
However, quantitative evaluation of its abundance in various in vitro hepatic models currently 
used for the study of drug-induced hepatotoxicity in comparison to human primary 
hepatocytes has not been considered. For this study, we first confirmed that the in vitro 
hepatic models examined express high levels of miR-122, in contrast to the non-hepatic 
models (Figure 4.1). The lower intracellular miR-122 levels in the various models in 
comparison to freshly-isolated human primary hepatocytes, suggest that the quantity of 
intracellular miR-122 broadly reflects the models’ degree of hepatic phenotype. HLCs 
differentiated in conventional two dimensional (2D) cultures have not yet been reported to 
display a full complement of drug metabolising enzymes at comparable levels to human 
primary hepatocytes (Kia, et al., 2013;  Sjogren et al., 2014;  Ulvestad et al., 2013), while 
HLCs derived from pluripotent stem cell lines with normal genotypes would be expected to 
exhibit a physiologically more relevant hepatic phenotype compared to liver cancer cell lines, 
as shown by previous studies directly comparing the drug metabolising capacity of 
pluripotent stem cell-derived HLCs and the hepatocellular cancer cell lines, HepG2 and 
HuH7 (Brolen, et al., 2010;  Sjogren, et al., 2014;  Soderdahl et al., 2007). Therefore, miR-
122 can also be potentially exploited as a biomarker of physiological relevance of current 
and emerging in vitro hepatic models for mechanistic studies of DILI, by correlating their 
intracellular level of miR-122 to the biochemical and functional phenotype.  
Figure 4.1 also supports a previous observation that the miR-122 expression increases 
during directed differentiation of hESCs towards HLCs (Kim, et al., 2011). In that study, only 
a single hESC line was used for HLC generation using a different protocol to those used in 
this study. Hence our study adds to that finding as we used two different hESC lines, 
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maintained in both feeder and feeder-free culture conditions, and were differentiated towards 
HLCs using two disparate protocols. This study also demonstrates for the first time, that 
HLCs differentiated from hiPSCs also exhibit a similar trend of increase in miR-122 
expression to hESC-derived HLCs, although only one hiPSC line was examined in this 
study.  
In homogeneous hepatic models, such as plated human primary hepatocytes or HLC 
cultures derived with high differentiation efficiencies, we propose that the miR-122 
cytotoxicity assay, which has marked concordance with the conventional assays utilising 
generic markers (Figures 4.2, 4.3 and 4.8), is a more relevant cell-type-specific assay to 
examine drug-induced toxicity of the hepatic cells. As alluded to earlier, one major 
advantage of using miR-122 as an in vitro biomarker is also the potential to translate such in 
vitro findings to in vivo animal models and human samples using the same assay, as miR-
122 in the plasma has been shown to be an appropriate marker of acetaminophen-induced 
liver injury in a mouse model and in humans (Antoine, et al., 2013;  Harrill, et al., 2012;  
Starkey Lewis, et al., 2011;  Wang, et al., 2009). In other words, miR-122 can be used to 
bridge results in in vitro experiments to clinical findings, and conversely used to link findings 
from clinical studies to inform on the relevance of in vitro models being developed for the 
study of DILI, which the current conventional in vitro markers including LDH and ATP could 
not provide. 
Similarly, in models where heterogeneity of the hepatic phenotype is present such as in HLC 
cultures with moderate or variable differentiation efficiencies, the miR-122 cytotoxicity assay 
may be essential as it allows for specific assessment of the effect of hepatotoxicants on the 
hepatic cells and the ability to discriminate from the “noise” of the surrounding non-
hepatocytes. For example, determining the relative intracellular ATP levels between mature 
HLCs and poorly differentiated endodermal progenitors or differentiated cells of other 
lineages in a typical HLC culture would not be possible, as the ATP assay readout reflects 
the composite of all the ATP content present within a culture. Therefore, the dose-response 
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of mature HLCs specifically towards hepatotoxicants in a heterogeneous culture cannot be 
reliably measured using the ATP assay or any other assays utilising biomarkers ubiquitously 
present in all cells, such as LDH. This was borne out in our study where the non-hepatocyte 
model of hiPSCs displayed higher levels of toxicity as measured by the reduction of 
intracellular ATP levels at lower concentrations of acetaminophen, likely through non-CYP 
dependent mechanisms, confirming ATP as a generic and non-cell-type specific marker of 
cellular perturbation (Figure 4.7A). Conversely, the ATP levels in hiPSCs treated with 
diclofenac increased up to 196% of baseline (Figure 4.7B). Although the effect of diclofenac 
on human pluripotent stem cells have not been reported in the literature, this increase is 
likely to be an effect of hormesis.  
The utility of the miR-122 cytotoxicity assay for the specific assessment of the effect of 
hepatotoxicants on hepatic cells is also potentially applicable in complex 2D or 3D hepatic 
models of human hepatocytes co-cultured with their non-parenchymal counterparts, which 
are widely considered to be the ideal in vitro hepatic models as they mimic the complex 
multicellular interactions that recapitulate the niche environment in the human liver (Godoy, 
et al., 2013). Indeed, exciting progress has been reported in using human hepatocytes and 
pluripotent stem cell-derived HLCs in co-cultures with non-hepatocyte cells to produce in 
vitro hepatic models with improved functional phenotype (Bhatia, et al., 1999;  Takebe, et al., 
2013). Although the co-culture with non-hepatocyte cells enhances the functional phenotype 
of the hepatic cells, their concomitant presence could conceivably complicate the analysis of 
toxicity specifically targeting the hepatocytes, using the currently available conventional 
cytotoxicity assays. Indeed, one reported approach in a co-culture model of rat primary 
hepatocytes and murine stromal support cells to calculate the hepatocyte-only responses for 
non-hepatocyte-specific endpoints such as intracellular ATP and glutathione in response to 
drug-induced toxicity, was to perform simultaneous assays on cultures of the stromal cells 
alone and to subtract subsequent values from that obtained from the co-cultures (Ukairo et 
al., 2013). However, this approach does not truly encompass the effect of the multicellular 
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interaction between the hepatocytes and the stromal cells in response to events causing 
cellular perturbation, such as drug-induced toxicity. An ideal biomarker in these co-cultures 
would be one which is specifically and dynamically changed only in the hepatic cells, and 
also measured directly in the co-cultures. We propose that miR-122 is one such hepatocyte-
enriched marker that can be applied in hepatic models that incorporate hepatocytes or HLCs 
that express high levels of miR-122.  
Although we have shown the utility of miR-122 in the human primary hepatocyte and HLC 
models, validation experiments of its predicted utility in complex co-culture hepatic models 
will still need to be conducted. Similarly, the utility of the miR-122 assay could be considered 
in high content cellular screening assays widely adopted by the pharmaceutical industry, 
which look at organelle-specific toxicity or screen for cellular perturbation events that are not 
hepatocyte-specific (Rausch, 2006). Therefore, changes in endpoints will be detected as 
readily in non-hepatocyte cells as in hepatocytes.  
In a practical sense, as the miR-122 cytotoxicity assay described here uses quantitative RT-
PCR, only a small amount of miR-122-containing media is required – we have extracted 
adequate miR-122 for analysis using as little as 50 μL of media from a total volume of 100 
μL used to maintain 2.2 x 104 hiPSCs in a 96-well format. This assay can also be 
multiplexed simultaneously with other cytotoxicity assays that require a portion of the media 
and/or cellular lysate components. Furthermore, the miR-122 assay allows for repetitive 
sampling during chronic dosing experiments, which may be a more relevant approach to 
studying DILI in humans, and will also enable sampling of hepatocyte damage in complex 
3D bioreactor cultures.  A disadvantage of this assay compared to other conventional 
cytotoxicity assays that mainly use plate readers for end-point readouts, is that the 
quantification of miR-122 in the media for each sample involves multiple pre-processing 
steps of RNA extraction and reverse transcription. So far, the miR-122 cytotoxicity assay has 
not been applied as high-throughput readouts, but our workflow in using this assay benefits 
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from the availability of automated platforms of RNA extraction, an automated instrument for 
PCR setup and a PCR platform for analysing a 384-well PCR plate format. 
Although the application of miR-122 for detecting drug-induced toxicity is shown in this 
study, the basis for the increase of miR-122 in the media during drug-induced toxicity is still 
unclear. However, our finding of a high correlation between the increases in LDH and miR-
122 in the media of human primary hepatocytes treated with hepatotoxicants, suggest that 
miR-122 may be passively released from necrotic cells (Figures 4.2 and 4.3), which is in 
keeping with the finding of miR-122 predominantly increased in the protein-rich fraction 
compared to the exosome-rich fraction in the plasma/serum samples of a mouse model of 
acetaminophen-induced liver injury (Bala et al., 2012). It was postulated that as 
acetaminophen-induced liver injury is severe and rapid, miRs may be released primarily 
through leakage from dying hepatocytes, as opposed to release through exosomes in liver 
injuries which are less severe and slower such as in alcoholic liver disease. However, 
increased cellular-mediated release of miR-122 in microparticles, exosomes or protein 
complexes as a response to toxic chemical exposure cannot be excluded (Salminen et al., 
2011). It is also unclear if drug-induced toxicity per se or individual drugs have any effect on 
the synthesis or degradation of mature miR-122, although data shown in Figure 4.4 and 
Figure 4.5 suggest that the hepatotoxicants examined in this study at least, have no effect 
on the steady state level or the total number of copies of miR-122 in the human primary 
hepatocyte cultures. Therefore, following on from the establishment of miR-122 as a useful 
in vitro marker of drug-induced toxicity, parallel bridging in vitro and in vivo studies can now 
be performed to define further the mechanism(s) of miR-122 release, which will further 
enhance the mechanism-based utility of miR-122 both as a quantitative and qualitative 
marker of liver injury.  
In summary, this chapter tested the hypothesis that miR-122 can be utilised as a hepatocyte-
enriched in vitro marker of drug-induced toxicity and our results confirmed this to be true in 
human primary hepatocytes and pluripotent stem cell-derived HLCs treated with the 
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prototypical hepatotoxicants acetaminophen and diclofenac. We have demonstrated that the 
detection of miR-122 in cell culture media can be used as an alternative in vitro marker of 
drug-induced cytotoxicity in homogeneous cultures of hepatic cells, and that this can be 
applied as a hepatocyte-enriched marker of toxicity in heterogeneous cultures of hepatic 
cells. The miR-122 cytotoxicity assay can also potentially be applied in hepatic models with 
co-culture of non-hepatocyte cells, where use of conventional cytotoxicity assays employing 
generic cellular markers may not be appropriate, though further validation experiments using 
in hepatic co-culture models will need to be conducted. We also showed that the sensitivity 
of the miR-122 cytotoxicity assay is similar to conventional assays measuring LDH activity 
and intracellular ATP levels in hepatic cultures, but further experiments with a more detailed 
dose-response of acetaminophen and diclofenac or with other model hepatotoxicants may 
clarify the potential of utilising the wider range of the miR-122 level to better discriminate the 
toxic concentration of a model hepatotoxicant, at least in comparison to LDH.  
One limitation of this study was that the CYP activity profile was not determined of the 
ChiPSC-18-derived HLCs used for the toxicity experiments, although data communicated by 
the manufacturer suggested that they possess CYP1A, 3A and 2C9 activity comparable to 
cryopreserved human hepatocytes, as measured by liquid chromatography-mass 
spectrometry (personal communication, Cellectis AB, July 2014). Therefore, it was 
presumed that the toxicity seen in the HLCs were secondary to bioactivation of the 
compounds in the presence of the relevant CYP enzymes. For future experiments, it may be 
useful to quantify the CYP activity level of HLCs used to ensure that the findings from the 
miR-122 cytotoxicity assays are reproducible in HLCs generated from different lines 
possessing a similar profile of CYP activity. Future challenges also include unravelling the 
mechanisms by which miR-122 is released into the media and understanding the effect of 
drugs on miR-122 biogenesis and stability.  
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5.1  INTRODUCTION 
As described throughout this thesis, our endeavour to develop relevant in vitro human 
hepatocyte models via novel investigative approaches was driven by the significant gaps in 
the availability of functional in vitro model systems to mechanistically understand DILI, and to 
screen for drug-induced hepatotoxicity at the early stages of drug development (Godoy et 
al., 2013;  LeCluyse et al., 2012). Ultimately, this contributes to the persistent clinical 
problem of DILI as a cause of patient morbidity and mortality, with huge financial and 
societal burden to the pharmaceutical industry and regulatory agencies (Olsen and Whalen, 
2009;  Russo et al., 2004;  Sgro et al., 2002).  
We investigated the potential of exploiting the epigenetic memory inherently present in 
hiPSCs to generate a more functional phenotype of HLCs, by performing a series of carefully 
controlled experiments of hiPSC derivation and HLC generation using liver and skin tissue 
donated by the same donor, and also explored the phenomenon of hepatic dedifferentiation 
in the gold standard in vitro hepatic model of freshly-isolated hPHs, from the novel 
perspective of understanding the potential effects of changing global miR profiles, using an 
unbiased bioinformatics approach. We also aimed to improve the extrapolation of results 
between pre-clinical and clinical studies by developing and validating a real-time quantitative 
RT-PCR-based assay of hepatocyte-enriched biomarker of miR-122, which has the unique 
potential to be applied in complex hepatic co-culture models, currently not afforded by 
conventional generic cell-based markers.   
This concluding chapter describes the implications of our findings and provides some future 
perspectives in relation to the ongoing multidisciplinary efforts to develop better hepatic 
models of DILI.  
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5.2 IMPLICATIONS OF FINDINGS AND FUTURE PERSPECTIVES 
5.2.1 The ongoing evaluation of HLCs generated from hPH-derived hiPSCs 
Results described in Chapter 2 which stemmed from the comparison of HLCs generated 
from isogenic hepatocyte- and fibroblast-derived hiPSC lines of a single donor, suggested 
that there is no advantage in the use of hPHs as the starting cell-type for deriving hiPSCs to 
generate functional HLCs (Figure 2.15 and 2.16), although it must be emphasised that 
further confirmation using tissue from other donors, preferably with at least three hPH-
derived hiPSC lines, would be important to firstly confirm the findings, and secondly to clarify 
the relative importance of donor and clonal differences in the generation of functional HLCs. 
Therefore, future comparisons using at least 3 of the 5 established hPH-derived hiPSC lines 
from Donor 2 (Table 2.3), should help to clarify our experimental findings using hiPSC lines 
from Donor 1.   
However, any potential definitive results from our ongoing experiments must be put into 
context in relation to our intended aim of improving the functional phenotype of HLCs for 
pharmaco-toxicology studies. Even if there is a proven advantage in using hPH-derived 
hiPSCs to generate HLCs, the peak functional phenotype of HLCs generated from hPH-
derived hiPSC lines is unlikely to match that of the gold standard comparator of freshly-
isolated hPHs using the current differentiation protocols. This is evidenced by the various 
reports of HLCs generated using different protocols from multiple starting cell-types, 
including hPHs (Liu et al., 2010), which showed suboptimal CYP activity profiles in 
comparison to hPHs (Kia et al., 2013), with limited information on Phase II and III enzymes 
and transporters. Furthermore, the generation of HLCs for pharmaco-toxicology studies is 
still hampered by the phenotypic instability of HLCs in extended in vitro culture (Baxter et al., 
2010;  Hay et al., 2011) – akin to the process of dedifferentiation of freshly-isolated hPH 
described in Chapter 3 – although promise has been shown in using novel polymer-based 
culture matrices to enhance stability (Hay, et al., 2011).  
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Nevertheless, understanding the contribution of different factors, such as the contribution of 
epigenetic memory of hiPSCs (Kim et al., 2010), causing variations in the hepatic 
differentiation propensity of hPSCs would be important. The attainment of a truly functional 
HLC phenotype suitable for pharmaco-toxicology studies is likely to require a combination of 
optimal conditions shown to positively influence HLC generation, starting from the choice of 
cell-types to use for hiPSC derivation, method of cellular reprogramming, culture conditions 
for hiPSC maintenance, variations of differentiation propensity between hiPSC clones, 
genetic variations between donors, to factors related to the hepatic differentiation process 
(Kajiwara et al., 2012).  
Conversely, if our hypothesis is proven to be false, our research would have contributed 
towards the conflicting findings about the role of epigenetic memory of iPSCs in influencing 
its hepatic differentiation propensity (Kajiwara, et al., 2012;  Kim et al., 2011a;  Lee et al., 
2012;  Liu et al., 2011). This would also mean that hepatic differentiation using hiPSCs 
derived from easily accessible tissue sources such as skin and peripheral blood would 
suffice, and simplify the practical considerations for in vitro modelling of normal and variant 
phenotypes from pre-selected adult donors, including donors who have suffered clinically 
relevant DILI (Kia, et al., 2013). 
Additionally, it is also possible that the potential advantage of using hiPSC lines derived from 
hPHs to generate functional HLCs may never be fully evaluated pending  the availability of a 
robust and validated hepatic differentiation protocol to generate HLCs with a functional 
phenotype more akin to a freshly-isolated hPH phenotype. Future planned experiments that 
may help address our hypothesis further that circumvent the current limitations of directed 
hepatic differentiation in monolayer culture, include phenotypic comparison of the 
spontaneous differentiation propensity of isogenic hPH- and hDF-derived hiPSCs towards 
cells of hepatic lineages using embryoid bodies. This approach was used to show the 
contribution of epigenetic memory in pancreatic beta-cell-derived hiPSCs that skewed its 
spontaneous differentiation propensity towards cells of the endodermal lineages that 
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expressed beta-cell genes (Bar-Nur et al., 2011). Alternatively, the “peak” functional 
phenotype of the HLCs may be more appropriately compared when matured further in three-
dimensional culture systems which resulted in higher gene expression of hepatic lineage 
markers, higher functional capabilities and longer duration of culture in comparison to 
conventional two-dimensional maturation of HLCs (Gieseck et al., 2014;  Subramanian et al., 
2014). 
 
5.2.2 Further definition of the utility of HLCs as a relevant model for DILI  
However, in our quest to generate HLCs with higher capabilities of metabolic bioactivation of 
xenobiotics through enhanced expression and activity of drug metabolising enzymes, the 
unique capability of patient-derived hiPSCs for in vitro modelling to capture the genetic 
factors associated with DILI caused by drugs that undergo minimal or no bioactivation, 
should not be overlooked (Kia, et al., 2013). One example is flucloxacillin-mediated liver 
injury, which is a type of idiosyncratic DILI (Godoy, et al., 2013), highly associated with a 
specific human leucocyte antigen (HLA) allele – HLA-B*5701 (Daly et al., 2009) – with 
clinical evidence of the immune component being involved (Park et al., 2005). Only 10% of a 
standard dose of flucloxacillin is metabolised to reactive metabolites by CYP3A4 (Andrews 
et al., 2010), and the parent compound have been shown to modify albumin and form drug-
protein conjugates in antigen-presenting cells to stimulate the secretion of cytokines and 
cytolytic molecules from CD8+ T-lymphocytes in a HLA-restricted manner (Jenkins et al., 
2009;  Monshi et al., 2013). However, to mechanistically study how and why flucloxacillin-
specific T-lymphocytes induce hepatocyte perturbation in a HLA-restricted manner, an in 
vitro model incorporating co-culture of isogenic hepatocytes and immune cells with HLA-
B*5701 will be needed. The only practical approach in fact to develop such a model would 
be the use of isogenic hiPSC-generated HLCs and isolated T-cells from a pre-selected 
donor or patient with that particular HLA allele (Figure 5.1), which we have started exploring 
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as part of our overall aim to develop relevant human hepatic models for DILI. The possibility 
of an in vitro model of immune-mediated DILI based on HLCs with pre-selected genotypes 
described above, exemplified the notion that despite the functional limitations of HLCs in 
recapitulating the metabolic phenotype with most if not all, important drug metabolising 
enzymes and transporters required of a hepatic model for pharmaco-toxicology studies and 
drug screening in pre-clinical drug development, further refinement of what HLCs can and 
cannot be used for will be important, while continuing progress is made in improving its 
functional status.  
For example, in a recent study which compared gene expression profiles between various in 
vitro hepatic models, HLCs have been suggested to be a good alternative to human 
cryopreserved hepatocytes for detection of compounds with direct apoptosis-driven 
cytotoxicity (Sjogren et al., 2014). The authors and others have also highlighted the potential 
role of HLCs for chronic toxicity studies as the CYP enzymes and transporter proteins 
remained relatively stable for one week, albeit at lower levels than human cryopreserved 
hepatocytes (Sjogren, et al., 2014;  Ulvestad et al., 2013). Although the CYP expression is 
lower compared to hPHs, the fact that its expression is stable and importantly do not display 
donor variations as exhibited by different batches of hPHs, may make HLCs of a single 
genetic background, a reliable in vitro model for application in the pharmaceutical industry 
for drug screening.   
Additionally, instead of focussing on attaining a certain percentage of basal CYP protein 
level in HLCs that match that of freshly-isolated hPHs, in deciding if the HLCs generated 
from a certain hPSC line using a specific differentiation protocol is functionally relevant for 
pharmaco-toxicology studies, perhaps a more relevant characterisation criteria is their CYP 
levels with drug induction. This was shown in a study using HLCs generated from hESCs 
which showed an increase in CYP3A4 and 1A2 activities of more than four-fold following 
induction with phenobarbital, and subsequently shown to have a comparable accuracy to 
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human cryopreserved hepatocytes in predicting drug-induced hepatotoxicity following 
compound incubation up to seven days (Szkolnicka et al., 2014).  
Therefore, whilst efforts continue to understand the factors that influence the functional 
status of HLCs, it is clear that HLCs have an important and unique role to play in the field of 
in vitro toxicology – the more pertinent question right now is how and where. 
 
Figure 5.1 Schematic diagram of a complex co-culture of isogenic human iPSC-
generated HLCs and isolated T-cells from a pre-selected donor or patient with HLA-
B*5701 as a potential model to study flucloxacillin-mediated liver injury. 
PBMC, peripheral blood mononuclear cells; HLA, human leucocyte antigen; iPSC, induced 
pluripotent stem cells; APC, antigen presenting cell; TC, T-cell. 
 
5.2.3  Unlocking the value of global microRNA profiling of dedifferentiating hPHs 
The detrimental process of dedifferentiation in the gold-standard in vitro model of hPH 
continue to limit its utility to acute toxicity studies only, and compromises their use in chronic 
toxicity studies with prolonged drug exposure, which would better reflect most clinical 
presentations of DILI (Guguen-Guillouzo and Guillouzo, 2010;  Kalgutkar and Soglia, 2005;  
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LeCluyse, 2001). Although the process and its detrimental effect on the metabolic phenotype 
in hPHs has been characterised extensively (Paine and Andreakos, 2004;  Vinken et al., 
2006), none of the strategies that aimed to reverse or prevent it have proved successful so 
far (Bolleyn et al., 2011;  Fraczek et al., 2013;  Naiki et al., 2004).  
Therefore, in Chapter 3, we described our contribution towards the understanding of this 
process from the novel perspective of global miR profiles of dedifferentiating hPHs. Broadly 
speaking, many of the perturbed biological processes and pathways that were linked to the 
differentially-expressed miRs have been described previously in the literature. For example, 
the ERK/MAPK and NF-ĸβ signalling pathways which are involved in proliferative and 
inflammatory responses – major mechanisms underlying hepatocyte dedifferentiation 
causing the loss of transcription of genes related to liver-specific functions – were identified 
as two of the most significantly perturbed pathways after 48 hours of in vitro culture (Figure 
3.6) (Fraczek, et al., 2013). The main implication of our study however, is the possibility of  
influencing these pathways by manipulating the expression of all or some of the relatively 
few differentially-expressed miRs that collectively target many of the genes involved in each 
pathway in a considered manner, using existing miR-targeting and/or miR replacement 
strategies (Li and Rana, 2014). Similarly, we also highlighted the fact that the differentially-
expressed miRs target many of the genes important for xenobiotic biotransformation either 
directly (Table 3.3), or indirectly via targeting associated liver-enriched transcription factors 
(LETFs) and nuclear factors (Table 3.4 and 3.5) known to regulate their expression. Perhaps 
one “simple” strategy to ensure the hPHs maintain their basal level of CYP expression and 
are fit for utility as a relevant model for pharmaco-toxicology studies is to manipulate the 
expression of miRs that negatively affect the expression of their CYP gene targets.  
Additionally, our study also identified that gene expression in general, is the most 
significantly perturbed function throughout the experiment with a large number of genes 
involved in the pre- and post-transcription levels being targeted by the differentially-
expressed miRs (Figure 3.5, Table 3.2, 3.7 and 3.8). The targets include the histone 
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deacetylases (HDACs) (Table 3.8) which are typically associated with transcriptional 
repression, hence lending credence to using HDAC inhibitors as an anti-dedifferentiation 
strategy to facilitate the restoration and maintenance of the fully differentiated phenotype of 
hepatocytes (Fraczek et al., 2009;  Henkens et al., 2007). However, as noted by some 
authors (Fraczek, et al., 2013), using broad spectrum HDAC inhibitors may not be ideal as it 
does not allow for discrimination between isozymes of HDACs that may play differing roles in 
hepatocellular processes. On the contrary, manipulation of differentially-expressed miRs that 
target specific isozymes of HDAC could potentially be a more selective HDAC inhibition 
strategy.  
However, validation studies will need to be performed to investigate the predicted effect(s) of 
targeted manipulation of the differentially-expressed miRs, and will be an ongoing focus of 
our group. Furthermore, it remains to be answered whether miRs are only silent observers or 
active participants in the process of hepatic dedifferentiation. To this end, as our group have 
also completed global proteomic profiling of dedifferentiating hPHs cultured in vitro using the 
same experimental design (n = 5 different donors, manuscript in preparation), systematic 
integration of information from both datasets will be useful to address this question. Similarly, 
concomitant analysis of previously published transcriptomic profiles of dedifferentiating hPHs 
(Richert et al., 2006) will be informative, especially for interrogating gene sets which are not 
readily detected using a proteomics approach.  
Another aim of our miR profiling study was to identify pattern(s) of miR changes that may 
inform new strategies for improved HLC functional capacity. Interestingly, the only study that 
had performed global miR profiling of the differentiation process of hPSCs towards HLCs 
(Kim et al., 2011b), found that miR-21-5p, which was the most up-regulated miR during hPH 
dedifferentiation after 48 hours of culture (Table 3.1), was also increased during 
differentiation of definitive endoderm towards HLCs. miR-21-5p is known to target genes 
associated with proliferation and cancer metastasis (Krichevsky and Gabriely, 2009) and has 
been shown to be up-regulated during the proliferative phase of liver regeneration in rat and 
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mice models (Castro et al., 2010;  Marquez et al., 2010). As the loss of the hepatic 
phenotype in hPHs during in vitro culture has been described to be partly due to its 
“proliferation-primed state” (Fraczek, et al., 2009), the up-regulation of miR-21-5p during 
HLC differentiation may be an important link to the limited attainment of a functional 
phenotype of HLCs.  
However, to truly draw parallels between the process of hPH dedifferentiation and HLC 
differentiation, future studies directly comparing the global miR, transcriptomic and/or 
proteomic profiles of HLCs, freshly-isolated hPHs and dedifferentiated hPHs would be 
needed to firstly delineate the biological functions and canonical pathways which are lacking 
or dysregulated in HLCs; and secondly to help formulate novel HLC differentiation strategies, 
such as possible miR targets for modulation. A similar transcriptomic approach had 
suggested that the CYP expression profile of HLCs were akin to that of hPHs cultured for 48 
hours (Ulvestad, et al., 2013), though a global analysis of the whole transcriptome was not 
employed. To reduce the confounding factor of genetic variability, perhaps our approach of 
using isogenic cells described in Chapter 2 could be combined by using hPHs and HLCs 
originating from the same donor(s) for comparative analyses.   
 
5.2.4  Utility of microRNA-122 as a hepatocyte-enriched in vitro biomarker  
In Chapter 4, we described the validation of miR-122 as a more relevant cell-type-specific 
assay to examine drug-induced toxicity of the hepatic cells, as opposed to conventional 
cytotoxicity assays which typically rely on the release of ubiquitous cellular enzymes or the 
measurement of generic cell health parameters (Sumantran, 2011). We also highlighted its 
potential utility in complex hepatic models when applied for toxicology research, where the 
miR-122 cytotoxicity assay may be essential as it allows for specific assessment of the effect 
of hepatotoxicants on the hepatic cells and the ability to discriminate from the “noise” of the 
surrounding non-hepatocyte cells. These non-hepatocyte cells could be in the form of poorly-
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differentiated cells present within HLC cultures with low differentiation efficiency, or non-
parenchymal cells used in co-cultures with hPHs and HLCs, which is increasingly applied as 
the basis for many novel two dimensional (2D) and 3D complex hepatic models (LeCluyse, 
et al., 2012;  Takebe et al., 2013). This is mainly in response to the increasing recognition 
that the ideal in vitro hepatic models are those that recapitulate the niche environment in the 
human liver by mimicking the complex multicellular interactions (Godoy, et al., 2013).  
One example is a commercially-available system of 2D micro-patterned co-cultures of 
hepatocytes with murine stromal cells which have been reported to have greater drug 
metabolising capacity, longer viability and phenotypic stability compared to conventional 
monocellular culture models (Khetani and Bhatia, 2008;  LeCluyse, et al., 2012). However, 
as shown in a recent toxicology study that used this platform, the concomitant presence of 
the stromal cells complicated the analysis of toxicity specifically targeting the hepatocytes 
when conventional cytotoxicity assays were used (Ukairo et al., 2013). The approach 
reported to calculate the hepatocyte-only toxicity using non-hepatocyte-specific endpoints 
such as ATP in response to hepatotoxicants, was to perform simultaneous assays on 
cultures of the stromal cells alone and to subtract subsequent values from that obtained from 
the co-cultures. This however, does not truly encompass the effect of the multicellular 
interaction between the hepatocytes and the stromal cells in response to cellular 
perturbation.  In contrast, the detection of miR-122 as a hepatocyte-enriched marker of drug-
induced toxicity in this situation would have been ideal, as it would have been measured 
directly in the co-cultures, and the endpoint specifically correlating with toxicity of the 
hepatocytes only. Furthermore, the miR-122 assay also allows for repetitive sampling during 
chronic dosing experiments, which may be a more relevant approach to studying DILI in 
humans, and will also enable sampling of hepatocyte damage in complex 3D bioreactor 
cultures. Therefore, the validation of miR-122 as a biomarker for drug-induced hepatotoxicity 
will hopefully help in the deployment of emerging complex hepatic models for pharmaco-
toxicology studies that may have otherwise been limited by conventional cytotoxicity assays.  
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Another aspect which has greatly contributed to the huge societal burden caused by DILI is 
the lack of qualified bridging biomarkers that allow for accurate translation between pre-
clinical and clinical studies (Antoine et al., 2014). However, there has been tremendous 
progress in recent years in validating many novel translational biomarkers such as high 
mobility group box-1 (HMGB1) and keratin-18 (CK18) in in vivo and clinical studies which 
reflect the different mechanisms of DILI (Antoine et al., 2009;  Harrill et al., 2012). This is 
also true for miR-122 which has been shown to be an appropriate marker of acetaminophen-
induced liver injury in a mouse model and in humans (Antoine et al., 2013;  Harrill, et al., 
2012;  Starkey Lewis et al., 2011;  Wang et al., 2009).  
Therefore, one further advantage of using miR-122 as an in vitro biomarker is its potential to 
bridge results in in vitro experiments to clinical findings using the same assay. Conversely, 
analysis of miR-122 release can also be used to assess the relevance of in vitro models 
being developed for the study of DILI by linkage with clinical findings, which the current 
conventional in vitro markers such as LDH and ATP could not provide. However, to fulfil its 
full potential, further studies are needed to delineate its mechanism(s) of miR-122 release 
during drug-induced toxicity, and are currently in progress in our group. 
 
 
 
 
 
 
 
  Chapter 5 
132 
 
5.3  FINAL COMMENTS 
In conclusion, the hypotheses addressed in this thesis will be commented on individually: 
 
Hypothesis 1 
 HLCs generated from hPH-derived hiPSCs display a closer resemblance to the hPH 
phenotype compared to HLCs generated from isogenic human dermal fibroblast-derived 
hiPSCs. 
Comment: HLCs generated from a single clone of hPH-derived hiPSCs did not show 
greater resemblance to hPHs as assessed by its transcriptomic and functional profile, 
compared to HLCs generated from isogenic human dermal fibroblast-derived hiPSCs. 
However, further clarification of these results is required using HLCs originating from 
other donors, ideally with more hPH-derived hiPSC clones available for comparison. The 
use of other differentiation protocols should also be considered. 
 
Hypothesis 2 
 Novel insights into the process of hPH dedifferentiation can be gained by investigating 
the changing global miR profiles of hPHs in extended in vitro culture. 
Comment: The global miR profiling of hPHs in extended in vitro culture have provided 
novel insights into the role of miRs in the detrimental process of hepatic dedifferentiation. 
This approach also defined a list of differentially-expressed miRs which could be 
modulated as a anti-dedifferentiation strategy. Validation studies are now required to 
confirm our findings from the bioinformatics analyses using miR mimics and antagomirs.  
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Hypothesis 3 
 miR-122 can be utilised as a relevant in vitro marker of drug-induced hepatotoxicity in 
hepatic models expressing high levels of miR-122. 
Comment: miR-122 was successfully validated as a hepatocyte-enriched in vitro marker 
of drug-induced hepatotoxicity in hPHs and HLCs generated from hiPSCs, which were 
both shown to have high intracellular levels of miR-122. Detection of miR-122 release 
may be a useful alternative to conventional cytotoxicity assays in complex co-culture 
hepatic models, and could be applied as a bridging biomarker of DILI between pre-
clinical and clinical studies.  
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